Medtronic (MDT) 10-Q 2 Mar 18 2018 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Jan. 26, 2018	Feb. 28, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	Medtronic plc
Entity Central Index Key	1,613,103
Document Period End Date	Jan. 26, 2018
Current Fiscal Year End Date	--04-27
Document Type	10-Q
Amendment Flag	false
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Ordinary Shares Outstanding		1,355,373,428
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2,018

Consolidated Statements of Inco

Consolidated Statements of Income - USD ($) shares in Millions	3 Months Ended		9 Months Ended
	Jan. 26, 2018	Jan. 27, 2017	Jan. 26, 2018	Jan. 27, 2017
Income Statement [Abstract]
Net sales	$ 7,369,000,000	$ 7,283,000,000	$ 21,809,000,000	$ 21,794,000,000
Costs and expenses:
Cost of products sold	2,191,000,000	2,268,000,000	6,660,000,000	6,855,000,000
Research and development expense	558,000,000	530,000,000	1,661,000,000	1,640,000,000
Selling, general, and administrative expense	2,499,000,000	2,388,000,000	7,422,000,000	7,232,000,000
Amortization of intangible assets	461,000,000	497,000,000	1,375,000,000	1,484,000,000
Restructuring charges, net	7,000,000	21,000,000	23,000,000	162,000,000
Acquisition-related items	26,000,000	68,000,000	77,000,000	148,000,000
Certain litigation charges	61,000,000	218,000,000	61,000,000	300,000,000
Divestiture-related items	0	0	114,000,000	0
Gain on sale of businesses	0	0	(697,000,000)	0
Special charge	0	100,000,000	80,000,000	100,000,000
Other expense, net	140,000,000	46,000,000	317,000,000	174,000,000
Operating profit (loss)	1,426,000,000	1,147,000,000	4,716,000,000	3,699,000,000
Investment loss	227,000,000	0	227,000,000	0
Interest income	(98,000,000)	(88,000,000)	(290,000,000)	(272,000,000)
Interest expense	270,000,000	268,000,000	829,000,000	804,000,000
Interest expense, net	172,000,000	180,000,000	539,000,000	532,000,000
Income before income taxes	1,027,000,000	967,000,000	3,950,000,000	3,167,000,000
Income tax provision	2,419,000,000	147,000,000	2,320,000,000	307,000,000
Net (loss) income	(1,392,000,000)	820,000,000	1,630,000,000	2,860,000,000
Net loss attributable to noncontrolling interests	3,000,000	1,000,000	14,000,000	5,000,000
Net (loss) income attributable to Medtronic	$ (1,389,000,000)	$ 821,000,000	$ 1,644,000,000	$ 2,865,000,000
Basic (loss) earnings per share (usd per share)	$ (1.03)	$ 0.60	$ 1.21	$ 2.07
Diluted (loss) earnings per share (usd per share)	$ (1.03)	$ 0.59	$ 1.20	$ 2.05
Basic weighted average shares outstanding (shares)	1,354	1,372.2	1,357.2	1,381.9
Diluted weighted average shares outstanding (shares)	1,354	1,383.1	1,368.9	1,394.7
Cash dividends declared per ordinary share (usd per share)	$ 0.46	$ 0.43	$ 1.38	$ 1.29

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jan. 26, 2018	Jan. 27, 2017	Jan. 26, 2018	Jan. 27, 2017
Statement of Comprehensive Income [Abstract]
Net (loss) income	$ (1,392)	$ 820	$ 1,630	$ 2,860
Other comprehensive income (loss), net of tax:
Unrealized (loss) gain on available-for-sale securities	(14)	(115)	41	(40)
Currency translation	897	(553)	1,525	(1,239)
Net change in retirement obligations	(3)	22	11	66
Unrealized (loss) gain on derivatives	(202)	95	(346)	202
Other comprehensive income (loss)	678	(551)	1,231	(1,011)
Comprehensive (loss) income including noncontrolling interests	(714)	269	2,861	1,849
Comprehensive loss attributable to noncontrolling interests	3	1	14	5
Comprehensive (loss) income attributable to Medtronic	$ (711)	$ 270	$ 2,875	$ 1,854

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Jan. 26, 2018	Apr. 28, 2017
Current assets:
Cash and cash equivalents	$ 6,358	$ 4,967
Investments	8,078	8,741
Accounts receivable, less allowances of $183 and $155, respectively	5,775	5,591
Inventories, net	3,751	3,338
Other current assets	2,645	1,865
Current assets held for sale	0	371
Total current assets	26,607	24,873
Property, plant, and equipment	10,006	9,691
Accumulated depreciation	(5,489)	(5,330)
Property, plant, and equipment, net	4,517	4,361
Goodwill	39,795	38,515
Other intangible assets, net	22,178	23,407
Tax assets	1,537	1,509
Other assets	1,166	1,232
Noncurrent assets held for sale	0	5,919
Total assets	95,800	99,816
Current liabilities:
Current debt obligations	2,902	7,520
Accounts payable	1,809	1,731
Accrued compensation	1,645	1,860
Accrued income taxes	925	633
Other accrued expenses	3,652	2,442
Current liabilities held for sale	0	34
Total current liabilities	10,933	14,220
Long-term debt	25,918	25,921
Accrued compensation and retirement benefits	1,524	1,641
Accrued income taxes	4,758	2,405
Deferred tax liabilities	1,363	2,978
Other liabilities	964	1,515
Noncurrent liabilities held for sale	0	720
Total liabilities	45,460	49,400
Commitments and contingencies
Shareholders’ equity:
Ordinary shares— par value $0.0001, 2.6 billion shares authorized, 1,355,260,722 and 1,369,424,818 shares issued and outstanding, respectively	0	0
Additional paid-in capital	28,190	29,551
Retained earnings	23,426	23,356
Accumulated other comprehensive loss	(1,382)	(2,613)
Total shareholders’ equity	50,234	50,294
Noncontrolling interests	106	122
Total equity	50,340	50,416
Total liabilities and equity	$ 95,800	$ 99,816

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Jan. 26, 2018	Apr. 28, 2017
Statement of Financial Position [Abstract]
Allowances for accounts receivable	$ 183	$ 155
Ordinary shares, par value (usd per share)	$ 0.0001	$ 0.0001
Ordinary shares authorized (in shares)	2,600,000,000	2,600,000,000
Ordinary shares issued (in shares)	1,355,260,722	1,369,424,818
Ordinary shares outstanding (in shares)	1,355,260,722	1,369,424,818

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Jan. 26, 2018	Jan. 27, 2017
Operating Activities:
Net income	$ 1,630,000,000	$ 2,860,000,000
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	1,980,000,000	2,199,000,000
Amortization of debt premium, discount, and issuance costs	(17,000,000)	21,000,000
Acquisition-related items	(37,000,000)	(43,000,000)
Provision for doubtful accounts	36,000,000	31,000,000
Deferred income taxes	(1,042,000,000)	(404,000,000)
Stock-based compensation	270,000,000	272,000,000
Gain on sale of businesses	(697,000,000)	0
Investment loss	227,000,000	0
Other, net	66,000,000	(113,000,000)
Change in operating assets and liabilities, net of acquisitions and divestitures:
Accounts receivable, net	19,000,000	18,000,000
Inventories, net	(318,000,000)	(261,000,000)
Accounts payable and accrued liabilities	13,000,000	32,000,000
Other operating assets and liabilities	1,516,000,000	495,000,000
Net cash provided by operating activities	3,646,000,000	5,107,000,000
Investing Activities:
Acquisitions, net of cash acquired	(111,000,000)	(1,328,000,000)
Proceeds from sale of businesses	6,058,000,000	0
Additions to property, plant, and equipment	(776,000,000)	(924,000,000)
Purchases of investments	(2,479,000,000)	(3,354,000,000)
Sales and maturities of investments	3,060,000,000	4,286,000,000
Other investing activities, net	(5,000,000)	21,000,000
Net cash provided by (used in) investing activities	5,747,000,000	(1,299,000,000)
Financing Activities:
Acquisition-related contingent consideration	(43,000,000)	(58,000,000)
Change in current debt obligations, net	(391,000,000)	1,118,000,000
Repayment of short-term borrowings (maturities greater than 90 days)	(44,000,000)	(2,000,000)
Proceeds from short-term borrowings (maturities greater than 90 days)	1,000,000	4,000,000
Issuance of long-term debt	21,000,000	131,000,000
Payments on long-term debt	(4,167,000,000)	(361,000,000)
Dividends to shareholders	(1,870,000,000)	(1,782,000,000)
Issuance of ordinary shares	333,000,000	309,000,000
Repurchase of ordinary shares	(1,964,000,000)	(3,409,000,000)
Other financing activities	(2,000,000)	80,000,000
Net cash provided by (used in) financing activities	(8,126,000,000)	(3,970,000,000)
Effect of exchange rate changes on cash and cash equivalents	124,000,000	54,000,000
Net change in cash and cash equivalents	1,391,000,000	(108,000,000)
Cash and cash equivalents at beginning of period	4,967,000,000	2,876,000,000
Cash and cash equivalents at end of period	6,358,000,000	2,768,000,000
Cash paid for:
Income taxes	911,000,000	474,000,000
Interest	$ 651,000,000	$ 626,000,000

Basis of Presentation

Basis of Presentation	9 Months Ended
	Jan. 26, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited consolidated financial statements of Medtronic plc and its subsidiaries (Medtronic plc, Medtronic, or the Company) have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S.) (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, the consolidated financial statements include all of the adjustments necessary for a fair statement in conformity with U.S. GAAP. Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates. The accompanying unaudited consolidated financial statements include the accounts of Medtronic plc, its wholly-owned subsidiaries, entities for which the Company has a controlling financial interest, and variable interest entities for which the Company is the primary beneficiary. Intercompany transactions and balances have been fully eliminated in consolidation. The accompanying unaudited consolidated financial statements and related notes should be read in conjunction with the audited consolidated financial statements of the Company and related notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended April 28, 2017 . The Company’s fiscal years 2018 , 2017 , and 2016 will end or ended on April 27, 2018 , April 28, 2017 , and April 29, 2016 , respectively.

New Accounting Pronouncements

New Accounting Pronouncements	9 Months Ended
	Jan. 26, 2018
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
New Accounting Pronouncements	New Accounting Pronouncements Recently Adopted In March 2016, the Financial Accounting Standards Board (FASB) issued guidance to simplify the accounting for share-based payment transactions by requiring all excess tax benefits and deficiencies to be recognized in income tax expense or benefit in earnings; eliminating the requirement to classify the excess tax benefits and deficiencies as additional paid-in capital. Cash flows related to excess tax benefits are to be classified in operating activities in the statement of cash flows rather than financing. Under the new guidance, an entity makes an accounting policy election to either estimate the expected forfeiture awards or account for forfeitures as they occur. The standard also allows an entity to withhold up to the maximum statutory tax rate and classify the awards as equity. The Company prospectively adopted this guidance in the first quarter of fiscal year 2018. The Company has elected to continue to estimate forfeitures. The adoption of this guidance resulted in no cumulative adjustment to retained earnings and, including the impacts of U.S. Tax Reform, decreases to net loss and diluted loss per share of $9 million and $0.01 , respectively, for the three months ended January 26, 2018 , and increases to net income and diluted earnings per share of $50 million and $0.04 , respectively, for the nine months ended January 26, 2018 . In October 2016, the FASB issued guidance that requires the tax effect of intra-entity transactions, other than sales of inventory, to be recognized when the transaction occurs. Previously, U.S. GAAP prohibited the recognition of current and deferred income taxes associated with an intra-entity asset transfer until an asset had been sold to a third-party. This update requires an entity to recognize the income tax consequences of an intra-entity transfer of an asset, such as equipment or intangibles, when the transfer occurs. The adoption of this guidance is to be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. The Company has early adopted this guidance, as permitted, in the first quarter of fiscal year 2018. As a result of this adoption, the Company increased its beginning retained earnings by $296 million . The adoption of this guidance, not considering the impacts of U.S. Tax Reform, resulted in an increase to net loss of $5 million and no change to diluted loss per share for the three months ended January 26, 2018 , and increases to net income and diluted earnings per share of $552 million and $0.40 , respectively, for the nine months ended January 26, 2018 . Not Yet Adopted In May 2014, the FASB issued amended revenue recognition guidance to clarify the principles for recognizing revenue from contracts with customers. The guidance requires an entity to recognize revenue in an amount that reflects the consideration to which an entity expects to be entitled in exchange for the transfer of goods or services. The guidance also requires expanded disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. This accounting guidance is effective for the Company beginning in the first quarter of fiscal year 2019, and may be applied either retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of the change recognized at the date of initial application (modified retrospective method). The Company intends to adopt this guidance under the modified retrospective method. Based on the Company's current evaluation of the amended revenue recognition guidance, the Company does not expect the adoption of the amended guidance to have a material impact on the Company's consolidated financial statements. The Company is continuing to evaluate the impact of the amended guidance as it pertains to presentation and disclosure. The Company will continue to monitor any modifications, clarifications, and interpretations communicated by the FASB that may impact its conclusions. In January 2016, the FASB issued guidance which requires equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income. The guidance also includes a simplified impairment assessment of equity investments without readily determinable fair values and presentation and disclosure changes. This accounting guidance is effective for the Company beginning in the first quarter of fiscal year 2019. The Company is unable to estimate the impact of the future adoption of this guidance on its financial statements as it will depend on the equity investments at the adoption date. In February 2016, the FASB issued guidance which requires lessees to recognize right-of-use assets and lease liabilities on the balance sheet. The guidance is to be applied using a modified retrospective approach at the beginning of the earliest comparative period in the financial statements and is effective for the Company beginning in the first quarter of fiscal year 2020. Early adoption is permitted. The Company is evaluating the impact of the lease guidance on the Company's consolidated financial statements and anticipates recording additional assets and corresponding liabilities on its consolidated balance sheets related to operating leases within its lease portfolio upon adoption of the guidance. In January 2017, the FASB issued guidance which simplifies the accounting for goodwill impairment. The guidance requires a goodwill impairment to be measured as the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The Company is required to adopt this guidance beginning in the first quarter of fiscal year 2021. Early adoption is permitted, and the guidance must be applied prospectively. The Company is unable to estimate the impact of the future adoption of this guidance on its financial statements, as it is dependent on the specific facts and circumstances of any future impairments, if applicable.

Acquisitions and Acquisition-Re

Acquisitions and Acquisition-Related Items	9 Months Ended
	Jan. 26, 2018
Business Combinations [Abstract]
Acquisitions and Acquisition-Related Items	Acquisitions and Acquisition-Related Items The Company had acquisitions and other acquisition-related activity during the three and nine months ended January 26, 2018 . The Company accounted for the acquisitions as business combinations using the acquisition method of accounting. The assets and liabilities of the businesses acquired were recorded and consolidated on the acquisition date at their respective fair values. Goodwill resulting from business combinations is largely attributable to future yet to be defined technologies, new customer relationships, existing workforce of the acquired businesses, and synergies expected to arise after the Company's acquisition of these businesses. The pro forma impact of these acquisitions was not significant, either individually or in the aggregate, to the results of the Company for the three and nine months ended January 26, 2018 . The results of operations of acquired businesses have been included in the Company's consolidated statements of income since the date each business was acquired. HeartWare International, Inc. On August 23, 2016, the Company's Cardiac and Vascular Group acquired HeartWare International, Inc. (HeartWare), a medical device company that develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat patients around the world suffering from advanced heart failure. Total consideration for the transaction was approximately $1.1 billion . The Company acquired $602 million of technology-based and customer-related intangible assets and $23 million of tradenames, with estimated useful lives of 15 and 5 years, respectively, and $481 million of goodwill. The acquired goodwill is not deductible for tax purposes. In addition, the Company acquired $245 million of debt through the acquisition, of which the Company redeemed $203 million as part of a cash tender offer in August 2016, and the remaining $42 million of debt acquired was repaid in December 2017. The acquisition date fair values of the assets and liabilities acquired were as follows: (in millions) HeartWare International, Inc. All Other Other current assets $ 351 $ 3 Property, plant, and equipment 14 6 Other intangible assets 625 93 Goodwill 481 27 Other assets 84 — Total assets acquired 1,555 129 Current liabilities 143 2 Deferred tax liabilities 6 3 Long-term debt 245 — Other liabilities 89 — Total liabilities assumed 483 5 Net assets acquired $ 1,072 $ 124 See Note 2 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 28, 2017 for additional information on the Company's fiscal year 2017 acquisitions. Acquisition-Related Items Acquisition-related items includes expenses incurred in connection with the integration of Covidien, the Company's $50.0 billion acquisition completed in the fourth quarter of fiscal year 2015, expenses incurred in connection with business acquisitions, and changes in fair value of contingent consideration. During the three and nine months ended January 26, 2018 , the Company recognized acquisition-related items expense of $30 million and $101 million , respectively, including $4 million and $24 million , respectively, recognized within cost of products sold in the consolidated statements of income. For the three and nine months ended January 26, 2018 , acquisition-related items expense includes $48 million and $137 million , respectively, of costs associated with the integration of Covidien manufacturing, distribution, and administrative facilities as well as information technology system implementation and benefits harmonization. For the three and nine months ended January 26, 2018 , acquisition-related items expenses were partially offset by changes in fair value of contingent consideration as a result of revised revenue forecasts and the timing of anticipated regulatory payments. During the three and nine months ended January 27, 2017 , the Company recognized acquisition-related items expense of $68 million and $148 million , respectively. For the three and nine months ended January 27, 2017 , acquisition-related items expense includes $51 million and $154 million , respectively, of costs associated with the integration of Covidien manufacturing, distribution, and administrative facilities as well as information technology system implementation and benefits harmonization, and $5 million and $21 million , respectively, of accelerated and incremental stock compensation expense. For the nine months ended January 27, 2017 , acquisition-related items expenses were partially offset by changes in fair value of contingent consideration as a result of revised revenue forecasts and the timing of anticipated regulatory payments. Contingent Consideration Certain of the Company’s business combinations involve potential payments of future consideration that are contingent upon the achievement of product development milestones and/or contingent on the acquired business reaching performance milestones. A liability is recorded for the estimated fair value of the contingent consideration on the acquisition date. The fair value of the contingent consideration is remeasured at each reporting period using Level 3 inputs, and the change in fair value is recognized within acquisition-related items in the consolidated statements of income. Contingent consideration payments made soon after the acquisition date are classified as investing activities in the consolidated statements of cash flows. Contingent consideration payments not made soon after the acquisition date that are related to the acquisition date fair value are reported as financing activities in the consolidated statements of cash flows and amounts paid in excess of the original acquisition date fair value are reported as operating activities in the consolidated statements of cash flows. The fair value of contingent consideration is measured using projected payment dates, discount rates, probabilities of payment, and projected revenues (for revenue-based consideration). Projected revenues are based on the Company's most recent internal operational budgets and long-range strategic plans. Changes in projected revenues, probabilities of payment, discount rates, and projected payment dates may result in adjustments to the fair value measurement. The recurring Level 3 fair value measurements of contingent consideration include the following significant unobservable inputs: Fair Value at (in millions) January 26, 2018 Valuation Technique Unobservable Input Range Discount rate 11% - 32.5% Revenue-based payments $88 Discounted cash flow Probability of payment 30% - 100% Projected fiscal year of payment 2018 - 2026 Discount rate 5.5% Product development and other milestone-based payments $83 Discounted cash flow Probability of payment 75% - 100% Projected fiscal year of payment 2018 - 2025 The fair value of contingent consideration at January 26, 2018 and April 28, 2017 was $171 million and $246 million , respectively. At January 26, 2018 , $80 million was recorded in other liabilities and $91 million was recorded in other accrued expenses in the consolidated balance sheets. At April 28, 2017 , $180 million was recorded in other liabilities and $66 million was recorded in other accrued expenses in the consolidated balance sheets. The following table provides a reconciliation of the beginning and ending balances of contingent consideration: Three months ended Nine months ended (in millions) January 26, 2018 January 27, 2017 January 26, 2018 January 27, 2017 Beginning Balance $ 190 $ 285 $ 246 $ 377 Purchase price contingent consideration 13 (4 ) 28 28 Payments (20 ) (23 ) (66 ) (62 ) Change in fair value (12 ) 4 (37 ) (81 ) Ending Balance $ 171 $ 262 $ 171 $ 262

Divestiture and Divestiture-Rel

Divestiture and Divestiture-Related Items	9 Months Ended
	Jan. 26, 2018
Discontinued Operations and Disposal Groups [Abstract]
Divestiture and Divestiture-Related Items	Divestiture and Divestiture-Related Items Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency Businesses In April 2017, the Company entered into a definitive agreement for the sale of the Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses within the Minimally Invasive Therapies Group segment to Cardinal Health, Inc. (Cardinal). The divestiture was completed on July 29, 2017. As a result of the transaction, the Company received proceeds of $6.1 billion , which was recorded in proceeds from sale of businesses in the consolidated statements of cash flows and recognized a before-tax gain of $697 million , which was recognized within gain on sale of businesses in the consolidated statements of income. Among the product lines included in the divestiture were the dental and animal health, chart paper, wound care, incontinence, electrodes, SharpSafety, thermometry, perinatal protection, blood collection, compression, and enteral feeding offerings. The divestiture also included 17 dedicated manufacturing sites. In connection with the transaction, the Company entered into Transition Service Agreements (TSAs) and Transition Manufacturing Agreements (TMAs) with Cardinal designed to ensure and facilitate an orderly transfer of business operations. The TSAs are primarily related to administrative services and continue for 12 months from the divestiture date, with an ability to extend upon mutual agreement of both parties. Certain of the TSAs have been extended beyond the initial 12 month period in accordance with the provisions of the original agreement. Under the TMAs, both the Company and Cardinal will manufacture and supply certain products to each other for a transition period of up to 5 years. The divestiture of the Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses did not meet the criteria to be classified as discontinued operations, as such, the results of operations of these businesses were included within net income through the date of the divestiture. The Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses met the criteria to be classified as held for sale in the fourth quarter of fiscal year 2017, at which time the Company ceased depreciation and amortization of property, plant, and equipment and intangible assets classified as held for sale. The following table presents information related to the assets and liabilities that were classified as held for sale in the consolidated balance sheets: (in millions) April 28, 2017 Inventories, net $ 371 Property, plant, and equipment, net 689 Goodwill 2,910 Other intangible assets, net 2,320 Total assets held for sale $ 6,290 Other accrued expenses $ 34 Accrued compensation and retirement benefits 12 Deferred tax liabilities 707 Other liabilities 1 Total liabilities held for sale $ 754 Divestiture-Related Items Divestiture-related items includes expenses incurred in connection with the divestiture of the Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses. During the nine months ended January 26, 2018 , the Company recognized divestiture-related items expense of $114 million , primarily comprised of expenses incurred for professional services, including banker, legal, tax, and advisory fees, as well as $16 million of accelerated stock compensation expense related to the acceleration of the vesting period for employees that transferred with the divestiture. There were no divestiture-related items expenses for the three months ended January 26, 2018 and for the three and nine months ended January 27, 2017 .

Special Charge

Special Charge	9 Months Ended
	Jan. 26, 2018
Commitments and Contingencies Disclosure [Abstract]
Special Charge	Special Charge During the nine months ended January 26, 2018 , continuing the Company's commitment to improve the health of people and communities throughout the world, the Company recognized a charge of $80 million for a commitment to fund the Medtronic Foundation. During the three months ended January 26, 2018 , the Company did no t recognize a special charge. During the three and nine months ended January 27, 2017 , the Company recognized a charge of $100 million for a charitable cash contribution to the Medtronic Foundation.

Restructuring

Restructuring	9 Months Ended
	Jan. 26, 2018
Restructuring and Related Activities [Abstract]
Restructuring	Restructuring Enterprise Excellence In the third quarter of fiscal year 2018, the Company announced its Enterprise Excellence restructuring program, which is expected to leverage the Company's global size and scale, as well as enhance the customer and employee experience with a focus on three objectives: global operations, functional optimization, and commercial optimization. Primary activities of the restructuring program include integrating and enhancing global manufacturing and supply processes, systems and site presence; enhancing and leveraging global operating models across several enabling functions; and optimizing certain commercial processes, systems and models. The Company estimates that, in connection with its Enterprise Excellence restructuring program, it will recognize pre-tax exit and disposal costs and other costs associated with the restructuring program across all reportable segments of approximately $1.6 billion to $1.8 billion , the majority of which are expected to be incurred by the end of fiscal year 2022. Approximately half of the estimated charges are related to employee termination benefits. The remaining restructuring charges are costs associated with the restructuring program, such as salaries for employees supporting the program and consulting expenses. These charges are recognized within restructuring charges, net, cost of products sold , and selling, general and administrative expense in the consolidated statements of income . For the three months ended January 26, 2018 , the Company recognized $32 million in charges. The following table summarizes the activity related to employee termination benefits liability and the associated costs for the nine months ended January 26, 2018 : (in millions) Employee Termination Benefits Associated Costs (1) Total April 28, 2017 $ — $ — $ — Charges 9 23 32 Cash payments — (23 ) (23 ) January 26, 2018 $ 9 $ — $ 9 (1) Associated costs include costs incurred as a direct result of the restructuring program, such as salaries for employees supporting the program and consulting expenses. For the three months ended January 26, 2018 , $13 million was recognized within cost of products sold and $10 million was recognized within selling, general and administrative expense in the consolidated statements of income. Cost Synergies The cost synergies program related to administrative office optimization, manufacturing and supply chain infrastructure, and certain general and administrative savings and completed in the third quarter of fiscal year 2018. Restructuring charges incurred throughout the life of the initiative were primarily related to employee termination costs and costs related to manufacturing and facility closures and affect all reportable segments. A summary of the restructuring accrual and related activity is presented below: (in millions) Employee Termination Benefits Other Costs Total April 28, 2017 $ 261 $ 30 $ 291 Charges 25 20 45 Cash payments (119 ) (30 ) (149 ) Accrual adjustments (17 ) 2 (15 ) January 26, 2018 $ 150 $ 22 $ 172 For the three months ended January 26, 2018 , the Company recognized no charges, and for the nine months ended January 26, 2018 , the Company recognized $45 million in charges. During the three and nine months ended January 26, 2018 , the Company recognized accrual adjustments of $2 million and $15 million , respectively. Accrual adjustments relate to certain employees identified for termination finding other positions within the Company, cancellations of employee terminations, and employee termination benefits being less than initially estimated. For the nine months ended January 26, 2018 , charges included $12 million recognized within cost of products sold and $4 million recognized within selling, general and administrative expense in the consolidated statements of income. For the three and nine months ended January 27, 2017 , the Company recognized $56 million and $214 million in charges, respectively, which were partially offset by accrual adjustments of $35 million and $42 million , respectively. Accrual adjustments relate to certain employees identified for termination finding other positions within the Company and employee termination benefits being less than initially estimated. For the three months and nine months ended January 27, 2017 , charges included asset disposal write-downs of $1 million and $8 million , respectively, related to property, plant, and equipment. For the nine months ended January 27, 2017 , asset disposal write-downs included $10 million related to inventory write-offs of discontinued product lines, which were recognized within cost of products sold in the consolidated statements of income.

Financial Instruments

Financial Instruments	9 Months Ended
	Jan. 26, 2018
Investments [Abstract]
Financial Instruments	Financial Instruments The Company holds investments, including marketable debt and equity securities, that are classified and accounted for as available-for-sale and are remeasured on a recurring basis. The Company also holds cost method, equity method, and other investments which are measured at fair value on a nonrecurring basis. For information regarding the valuation techniques and inputs used in the fair value measurements, refer to Note 1 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 28, 2017. The following table summarizes the Company's investments by significant investment category and the related consolidated balance sheet classification at January 26, 2018 : Valuation Balance Sheet Classification (in millions) Cost Unrealized Gains Unrealized Losses Fair Value Investments Other Assets Available-for-sale securities: Level 1: U.S. government and agency securities $ 618 $ — $ (16 ) $ 602 $ 602 $ — Marketable equity securities 69 126 (2 ) 193 — 193 Total Level 1 687 126 (18 ) 795 602 193 Level 2: Corporate debt securities 4,254 42 (30 ) 4,266 4,266 — U.S. government and agency securities 882 — (18 ) 864 864 — Mortgage-backed securities 753 3 (26 ) 730 730 — Foreign government and agency securities 66 — (1 ) 65 65 — Other asset-backed securities 337 1 (2 ) 336 336 — Debt funds 939 7 (126 ) 820 820 — Total Level 2 7,231 53 (203 ) 7,081 7,081 — Level 3: Corporate debt securities 1 — — 1 — 1 Auction rate securities 47 — (3 ) 44 — 44 Total Level 3 48 — (3 ) 45 — 45 Investments measured at net asset value (1) : Debt funds 400 — (5 ) 395 395 — Total available-for-sale securities 8,366 179 (229 ) 8,316 8,078 238 Cost method, equity method, and other investments: Level 3: Cost method, equity method, and other investments 407 — — N/A — 407 Total Level 3 407 — — N/A — 407 Total cost method, equity method, and other investments 407 — — N/A — 407 Total investments $ 8,773 $ 179 $ (229 ) $ 8,316 $ 8,078 $ 645 (1) Certain investments that are measured at the net asset value per share (or its equivalent) as a practical expedient are excluded from the fair value hierarchy. The fair value amounts presented herein are intended to permit reconciliation to the consolidated balance sheets. The following table summarizes the Company's investments by significant investment category and the related consolidated balance sheet classification at April 28, 2017 : Valuation Balance Sheet Classification (in millions) Cost Unrealized Gains Unrealized Losses Fair Value Investments Other Assets Available-for-sale securities: Level 1: U.S. government and agency securities $ 613 $ 2 $ (5 ) $ 610 $ 610 $ — Marketable equity securities 58 49 (4 ) 103 — 103 Total Level 1 671 51 (9 ) 713 610 103 Level 2: Corporate debt securities 4,643 62 (23 ) 4,682 4,682 — U.S. government and agency securities 860 — (10 ) 850 850 — Mortgage-backed securities 766 9 (16 ) 759 759 — Foreign government and agency securities 49 — — 49 49 — Other asset-backed securities 228 1 (1 ) 228 228 — Debt funds 1,246 4 (178 ) 1,072 1,072 — Total Level 2 7,792 76 (228 ) 7,640 7,640 — Level 3: Corporate debt securities 1 — — 1 — 1 Auction rate securities 47 — (3 ) 44 — 44 Total Level 3 48 — (3 ) 45 — 45 Investments measured at net asset value (1) : Debt funds 497 — (6 ) 491 491 — Total available-for-sale securities 9,008 127 (246 ) 8,889 8,741 148 Cost method, equity method, and other investments: Level 3: Cost method, equity method, and other investments 589 — — N/A — 589 Total Level 3 589 — — N/A — 589 Total cost method, equity method, and other investments 589 — — N/A — 589 Total investments $ 9,597 $ 127 $ (246 ) $ 8,889 $ 8,741 $ 737 (1) Certain investments that are measured at the net asset value per share (or its equivalent) as a practical expedient are excluded from the fair value hierarchy. The fair value amounts presented herein are intended to permit reconciliation to the consolidated balance sheets. Marketable Debt and Equity Securities The following tables present the gross unrealized losses and fair values of the Company’s available-for-sale securities that have been in a continuous unrealized loss position deemed to be temporary, aggregated by investment category at January 26, 2018 and April 28, 2017 : January 26, 2018 Less than 12 months More than 12 months (in millions) Fair Value Unrealized Losses Fair Value Unrealized Losses Corporate debt securities $ 1,675 $ (19 ) $ 295 $ (11 ) Auction rate securities — — 44 (3 ) Mortgage-backed securities 435 (9 ) 107 (17 ) U.S. government and agency securities 658 (20 ) 454 (14 ) Foreign government and agency securities — — 36 (1 ) Debt funds — — 1,001 (131 ) Other asset-backed securities 184 (1 ) 61 (1 ) Marketable equity securities — — 1 (2 ) Total $ 2,952 $ (49 ) $ 1,999 $ (180 ) April 28, 2017 Less than 12 months More than 12 months (in millions) Fair Value Unrealized Losses Fair Value Unrealized Losses Corporate debt securities $ 1,263 $ (19 ) $ 46 $ (4 ) Auction rate securities — — 44 (3 ) Mortgage-backed securities 276 (4 ) 95 (12 ) U.S. government and agency securities 896 (15 ) — — Other asset-backed securities 127 (1 ) — — Debt funds 173 (1 ) 1,125 (183 ) Marketable equity securities 14 (3 ) 2 (1 ) Total $ 2,749 $ (43 ) $ 1,312 $ (203 ) The following table presents the unobservable inputs utilized in the fair value measurement of the auction rate securities classified as Level 3 at January 26, 2018 : Valuation Technique Unobservable Input Range (Weighted Average) Auction rate securities Discounted cash flow Years to principal recovery 2 yrs. - 12 yrs. (3 yrs.) Illiquidity premium 6% The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. The Company’s policy is to recognize transfers into and out of levels within the fair value hierarchy at the end of the fiscal quarter in which the actual event or change in circumstances that caused the transfer occurs. There were no transfers between Level 1, Level 2, or Level 3 during the three and nine months ended January 26, 2018 and January 27, 2017 . When a determination is made to classify an asset or liability within Level 3, the determination is based upon the significance of the unobservable inputs to the overall fair value measurement. There were no purchases, sales, settlements, or gains or losses recognized in earnings or other comprehensive income for available-for-sale securities classified as Level 3 during the three and nine months ended January 26, 2018 and January 27, 2017 . Activity related to the Company’s investment portfolio is as follows: Three months ended January 26, 2018 January 27, 2017 (in millions) Debt (1) Equity (2) Debt (1) Equity (2) Proceeds from sales $ 667 $ 39 $ 661 $ 1 Gross realized gains 3 8 10 — Gross realized losses (2 ) — (7 ) — Impairment losses recognized — (227 ) — (10 ) Nine months ended January 26, 2018 January 27, 2017 (in millions) Debt (1) Equity (2) Debt (1) Equity (2) Proceeds from sales $ 3,021 $ 39 $ 4,203 $ 83 Gross realized gains 22 15 74 29 Gross realized losses (17 ) — (56 ) — Impairment losses recognized — (228 ) — (20 ) (1) Includes available-for-sale debt securities and debt funds. (2) Includes marketable equity securities and cost and equity method investments. Credit losses represent the difference between the present value of cash flows expected to be collected on certain mortgage-backed securities and auction rate securities and the amortized cost of these securities. Based on the Company’s assessment of the credit quality of the underlying collateral and credit support available to each of the remaining securities in which the Company is invested, the Company believes it has recognized all necessary other-than-temporary impairments, as the Company does not have the intent to sell, nor is it more likely than not that the Company will be required to sell, before recovery of the amortized cost. At January 26, 2018 and April 28, 2017 , the credit loss portion of other-than-temporary impairments on debt securities was no t significant. The total reductions of available-for-sale debt securities sold during the three and nine months ended January 26, 2018 and January 27, 2017 were no t significant. The January 26, 2018 balance of available-for-sale debt securities, excluding debt funds which have no single maturity date, by contractual maturity is shown in the following table. Within the table, maturities of mortgage-backed securities have been allocated based upon timing of estimated cash flows assuming no change in the current interest rate environment. Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties. (in millions) January 26, 2018 Due in one year or less $ 885 Due after one year through five years 2,748 Due after five years through ten years 3,161 Due after ten years 114 Total $ 6,908 The Company holds investments in marketable equity securities, which are classified as other assets in the consolidated balance sheets. The aggregate carrying amount of these investments was $193 million and $103 million at January 26, 2018 and April 28, 2017 , respectively. The Company did no t recognize any significant impairment charges related to marketable equity securities during the three and nine months ended January 26, 2018 and January 27, 2017 . Cost method, equity method, and other investments The Company holds investments in equity and other securities that are accounted for using the cost or equity method, which are classified as other assets in the consolidated balance sheets. At January 26, 2018 and April 28, 2017 , the aggregate carrying amount of equity and other securities accounted for using the cost or equity method was $407 million and $589 million , respectively. Cost and equity method investments are measured at fair value on a nonrecurring basis. Changes in circumstance or the occurrence of events that suggest the Company’s investment may not be recoverable are assessed quarterly. If events or changes in circumstances are identified that may have a material adverse effect on the fair value of the investment, the investment is assessed for impairment. Cost and equity method investments are included within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs to determine fair value. To determine the fair value of these investments, the Company uses all pertinent financial information available related to the investees, including financial statements, market participant valuations from recent and proposed equity offerings, and other third-party data. During the three months ended January 26, 2018 , the Company received bids from potential buyers and investors for some or all of its ownership in a portfolio of selected investments, which indicated that the fair values of certain of the underlying cost and equity method investments in the portfolio may be below the respective carrying values. The Company determined that the decline in the fair values was other-than-temporary given the uncertainty regarding the Company’s intent to hold the investments for a period of time that would be sufficient to recover the carrying values. As a result, the Company recognized impairment charges of $227 million during the three and nine months ended January 26, 2018 , which were recognized within investment loss in the consolidated statements of income. The fair values of the investments were determined based on Level 3 inputs. The carrying values of the investments prior to recognizing the impairment charges was $317 million . There were no other significant impairments charges recognized during the three and nine months ended January 26, 2018 . During the three and nine months ended January 27, 2017 , the Company determined that the fair values of certain cost method investments were below their carrying values and that the carrying values of these investments were not expected to be recoverable within a reasonable period of time. As a result, the Company recognized $10 million and $20 million in impairment charges during the three and nine months ended January 27, 2017 , respectively, which were recognized in other expense, net in the consolidated statements of income.

Financing Arrangements

Financing Arrangements	9 Months Ended
	Jan. 26, 2018
Debt Disclosure [Abstract]
Financing Arrangements	Financing Arrangements Commercial Paper The Company maintains a commercial paper program that allows the Company to have a maximum of $3.5 billion in commercial paper outstanding. Commercial paper outstanding at January 26, 2018 was $504 million , as compared to $901 million at April 28, 2017 . During the three and nine months ended January 26, 2018 , the weighted average original maturity of the commercial paper outstanding was approximately 24 and 29 days, respectively, and the weighted average interest rate was 1.44 percent and 1.33 percent , respectively. The issuance of commercial paper reduces the amount of credit available under the Company’s existing Credit Facility, as defined below. Line of Credit The Company has a $3.5 billion five year revolving syndicated line of credit facility (Credit Facility) which provides back-up funding for the commercial paper program described above. At January 26, 2018 and April 28, 2017 , no amounts were outstanding. Interest rates on advances on the Credit Facility are determined by a pricing matrix, based on the Company’s long-term debt ratings, assigned by Standard & Poor’s Ratings Services and Moody’s Investors Service. Facility fees are payable on the Credit Facility and are determined in the same manner as the interest rates. The agreements also contain customary covenants, all of which the Company remained in compliance with at January 26, 2018 . Debt Obligations The Company's debt obligations consisted of the following: (in millions, except interest rates) Maturity by Fiscal Year January 26, 2018 April 28, 2017 Current debt obligations 2018 - 2019 $ 2,902 $ 7,520 Long-term debt 5.600 percent ten-year 2009 senior notes 2019 400 400 1.700 percent two-year 2017 senior notes 2019 1,000 1,000 4.450 percent ten-year 2010 senior notes 2020 766 766 2.500 percent five-year 2015 senior notes 2020 2,500 2,500 Floating rate five-year 2015 senior notes 2020 500 500 4.200 percent ten-year 2010 CIFSA senior notes 2021 600 600 4.125 percent ten-year 2011 senior notes 2021 500 500 3.125 percent ten-year 2012 senior notes 2022 675 675 3.150 percent seven-year 2015 senior notes 2022 2,500 2,500 3.200 percent ten-year 2012 CIFSA senior notes 2023 650 650 2.750 percent ten-year 2013 senior notes 2023 530 530 2.950 percent ten-year 2013 CIFSA senior notes 2024 310 310 3.625 percent ten-year 2014 senior notes 2024 850 850 3.500 percent ten-year 2015 senior notes 2025 4,000 4,000 3.350 percent ten-year 2017 senior notes 2027 850 850 4.375 percent twenty-year 2015 senior notes 2035 2,382 2,382 6.550 percent thirty-year 2008 CIFSA senior notes 2038 374 374 6.500 percent thirty-year 2009 senior notes 2039 300 300 5.550 percent thirty-year 2010 senior notes 2040 500 500 4.500 percent thirty-year 2012 senior notes 2042 400 400 4.000 percent thirty-year 2013 senior notes 2043 325 325 4.625 percent thirty-year 2014 senior notes 2044 650 650 4.625 percent thirty-year 2015 senior notes 2045 4,150 4,150 Interest rate swaps (Note 9) 2021 - 2022 10 40 Capital lease obligations 2019 - 2025 22 23 Bank borrowings 2019 - 2021 165 139 Debt premium, net 2019 - 2045 123 135 Deferred financing costs 2019 - 2045 (114 ) (128 ) Long-term debt $ 25,918 $ 25,921 Senior Notes The Company has outstanding unsecured senior debt obligations, described both as senior notes and current debt obligations in the table above (collectively, the Senior Notes). The Senior Notes rank equally with all other unsecured and unsubordinated indebtedness of the Company. The indentures under which the Senior Notes were issued contain customary covenants, all of which the Company remained in compliance with at January 26, 2018 . For additional information regarding the terms of these agreements, refer to Note 8 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 28, 2017 . Financial Instruments Not Measured at Fair Value At January 26, 2018 , the estimated fair value of the Company’s Senior Notes was $29.3 billion compared to a principal value of $27.7 billion . At April 28, 2017 , the estimated fair value was $30.4 billion compared to a principal value of $28.9 billion . The fair value was estimated using quoted market prices for the publicly registered Senior Notes, which are classified as Level 2 within the fair value hierarchy. The fair values and principal values consider the terms of the related debt and exclude the impacts of debt discounts and hedging activity.

Derivatives and Currency Exchan

Derivatives and Currency Exchange Risk Management	9 Months Ended
	Jan. 26, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives and Currency Exchange Risk Management	Derivatives and Currency Exchange Risk Management The Company uses operational and economic hedges, as well as currency exchange rate derivative contracts and interest rate derivative instruments, to manage the impact of currency exchange and interest rate changes on earnings and cash flows. In addition, the Company uses cross currency interest rate swaps to manage currency risk related to certain debt. In order to minimize earnings and cash flow volatility resulting from currency exchange rate changes, the Company enters into derivative instruments, principally forward currency exchange rate contracts. These contracts are designed to hedge anticipated foreign currency transactions and changes in the value of specific assets and liabilities. At inception of the contract, the derivative is designated as either a freestanding derivative or a cash flow hedge. The cash flows related to all of the Company's derivative instruments are reported as operating activities in the consolidated statement of cash flows. The primary currencies of the derivative instruments are the Euro, Japanese Yen, and British Pound. The Company does not enter into currency exchange rate derivative contracts for speculative purposes. The gross notional amount of all currency exchange rate derivative instruments outstanding was $12.6 billion and $10.8 billion at January 26, 2018 and April 28, 2017 , respectively. The information that follows explains the various types of derivatives and financial instruments used by the Company, reasons the Company uses such instruments, and the impact such instruments have on the Company’s consolidated balance sheets and statements of income. Freestanding Derivative Contracts Freestanding derivative contracts are used to offset the Company’s exposure to the change in value of specific foreign currency denominated assets and liabilities and to offset variability of cash flows associated with forecasted transactions denominated in foreign currencies. These derivatives are not designated as hedges, and therefore, changes in the value of these contracts are recognized in earnings, thereby offsetting the current earnings effect of the related change in value of foreign currency denominated assets, liabilities, and cash flows. The gross notional amount of these contracts outstanding at January 26, 2018 and April 28, 2017 was $5.5 billion and $4.9 billion , respectively. The amounts and classification of the gains (losses) in the consolidated statements of income related to derivative instruments, not designated as hedging instruments, for the three and nine months ended January 26, 2018 and January 27, 2017 were as follows: Three months ended Nine months ended (in millions) Classification January 26, 2018 January 27, 2017 January 26, 2018 January 27, 2017 Currency exchange rate contract (losses) gains Other expense, net $ (181 ) $ 67 $ (318 ) $ 27 Cash Flow Hedges Currency Exchange Rate Risk Forward contracts designated as cash flow hedges are designed to hedge the variability of cash flows associated with forecasted transactions denominated in a foreign currency that will take place in the future. For derivative instruments that are designated and qualify as a cash flow hedge, the effective portion of the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss . The effective portion of the gain or loss on the derivative instrument is reclassified into earnings and is included in other expense, net in the consolidated statements of income in the same period or periods during which the hedged transaction affects earnings. No gains or losses relating to ineffectiveness of cash flow hedges were recognized in earnings during the three and nine months ended January 26, 2018 and January 27, 2017 . No components of the hedge contracts were excluded in the measurement of hedge ineffectiveness and no hedges were derecognized or discontinued during the three and nine months ended January 26, 2018 and January 27, 2017 . The gross notional amount of these contracts, designated as cash flow hedges, outstanding at January 26, 2018 and April 28, 2017 , was $7.0 billion and $5.8 billion , respectively, and will mature within the subsequent three -year period. The amount of gross gains (losses), classification of the gains (losses) in the consolidated statements of income, and the accumulated other comprehensive income (loss) (AOCI) related to the effective portion of currency exchange rate contract derivative instruments designated as cash flow hedges for the three and nine months ended January 26, 2018 and January 27, 2017 were as follows: Three months ended January 26, 2018 Recognized in AOCI Recognized in Income (in millions) Amount Classification Amount Currency exchange rate contracts $ (287 ) Other expense, net $ (11 ) Three months ended January 27, 2017 Recognized in AOCI Recognized in Income (in millions) Amount Classification Amount Currency exchange rate contracts $ 190 Other expense, net $ 68 Nine months ended January 26, 2018 Recognized in AOCI Recognized in Income (in millions) Amount Classification Amount Currency exchange rate contracts $ (507 ) Other expense, net $ 1 Nine months ended January 27, 2017 Recognized in AOCI Recognized in Income (in millions) Amount Classification Amount Currency exchange rate contracts $ 378 Other expense, net $ 89 Forecasted Debt Issuance Interest Rate Risk Forward starting interest rate derivative instruments designated as cash flow hedges are designed to manage the exposure to interest rate volatility with regard to future issuances of fixed-rate debt. The effective portion of the gains or losses on forward starting interest rate derivative instruments that are designated and qualify as cash flow hedges is reported as a component of accumulated other comprehensive loss . Beginning in the period in which the planned debt issuance occurs and the related derivative instruments are terminated, the effective portion of the gains or losses are then reclassified into interest expense, net over the term of the related debt. Any portion of the gains or losses that is determined to be ineffective is immediately recognized in interest expense, net . The Company had $300 million of fixed pay, forward starting interest rate swaps with a weighted average fixed rate of 3.10 percent in anticipation of planned debt issuances. During the fourth quarter of fiscal year 2017 , in connection with the issuance of the 2017 Senior Notes, these swaps were terminated. For the three and nine months ended January 27, 2017 , there were $28 million and $22 million , respectively, of unrealized gains recorded in accumulated other comprehensive loss . No gains or losses relating to ineffectiveness of forward starting interest rate derivative instruments were recognized in interest expense, net during the three and nine months ended January 27, 2017 . No components of the hedge contracts were excluded in the measurement of hedge ineffectiveness during the three and nine months ended January 27, 2017 . For the three and nine months ended January 27, 2017 , there were no reclassifications of the effective portion of net losses on forward starting interest rate derivative instruments from accumulated other comprehensive loss to interest expense, net . At January 26, 2018 and April 28, 2017 , the Company had $(309) million and $37 million , respectively, in after-tax net unrealized (losses) gains associated with cash flow hedging instruments recorded in accumulated other comprehensive loss . The Company expects that $169 million of after-tax net unrealized losses at January 26, 2018 will be recognized in the consolidated statements of income over the next 12 months. Fair Value Hedges Interest rate derivative instruments designated as fair value hedges are designed to manage the exposure to interest rate movements and to reduce borrowing costs by converting fixed-rate debt into floating-rate debt. Under these agreements, the Company agrees to exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. Changes in the fair value of the derivative instruments are recognized in interest expense, net , and are offset by changes in the fair value of the underlying debt instrument. The gains (losses) from terminated interest rate swap agreements are recognized in long-term debt , increasing (decreasing) the outstanding balances of the debt, and amortized as a reduction of (addition to) interest expense, net over the remaining life of the related debt. At both January 26, 2018 and April 28, 2017 , the Company had interest rate swaps in gross notional amounts of $1.2 billion , designated as fair value hedges of underlying fixed-rate senior note obligations, including the Company's $500 million 4.125 percent 2011 Senior Notes due fiscal year 2021 and the $675 million 3.125 percent 2012 Senior Notes due fiscal year 2022 . At January 26, 2018 and April 28, 2017 , the market value of outstanding interest rate swap agreements was an unrealized gain of $10 million and $41 million , respectively, and the market value of the hedged item was an unrealized loss of $10 million and $41 million , respectively. The amounts were recorded in other assets with the offsets recorded in long-term debt on the consolidated balance sheets. No significant hedge ineffectiveness was recognized as a result of these fair value hedges for the three and nine months ended January 26, 2018 and January 27, 2017 . In addition, the Company did no t recognize any gains or losses during the three and nine months ended January 26, 2018 and January 27, 2017 on firm commitments that no longer qualify as fair value hedges. Balance Sheet Presentation The following tables summarize the balance sheet classification and fair value of derivative instruments included in the consolidated balance sheets at January 26, 2018 and April 28, 2017 . The fair value amounts are presented on a gross basis and are segregated between derivatives that are designated and qualify as hedging instruments and those that are not designated and do not qualify as hedging instruments and are further segregated by type of contract within those two categories. January 26, 2018 Derivative Assets Derivative Liabilities (in millions) Balance Sheet Classification Fair Value Balance Sheet Classification Fair Value Derivatives designated as hedging instruments Currency exchange rate contracts Other current assets $ 23 Other accrued expenses $ 249 Interest rate contracts Other assets 15 Other liabilities 5 Currency exchange rate contracts Other assets 8 Other liabilities 113 Total derivatives designated as hedging instruments $ 46 $ 367 Derivatives not designated as hedging instruments Currency exchange rate contracts Other current assets $ 52 Other accrued expenses $ 73 Total return swap Other current assets 22 Other accrued expenses — Stock warrants Other assets 29 Other liabilities — Cross currency interest rate contracts Other assets 6 Other liabilities 8 Total derivatives not designated as hedging instruments $ 109 $ 81 Total derivatives $ 155 $ 448 April 28, 2017 Derivative Assets Derivative Liabilities (in millions) Balance Sheet Classification Fair Value Balance Sheet Classification Fair Value Derivatives designated as hedging instruments Currency exchange rate contracts Other current assets $ 152 Other accrued expenses $ 43 Interest rate contracts Other assets 41 Other liabilities — Currency exchange rate contracts Other assets 48 Other liabilities 14 Total derivatives designated as hedging instruments $ 241 $ 57 Derivatives not designated as hedging instruments Currency exchange rate contracts Other current assets 16 Other accrued expenses 36 Cross currency interest rate contracts Other assets 5 Other liabilities 11 Total derivatives not designated as hedging instruments $ 21 $ 47 Total derivatives $ 262 $ 104 The following table provides information by level for the derivative assets and liabilities that are measured at fair value on a recurring basis. January 26, 2018 April 28, 2017 (in millions) Level 1 Level 2 Level 1 Level 2 Derivative assets $ 83 $ 72 $ 216 $ 46 Derivative liabilities 435 13 93 11 The Company has elected to present the fair value of derivative assets and liabilities within the consolidated balance sheets on a gross basis, even when derivative transactions are subject to master netting arrangements and may otherwise qualify for net presentation. The following table provides information as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria as stipulated by the terms of the master netting arrangements with each of the counterparties. Derivatives not subject to master netting arrangements are not eligible for net presentation. January 26, 2018 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recorded Assets (Liabilities) Financial Instruments Collateral (Received) Posted Net Amount Derivative assets: Currency exchange rate contracts $ 83 $ (56 ) $ — $ 27 Interest rate contracts 15 (12 ) — 3 Cross currency interest rate contracts 6 (2 ) — 4 Stock warrants 29 — — 29 Total return swap 22 — — 22 $ 155 $ (70 ) $ — $ 85 Derivative liabilities: Currency exchange rate contracts $ (435 ) $ 66 $ 98 $ (271 ) Interest rate contracts (5 ) 2 1 (2 ) Cross currency interest rate contracts (8 ) 2 — (6 ) $ (448 ) $ 70 $ 99 $ (279 ) Total $ (293 ) $ — $ 99 $ (194 ) April 28, 2017 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recorded Assets (Liabilities) Financial Instruments Collateral (Received) Posted Net Amount Derivative assets: Currency exchange rate contracts $ 216 $ (58 ) $ (55 ) $ 103 Interest rate contracts 41 (15 ) (5 ) 21 Cross currency interest rate contracts 5 (2 ) — 3 $ 262 $ (75 ) $ (60 ) $ 127 Derivative liabilities: Currency exchange rate contracts $ (93 ) $ 73 $ — $ (20 ) Cross currency interest rate contracts (11 ) 2 — (9 ) $ (104 ) $ 75 $ — $ (29 ) Total $ 158 $ — $ (60 ) $ 98

Inventories

Inventories	9 Months Ended
	Jan. 26, 2018
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories are stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. The Company reduces the carrying value of inventories for items that are potentially excess, obsolete or slow-moving based on changes in customer demand, technology developments, or other economic factors. Inventory balances, net of reserves, were as follows: (in millions) January 26, 2018 April 28, 2017 Finished goods $ 2,472 $ 2,211 Work in-process 523 458 Raw materials 756 669 Total $ 3,751 $ 3,338

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	9 Months Ended
	Jan. 26, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets	Goodwill and Other Intangible Assets Goodwill The following table presents the changes in the carrying amount of goodwill by reportable segment: (in millions) Cardiac and Vascular Group Minimally Invasive Therapies Group Restorative Therapies Group Diabetes Group Total April 28, 2017 $ 6,651 $ 20,411 $ 9,600 $ 1,853 $ 38,515 Goodwill as a result of acquisitions — 11 9 7 27 Purchase accounting adjustments 54 — — — 54 Currency translation 110 959 130 — 1,199 January 26, 2018 $ 6,815 $ 21,381 $ 9,739 $ 1,860 $ 39,795 The Company assesses goodwill for impairment annually in the third quarter of the fiscal year and whenever an event occurs or circumstances change that would indicate that the carrying amount may be impaired. Impairment testing for goodwill is performed at the reporting unit level. The test for impairment of goodwill requires the Company to make several estimates about fair value, most of which are based on projected future cash flows. The Company calculates the excess of each reporting unit's fair value over its carrying amount, including goodwill, utilizing a discounted cash flow analysis. The Company did no t recognize any goodwill impairment during the three or nine months ended January 26, 2018 or January 27, 2017 . Intangible Assets The following table presents the gross carrying amount and accumulated amortization of intangible assets: January 26, 2018 April 28, 2017 (in millions) Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Definite-lived: Customer-related $ 16,989 $ (2,901 ) $ 16,862 $ (2,166 ) Purchased technology and patents 11,548 (4,248 ) 11,461 (3,690 ) Trademarks and tradenames 822 (562 ) 772 (461 ) Other 84 (48 ) 77 (42 ) Total $ 29,443 $ (7,759 ) $ 29,172 $ (6,359 ) Indefinite-lived: IPR&D $ 494 $ 594 The Company assesses definite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an intangible asset (asset group) may not be recoverable. When events or changes in circumstances indicate that the carrying amount of an intangible asset may not be recoverable, the Company calculates the excess of an intangible asset's carrying value over its undiscounted future cash flows. If the carrying value is not recoverable, an impairment loss is recognized based on the amount by which the carrying value exceeds the fair value. The inputs used in the fair value analysis fall within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs to determine fair value. The Company did no t recognize any definite-lived intangible asset impairments during the three or nine months ended January 26, 2018 or January 27, 2017 . The Company assesses indefinite-lived intangibles for impairment annually in the third quarter of the fiscal year and whenever an event occurs or circumstances change that would indicate that the carrying amount may be impaired. During the three and nine months ended January 26, 2018 , the Company recognized impairment losses on indefinite-lived intangibles of $63 million and $68 million , respectively, which were recognized within other expense, net in the consolidated statements of income. During the three months ended January 26, 2018 , impairment losses of $63 million were recognized as a result of the discontinuation of certain IPR&D projects within the Restorative Therapies Group segment. The Company did no t recognize any significant indefinite-lived intangibles impairments during the three or nine months ended January 27, 2017 . Due to the nature of IPR&D projects, the Company may experience future delays or failures to obtain regulatory approvals to conduct clinical trials, failures of such clinical trials, delays or failures to obtain required market clearances, other failures to achieve a commercially viable product, or the discontinuation a certain projects, and as a result, may recognize impairment losses in the future. Amortization Expense Intangible asset amortization expense for the three and nine months ended January 26, 2018 was $461 million and $1.4 billion , respectively, as compared to $ 497 million and $1.5 billion for the three and nine months ended January 27, 2017 , respectively. Estimated aggregate amortization expense by fiscal year based on the carrying value of definite-lived intangible assets at January 26, 2018 , excluding any possible future amortization associated with acquired IPR&D which has not yet met technological feasibility, is as follows: (in millions) Amortization Expense Remaining 2018 $ 433 2019 1,684 2020 1,631 2021 1,611 2022 1,572 2023 1,494

Income Taxes

Income Taxes	9 Months Ended
	Jan. 26, 2018
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company’s effective tax rates for the three and nine months ended January 26, 2018 were 235.5 percent and 58.7 percent , respectively, as compared to 15.2 percent and 9.7 percent for the three and nine months ended January 27, 2017 , respectively. The increase in the effective tax rate for the three and nine months ended January 26, 2018 was primarily due to the impacts from U.S. Tax Reform. On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the "Tax Act"), which significantly revises U.S. corporate income taxation by, among other things, lowering the U.S. corporate income tax rate from 35.0 percent to 21.0 percent effective January 1, 2018, broadening the base of taxation, implementing a territorial tax system, and imposing a repatriation tax on deemed repatriated earnings of foreign subsidiaries. U.S. GAAP requires that the impact of tax legislation be recognized in the period in which the law was enacted. The decrease in the U.S. federal corporate tax rate from 35.0 percent to 21.0 percent results in a blended statutory tax rate of 30.5 percent for the fiscal year ending April 27, 2018 . In December 2017, the Securities and Exchange Commission issued Staff Accounting Bulletin 118, which allows a measurement period, not to exceed one year, to finalize the accounting for the income tax impacts of the Tax Act. Until the accounting for the income tax impacts of the Tax Act is complete, the reported amounts are based on reasonable estimates and are disclosed as provisional. As of January 26, 2018 , the Company had not fully completed its accounting for the tax effects of the enactment of the Tax Act. The Company’s provision for income taxes for the three and nine months ended January 26, 2018 is based on a reasonable estimate of the transition tax and expected reversal of existing deferred tax balances. As a result of the Tax Act, the Company has removed its permanently reinvested assertion on historical earnings for legal entities with accumulated earnings subject to the transition tax. The Company continues to evaluate its permanently reinvested assertion for certain legal entities. For the amounts which the Company was able to reasonably estimate, the Company recognized a provisional net tax charge of $2.2 billion within income tax provision in the consolidated statements of income. The components of the provisional tax amounts are as follows: • The Company recognized a provisional tax charge of $2.4 billion for the transition tax liability. The Company has not yet completed the calculation of the total post-1986 foreign earnings & profits (E&P) and the income tax pools for all foreign subsidiaries. Further, the transition tax is based in part on the amount of those earnings held in cash and other specified assets. This amount may change when the Company finalizes the calculation of post-1986 foreign E&P previously deferred from U.S. federal taxation and finalizes the amounts held in cash or other specified assets. In addition, further interpretations from U.S. federal and state governments and regulatory organizations may change the provisional tax liability or the accounting treatment of the provisional tax liability. • The Company recognized a provisional net tax benefit of $155 million to remeasure certain deferred tax assets, liabilities, and valuation allowances as a result of the enactment of the Tax Act. The Company is still analyzing certain aspects of the Tax Act and refining the estimate of the expected reversal of its deferred tax balances. This can potentially affect the measurement of these balances or potentially give rise to new deferred tax amounts. Because of the complexity of the new Global Intangible Low-Taxed Income (GILTI) tax rules, the Company continues to evaluate this provision of the Tax Act. The Company is allowed to make an accounting policy election of either (1) treating taxes due on future U.S. inclusions in taxable income related to GILTI as a current period expense when incurred (the “period cost method”) or (2) factoring such amounts into the Company's measurement of its deferred taxes (the “deferred method”). The Company's selection of an accounting policy with respect to the new GILTI tax rules will depend, in part, on analyzing its global income to determine whether it can reasonably estimate the tax impact. The Company is currently in the process of analyzing its structure and is not yet able to determine the effect of this provision of the Tax Act. Therefore, the Company has not yet made a policy decision regarding whether to record deferred tax on GILTI and has not made any adjustments related to potential GILTI tax in its consolidated financial statements. During the nine months ended January 26, 2018 , the Company recognized a $1.9 billion net tax charge comprised of a $2.2 billion net tax cost associated with U.S. tax reform, a $398 million net tax benefit associated with the intercompany sales of certain intellectual property and a $37 million net tax charge primarily associated with the sale of the Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses. These net charges were recorded within income tax provision in the consolidated statement of income for the nine months ended January 26, 2018 . During the three months ended January 27, 2017 , the Company recognized a charge of $86 million associated with the IRS’s disallowance of the utilization of certain net operating losses, and the recording of a valuation allowance against the net operating loss deferred tax asset. During the nine months ended January 27, 2017 , the Company also recognized a $371 million charge associated with the expected resolution with the IRS for the Ardian, CoreValve, Inc. and Ablation Frontiers, Inc. acquisition-related issues and the allocation of income between Medtronic, Inc. and its wholly owned subsidiary operating in Puerto Rico for certain businesses. This resolution does not include the businesses that are the subject of the Medtronic, Inc. U.S. Tax Court case for fiscal years 2005 and 2006. The Company also recognized a $29 million charge in connection with the redemption of an intercompany minority interest. These charges were partially offset by a $431 million tax benefit recognized as the result of the resolution of Covidien's previously disclosed Tyco International plc intercompany debt issues with the U.S. Tax Court and the Appeals Division of the IRS. These net charges were recorded within income tax provision in the consolidated statement of income for the nine months ended January 27, 2017 . During the nine months ended January 26, 2018 , the Company's gross unrecognized tax benefits decreased from $1.9 billion to $1.8 billion . In addition, accrued gross interest and penalties were $420 million at January 26, 2018 . If all of the Company’s unrecognized tax benefits were recognized, approximately $1.7 billion would impact the Company’s effective tax rate. At January 26, 2018 , the Company had $15 million of gross unrecognized tax benefits recorded as a current liability within accrued income taxes with the balance recorded as a noncurrent liability within accrued income taxes on the consolidated balance sheet. At April 28, 2017 , the total balance of the Company's gross unrecognized tax benefits was recorded as a noncurrent liability within accrued income taxes on the consolidated balance sheet. The Company recognizes interest and penalties related to income tax matters within income tax provision in the consolidated statements of income and records the liability within either current or noncurrent accrued income taxes on the consolidated balance sheet. See Note 17 to the consolidated financial statements for additional information regarding the status of current tax audits and proceedings.

Earnings Per Share

Earnings Per Share	9 Months Ended
	Jan. 26, 2018
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share Earnings per share is calculated using the two-class method, as the Company's A Preferred Shares are considered participating securities. Accordingly, earnings are allocated to both ordinary shares and participating securities in determining earnings per ordinary share. Due to the limited number of A Preferred Shares outstanding, this allocation had no effect on ordinary earnings per share; therefore, it is not presented below. Basic earnings per share is computed based on the weighted average number of ordinary shares outstanding. Diluted earnings per share is computed based on the weighted average number of ordinary shares outstanding, increased by the number of additional shares that would have been outstanding had the potentially dilutive ordinary shares been issued, and reduced by the number of shares the Company could have repurchased with the proceeds from issuance of the potentially dilutive shares. Potentially dilutive ordinary shares include stock-based awards granted under stock-based compensation plans and shares committed to be purchased under the employee stock purchase plan. The table below sets forth the computation of basic and diluted earnings (loss) per share: Three months ended Nine months ended (in millions, except per share data) January 26, 2018 January 27, 2017 January 26, 2018 January 27, 2017 Numerator: Net (loss) income attributable to ordinary shareholders $ (1,389 ) $ 821 $ 1,644 $ 2,865 Denominator: Basic – weighted average shares outstanding 1,354.0 1,372.2 1,357.2 1,381.9 Effect of dilutive securities: Employee stock options — 7.9 8.1 9.2 Employee restricted stock units — 3.0 3.4 3.4 Other — — 0.2 0.2 Diluted – weighted average shares outstanding 1,354.0 1,383.1 1,368.9 1,394.7 Basic (loss) earnings per share $ (1.03 ) $ 0.60 $ 1.21 $ 2.07 Diluted (loss) earnings per share $ (1.03 ) $ 0.59 $ 1.20 $ 2.05 As a result of the net loss for the three months ended January 26, 2018 , the Company excluded 10.5 million potentially dilutive common shares from the diluted loss per share calculation. The calculation of weighted average diluted shares outstanding excludes options to purchase approximately 10 million and 9 million ordinary shares for the three and nine months ended January 26, 2018 , respectively, and 10 million and 6 million ordinary shares for the three and nine months ended January 27, 2017 , respectively, because the effect would have been anti-dilutive on the Company’s earnings per share.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Jan. 26, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	Stock-Based Compensation The following table presents the components and classification of stock-based compensation expense for stock options, restricted stock, and employee stock purchase plan shares recognized for the three and nine months ended January 26, 2018 and January 27, 2017 : Three months ended Nine months ended (in millions) January 26, 2018 January 27, 2017 January 26, 2018 January 27, 2017 Stock options $ 28 $ 37 $ 105 $ 128 Restricted stock 38 40 145 128 Employee stock purchase plan 6 5 20 16 Total stock-based compensation expense $ 72 $ 82 $ 270 $ 272 Cost of products sold $ 10 $ 12 $ 34 $ 38 Research and development expense 8 10 29 32 Selling, general, and administrative expense 53 55 187 179 Restructuring charges, net — — — 2 Acquisition-related items 1 5 4 21 Divestiture-related items — — 16 — Total stock-based compensation expense 72 82 270 272 Income tax benefits (12 ) (23 ) (69 ) (77 ) Total stock-based compensation expense, net of tax $ 60 $ 59 $ 201 $ 195

Retirement Benefit Plans

Retirement Benefit Plans	9 Months Ended
	Jan. 26, 2018
Retirement Benefits [Abstract]
Retirement Benefit Plans	Retirement Benefit Plans The Company sponsors various retirement benefit plans, including defined benefit pension plans, post-retirement medical plans, defined contribution savings plans, and termination indemnity plans, covering substantially all U.S. employees and many employees outside the U.S. The net periodic benefit cost of the defined benefit pension plans included the following components for the three and nine months ended January 26, 2018 and January 27, 2017 : U.S. Non-U.S. Three months ended Three months ended (in millions) January 26, 2018 January 27, 2017 January 26, 2018 January 27, 2017 Service cost $ 29 $ 29 $ 17 $ 19 Interest cost 29 27 7 6 Expected return on plan assets (51 ) (47 ) (13 ) (12 ) Amortization of net actuarial loss 20 23 4 4 Plan settlement 15 — — — Net periodic benefit cost $ 42 $ 32 $ 15 $ 17 U.S. Non-U.S. Nine months ended Nine months ended (in millions) January 26, 2018 January 27, 2017 January 26, 2018 January 27, 2017 Service cost $ 87 $ 87 $ 51 $ 57 Interest cost 89 81 21 18 Expected return on plan assets (155 ) (141 ) (39 ) (36 ) Amortization of net actuarial loss 60 69 12 12 Plan settlement 15 — — — Net periodic benefit cost $ 96 $ 96 $ 45 $ 51

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income and Supplemental Equity Disclosure	9 Months Ended
	Jan. 26, 2018
Equity [Abstract]
Accumulated Other Comprehensive Income and Supplemental Equity Disclosure	Accumulated Other Comprehensive Income and Supplemental Equity Disclosure The following table provides changes in AOCI, net of tax, and by component. (in millions) Unrealized (Loss) Gain on Available-for-Sale Securities Cumulative Translation Adjustment Net Change in Retirement Obligations Unrealized (Loss) Gain on Derivative Financial Instruments Total Accumulated Other Comprehensive (Loss) Income April 28, 2017 $ (69 ) $ (1,452 ) $ (1,129 ) $ 37 $ (2,613 ) Other comprehensive income (loss) before reclassifications 50 1,559 (38 ) (351 ) 1,220 Reclassifications (9 ) (34 ) 49 5 11 Other comprehensive income (loss) 41 1,525 11 (346 ) 1,231 January 26, 2018 $ (28 ) $ 73 $ (1,118 ) $ (309 ) $ (1,382 ) (in millions) Unrealized (Loss) Gain on Available-for-Sale Securities Cumulative Translation Adjustment Net Change in Retirement Obligations Unrealized (Loss) Gain on Derivative Financial Instruments Total Accumulated Other Comprehensive (Loss) Income April 29, 2016 $ (107 ) $ (474 ) $ (1,197 ) $ (90 ) $ (1,868 ) Other comprehensive income (loss) before reclassifications (25 ) (1,239 ) — 255 (1,009 ) Reclassifications (15 ) — 66 (53 ) (2 ) Other comprehensive income (loss) (40 ) (1,239 ) 66 202 (1,011 ) January 27, 2017 $ (147 ) $ (1,713 ) $ (1,131 ) $ 112 $ (2,879 ) The income tax on gains and losses on available-for-sale securities in other comprehensive income before reclassifications during the nine months ended January 26, 2018 and January 27, 2017 was an expense of $33 million and $5 million , respectively. During the nine months ended January 26, 2018 and January 27, 2017 , realized gains and losses on available-for-sale securities reclassified from AOCI were reduced by income taxes of $4 million and $8 million , respectively. When realized, gains and losses on available-for-sale securities reclassified from AOCI are recognized within other expense, net . Refer to Note 7 to the consolidated financial statements for additional information. For the nine months ended January 26, 2018 , there was no tax impact on cumulative translation adjustments. However, due to recently enacted U.S. Tax Reform and change in permanently reinvested assertion with respect to certain earnings, the Company continues to evaluate the tax impact these events may have on cumulative translation adjustments. For the nine months ended January 27, 2017 , taxes were no t provided on cumulative translation adjustments as substantially all translation adjustments relate to earnings that were intended to be indefinitely reinvested outside the U.S. The net change in retirement obligations in other comprehensive income includes net amortization of actuarial losses included in net periodic benefit cost. The income tax on the net change in retirement obligations in other comprehensive income before reclassifications during the nine months ended January 26, 2018 was a benefit of $6 million . During the nine months ended January 27, 2017 , there was no income tax impact on the net change in retirement obligations in other comprehensive income before reclassifications. During the nine months ended January 26, 2018 and January 27, 2017 , the gains and losses on defined benefit and pension items reclassified from AOCI were reduced by income taxes of $21 million and $15 million , respectively. Refer to Note 15 to the consolidated financial statements for additional information. The income tax on unrealized gains and losses on derivative financial instruments in other comprehensive income before reclassifications during the nine months ended January 26, 2018 and January 27, 2017 was a benefit of $156 million and an expense of $145 million , respectively. During the nine months ended January 26, 2018 , there was no income tax impact on the gains and losses on derivative financial instruments reclassified from AOCI. During the nine months ended January 27, 2017 , gains and losses on derivative financial instruments reclassified from AOCI were reduced by income taxes of $32 million . When realized, cash flow hedge gains and losses reclassified from AOCI are recognized within other expense, net, and forward starting interest rate derivative financial instrument gains and losses reclassified from AOCI are recognized within interest expense, net . Refer to Note 9 to the consolidated financial statements for additional information. The supplemental equity schedule below presents changes in the Company's total shareholders' equity and noncontrolling interests for the nine months ended January 26, 2018 and January 27, 2017 . (in millions) Total Shareholders' Equity Noncontrolling Interests Total Equity April 28, 2017 $ 50,294 $ 122 $ 50,416 Net income (loss) 1,644 (14 ) 1,630 Other comprehensive income 1,231 — 1,231 Dividends to shareholders (1,870 ) — (1,870 ) Issuance of shares under stock purchase and award plans 266 — 266 Repurchase of ordinary shares (1,897 ) — (1,897 ) Stock-based compensation 270 — 270 Cumulative effect of change in accounting principle 296 — 296 Additions (reductions) of noncontrolling ownership interests — (2 ) (2 ) January 26, 2018 $ 50,234 $ 106 $ 50,340 (in millions) Total Shareholders' Equity Noncontrolling Interests Total Equity April 29, 2016 $ 52,063 $ — $ 52,063 Net income (loss) 2,865 (5 ) 2,860 Other comprehensive loss (1,011 ) — (1,011 ) Dividends to shareholders (1,782 ) — (1,782 ) Issuance of shares under stock purchase and award plans 309 — 309 Repurchase of ordinary shares (3,409 ) — (3,409 ) Tax benefit from exercise of stock-based awards 80 — 80 Stock-based compensation 272 — 272 Additions (reductions) of noncontrolling ownership interests — 111 111 January 27, 2017 $ 49,387 $ 106 $ 49,493

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Jan. 26, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Legal Matters The Company and its affiliates are involved in a number of legal actions involving product liability, intellectual property and commercial disputes, shareholder related matters, environmental proceedings, income tax disputes, and governmental proceedings and investigations, including those described below. With respect to governmental proceedings and investigations, like other companies in our industry, the Company is subject to extensive regulation by national, state and local governmental agencies in the United States and in other jurisdictions in which the Company and its affiliates operate. As a result, interaction with governmental agencies is ongoing. The Company’s standard practice is to cooperate with regulators and investigators in responding to inquiries. The outcomes of legal actions are not within the Company’s complete control and may not be known for prolonged periods of time. In some actions, the enforcement agencies or private claimants seek damages, as well as other civil or criminal remedies (including injunctions barring the sale of products that are the subject of the proceeding), that could require significant expenditures, result in lost revenues, or limit the Company's ability to conduct business in the applicable jurisdictions. The Company records a liability in the consolidated financial statements on an undiscounted basis for loss contingencies related to legal actions when a loss is known or considered probable and the amount may be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of loss is disclosed. When determining the estimated loss or range of loss, significant judgment is required. Estimates of probable losses resulting from litigation and governmental proceedings involving the Company are inherently difficult to predict, particularly when the matters are in early procedural stages, with incomplete scientific facts or legal discovery, involve unsubstantiated or indeterminate claims for damages, potentially involve penalties, fines or punitive damages, or could result in a change in business practice. At January 26, 2018 and April 28, 2017 , accrued litigation was approximately $1.0 billion and $1.1 billion , respectively. The ultimate cost to the Company with respect to accrued litigation could be materially different than the amount of the current estimates and accruals and could have a material adverse impact on the Company’s consolidated earnings, financial position, and/or cash flows. The Company includes accrued litigation in other accrued expenses and other liabilities on the consolidated balance sheets. While it is not possible to predict the outcome for most of the legal matters discussed below, the Company believes it is possible that the costs associated with these matters could have a material adverse impact on the Company’s consolidated earnings, financial position, and/or cash flows. Product Liability Matters Sprint Fidelis In 2007, a putative class action was filed in the Ontario Superior Court of Justice in Canada seeking damages for personal injuries allegedly related to the Company's Sprint Fidelis family of defibrillation leads. On October 20, 2009, the court certified a class proceeding but denied class certification on plaintiffs' claim for punitive damages. Pretrial proceedings are underway. The Company has recognized an expense for probable and estimable damages related to this matter, and accrued expenses for this matter are included within accrued litigation as discussed above. INFUSE Litigation The Company estimated law firms representing approximately 6,000 claimants asserted or intended to assert personal injury claims against Medtronic in the U.S. state and federal courts involving the INFUSE bone graft product. As of June 1, 2017, the Company had reached agreements to settle substantially all of these claims, resolving this litigation. The Company's accrued expenses for this matter are included within accrued litigation as discussed above. Pelvic Mesh Litigation The Company, through the acquisition of Covidien, is currently involved in litigation in various state and federal courts against manufacturers of pelvic mesh products alleging personal injuries resulting from the implantation of those products. Two subsidiaries of Covidien supplied pelvic mesh products to one of the manufacturers, C.R. Bard (Bard), named in the litigation. The litigation includes a federal multi-district litigation in the U.S. District Court for the Northern District of West Virginia and cases in various state courts and jurisdictions outside the U.S. Generally, complaints allege design and manufacturing claims, failure to warn, breach of warranty, fraud, violations of state consumer protection laws and loss of consortium claims. In fiscal year 2016, Bard paid the Company $121 million towards the settlement of 11,000 of these claims. In May 2017, the agreement with Bard was amended to extend the terms to apply to up to an additional 5,000 claims. That agreement does not resolve the dispute between the Company and Bard with respect to claims that do not settle, if any. As part of the agreement, the Company and Bard agreed to dismiss without prejudice their pending litigation with respect to Bard’s obligation to defend and indemnify the Company. The Company estimates law firms representing approximately 15,800 claimants have asserted or may assert claims involving products manufactured by Covidien’s subsidiaries. As of March 1, 2018, the Company had reached agreements to settle approximately 13,400 of these claims. The Company's accrued expenses for this matter are included within accrued litigation as discussed above. Patent Litigation Ethicon On December 14, 2011, Ethicon filed an action against Covidien in the U.S. District Court for the Southern District of Ohio, alleging patent infringement and seeking monetary damages and injunctive relief. On January 22, 2014, the district court entered summary judgment in Covidien's favor, and the majority of this ruling was affirmed by the Federal Circuit on August 7, 2015. Following appeal, the case was remanded back to the District Court with respect to one patent. On January 21, 2016, Covidien filed a second action in the U.S. District Court for the Southern District of Ohio, seeking a declaration of non-infringement with respect to a second set of patents held by Ethicon. The court consolidated this second action with the remaining patent issues from the first action. Following consolidation of the cases, Ethicon dismissed six of the asserted patents, leaving a single asserted patent. In addition to claims of non-infringement, the Company asserts an affirmative defense of invalidity. The Company has not recognized an expense related to damages in connection with this matter, because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from this matter. Shareholder Related Matters INFUSE On March 12, 2012, Charlotte Kokocinski (Kokocinski) filed a shareholder derivative action against both Medtronic, Inc. and certain of its current and former officers and directors in the U.S. District Court for the District of Minnesota, setting forth certain allegations, including a claim that defendants violated various purported duties in connection with the INFUSE bone graft product and otherwise. On March 25, 2013, the District Court dismissed the case without prejudice, and Kokocinski subsequently filed an amended complaint. On March 30, 2015, the District Court granted defendants’ motion to dismiss the amended complaint, dismissing the case with prejudice. Kokocinski sought reconsideration of that decision, and, on September 30, 2015, the District Court denied Kokocinski’s request for reconsideration. Kokocinski appealed the District Court’s decision to the U.S. Court of Appeals for the Eighth Circuit. On March 1, 2017, the Eighth Circuit Court of Appeals affirmed the lower Court’s dismissal of the case with prejudice, and on April 11, 2017, the Eighth Circuit rejected Kokocinski’s request for reconsideration. In September 2017, Kokocinski filed a petition for certiorari requesting review of the Eighth Circuit decision by the United States Supreme Court. On January 18, 2018, the United States Supreme Court denied Kokocinski’s petition for certiorari, allowing the lower court’s dismissal of the case with prejudice to stand and bringing this matter to a conclusion. West Virginia Pipe Trades and Phil Pace, on June 27, 2013 and July 3, 2013, respectively, filed putative class action complaints against Medtronic, Inc. and certain of its officers in the U.S. District Court for the District of Minnesota, alleging that the defendants made false and misleading public statements and engaged in a scheme to defraud regarding the INFUSE Bone Graft product during the period of December 8, 2010 through August 3, 2011. The matters were consolidated in September 2013, and in the consolidated complaint plaintiffs alleged a class period of September 28, 2010 through August 3, 2011. On September 30, 2015, the District Court granted defendants’ motion for summary judgment in the consolidated matters. Plaintiffs appealed the dismissal to the U.S. Court of Appeals for the Eighth Circuit, and in December of 2016 the Eighth Circuit Court reversed and remanded the case to the District Court for further proceedings. On January 30, 2018, the District Court issued an order certifying a class for the period of September 8, 2010 through June 28, 2011. The Company has not recognized an expense related to damages in connection with this matter, because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from these matters. COVIDIEN ACQUISITION On July 2, 2014, Lewis Merenstein filed a putative shareholder class action in Hennepin County, Minnesota, District Court seeking to enjoin the then-potential acquisition of Covidien. The lawsuit named Medtronic, Inc., Covidien, and each member of the Medtronic, Inc. Board of Directors at the time as defendants, and alleged that the directors breached their fiduciary duties to shareholders with regard to the then-potential acquisition. On August 21, 2014, Kenneth Steiner filed a putative shareholder class action in Hennepin County, Minnesota, District Court, also seeking an injunction to prevent the potential Covidien acquisition. In September 2014, the Merenstein and Steiner matters were consolidated and in December 2014, the plaintiffs filed a preliminary injunction motion seeking to enjoin the Covidien transaction. On December 30, 2014, a hearing was held on plaintiffs’ motion for preliminary injunction and on defendants’ motion to dismiss. On January 2, 2015, the District Court denied the plaintiffs’ motion for preliminary injunction and on January 5, 2015 issued its opinion. On March 20, 2015, the District Court issued its order and opinion granting Medtronic’s motion to dismiss the case. In May of 2015, the plaintiffs filed an appeal, and, in January of 2016, the Minnesota State Court of Appeals affirmed in part, reversed in part, and remanded the case to the District Court for further proceedings. In February of 2016, the Company petitioned the Minnesota Supreme Court to review the decision of the Minnesota State Court of Appeals, and on April 19, 2016 the Minnesota Supreme Court granted the Company’s petition on the issue of whether most of the original claims are properly characterized as direct or derivative under Minnesota law. In August of 2017, the Minnesota Supreme Court affirmed the decision of the Minnesota State Court of Appeals, sending the matter back to the trial court for further proceedings. The Company has not recognized an expense related to damages in connection with this matter, because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from these matters. HEARTWARE On January 22, 2016, the St. Paul Teachers’ Retirement Fund Association filed a putative class action complaint (the “Complaint”) in the United States District Court for the Southern District of New York against HeartWare on behalf of all persons and entities who purchased or otherwise acquired shares of HeartWare from June 10, 2014 through January 11, 2016 (the “Class Period”). The Complaint was amended on June 29, 2016 and claims HeartWare and one of its executives violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 by making false and misleading statements about, among other things, HeartWare’s response to a June 2014 U.S. FDA warning letter, the development of the Miniaturized Ventricular Assist Device (MVAD) System and the proposed acquisition of Valtech Cardio Ltd. The Complaint seeks to recover damages on behalf of all purchasers or acquirers of HeartWare’s stock during the Class Period. In August of 2016 the Company acquired HeartWare. The Company's accrued expenses for this matter are included within accrued litigation as discussed above. Environmental Proceedings The Company, through the acquisition of Covidien, is involved in various stages of investigation and cleanup related to environmental remediation matters at a number of sites. These projects relate to a variety of activities, including removal of solvents, metals and other hazardous substances from soil and groundwater. The ultimate cost of site cleanup and timing of future cash flows is difficult to predict given uncertainties regarding the extent of the required cleanup, the interpretation of applicable laws and regulations, and alternative cleanup methods. The Company is a successor to a company which owned and operated a chemical manufacturing facility in Orrington, Maine from 1967 until 1982, and is responsible for the costs of completing an environmental site investigation as required by the Maine Department of Environmental Protection (MDEP). MDEP served a compliance order on Mallinckrodt LLC and U.S. Surgical Corporation, subsidiaries of Covidien, in December 2008, which included a directive to remove a significant volume of soils at the site. After a hearing on the compliance order before the Maine Board of Environmental Protection (Maine Board) to challenge the terms of the compliance order, the Maine Board modified the MDEP order and issued a final order requiring removal of two landfills, capping of the remaining three landfills, installation of a groundwater extraction system and long-term monitoring of the site and the three remaining landfills. The Company has proceeded with implementation of the investigation and remediation at the site in accordance with the MDEP order as modified by the Maine Board order. The Company has also been involved in a lawsuit filed in the U.S. District Court for the District of Maine by the Natural Resources Defense Council and the Maine People’s Alliance. Plaintiffs sought an injunction requiring Covidien to conduct extensive studies of mercury contamination of the Penobscot River and Bay and options for remediating such contamination, and to perform appropriate remedial activities, if necessary. On July 29, 2002, following a March 2002 trial, the District Court entered an opinion and order which held that conditions in the Penobscot River and Bay may pose an imminent and substantial endangerment and that Covidien was liable for the cost of performing a study of the river and bay. The District Court subsequently appointed an independent study panel to oversee the study and ordered Covidien to pay costs associated with the study. A report issued by the study panel contains recommendations for a variety of potential remedial options which could be implemented individually or in a variety of combinations, and included preliminary cost estimates for a variety of potential remedial options, which the report describes as “very rough estimates of cost,” ranging from $25 million to $235 million . The report indicates that these costs are subject to uncertainties, and that before any remedial option is implemented, further engineering studies and engineering design work are necessary to determine the feasibility of the proposed remedial options. In June of 2014, a trial was held to determine if remediation was necessary and feasible, and on September 2, 2015, the District Court issued an order concluding that further engineering study and engineering design work is appropriate to determine the nature and extent of remediation in the Penobscot River and Bay. In January of 2016, the Court appointed an engineering firm to conduct the next phase of the study. The study is targeted for completion in calendar year 2018. The Company's accrued expenses for environmental proceedings are included within accrued litigation as discussed above. Government Matters Medtronic received subpoenas or document requests from the Attorneys General in Massachusetts, California, Oregon, Illinois, and Washington seeking information regarding sales, marketing, clinical, and other information relating to the INFUSE bone graft product. In December 2017, Medtronic and the states reached agreement to resolve these matters. Medtronic admitted no wrongdoing in connection with the agreement. Since 2011, the Company has responded to requests from the U.S. Department of Justice for information about business practices relating to several neurovascular products. The requests seek information dating back to 2010, in connection with neurovascular products developed and first marketed by Covidien or one of its predecessors, including ev3. The Company has fully cooperated and continues to cooperate with the requests, which are at various stages. The Company’s accrued expenses for the matters are included within accrued litigation as discussed above. Since 2014, the Company has responded to requests from the U.S. Department of Health and Human Services and the U.S. Department of Justice for information about business practices relating to several peripheral vascular products. The requests seek information dating back to 2009, in connection with peripheral vascular products developed and first marketed by Covidien or one of its predecessors, including ev3. The Company has fully cooperated and continues to cooperate with the requests, which are at various stages. The Company has not recognized an expense related to damages in connection with this matter because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from this matter. Income Taxes In March 2009, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2005 and 2006. Medtronic, Inc. reached agreement with the IRS on some, but not all matters related to these fiscal years. On December 23, 2010, the IRS issued a statutory notice of deficiency with respect to the remaining issues. Medtronic, Inc. filed a petition with the U.S. Tax Court on March 21, 2011 objecting to the deficiency. During October and November 2012, Medtronic, Inc. reached resolution with the IRS on various matters, including the deductibility of a settlement payment. Medtronic, Inc. and the IRS agreed to hold one issue, the calculation of amounts eligible for the one-time repatriation holiday, because such specific issue was being addressed by other taxpayers in litigation with the IRS. The remaining unresolved issue for fiscal years 2005 and 2006 relates to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico, which is one of the Company's key manufacturing sites. The U.S. Tax Court proceeding with respect to this issue began on February 3, 2015 and ended on March 12, 2015. On June 9, 2016, the U.S. Tax court issued its opinion with respect to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico for fiscal years 2005 and 2006. The U.S. Tax Court generally rejected the IRS’s position, but also made certain modifications to the Medtronic, Inc. tax returns as filed. During November 2016, Medtronic and the IRS entered into a Stipulation of Settled Issues with the Tax Court which resolved the one-time repatriation holiday as an outstanding issue unless either party decided to appeal the Tax Court Opinion and a final decision is inconsistent with the U.S. Tax Court Opinion. The U.S. Tax Court entered their final decision on January 25, 2017. On April 21, 2017, the IRS filed their Notice of Appeal to the U.S. Court of Appeals for the 8th Circuit regarding the Tax Court Opinion. Oral argument for the Appeal has been scheduled for March 14, 2018. In October 2011, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2007 and 2008. Medtronic, Inc. reached agreement with the IRS on some, but not all matters related to these fiscal years. During the first quarter of fiscal year 2016, the Company finalized its agreement with the IRS on the proposed adjustments associated with the tax effects of the Company's acquisition of Kyphon Inc. (Kyphon). The settlement was consistent with the certain tax adjustment recorded during the fourth quarter of fiscal year 2015. During the first quarter of fiscal year 2017, an expected settlement was reached with the IRS for all outstanding issues for fiscal years 2007 and 2008 except for the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico for the businesses that are the subject of the U.S. Tax Court Case for fiscal years 2005 and 2006. In April 2014, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2009, 2010, and 2011. Medtronic, Inc. reached agreement with the IRS on some but not all matters related to these fiscal years. During the first quarter of fiscal year 2017, an expected settlement was reached with the IRS for all outstanding issues for fiscal years 2009, 2010, and 2011 except for the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico for the businesses that are the subject of the U.S. Tax Court Case for fiscal years 2005 and 2006. In May 2017, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2012, 2013, and 2014. Medtronic, Inc. reached agreement with the IRS on some but not all matters related to these fiscal years. The significant issues that remain unresolved relate to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico, and proposed adjustments associated with the utilization of certain net operating losses. The Company disagrees with the IRS and will attempt to resolve these matters at the IRS Appellate level. Medtronic, Inc.’s fiscal years 2015 and 2016 U.S. federal income tax returns are currently being audited by the IRS. Covidien and the IRS have concluded and reached agreement on its audit of Covidien’s U.S. federal income tax returns for all tax years through 2009. The IRS continues to audit Covidien’s U.S. federal income tax returns for the years 2010 through 2012. The statute of limitations for Covidien’s 2013 U.S. federal income tax returns lapsed during the first quarter of fiscal year 2018. While it is not possible to predict the outcome for most of the income tax matters discussed above, the Company believes it is possible that charges associated with these matters could have a material adverse impact on the Company’s consolidated earnings, financial position, and/or cash flows. See Note 12 for additional discussion of income taxes. Guarantees As a result of the acquisition of Covidien, the Company has guarantee commitments and indemnifications with Tyco International, TE Connectivity Ltd. (TE Connectivity), and Mallinckrodt plc (Mallinckrodt) which relate to certain contingent tax liabilities. On June 29, 2007, Covidien entered into the Tax Sharing Agreement, under which Covidien shares responsibility for certain of its, Tyco International’s and TE Connectivity’s income tax liabilities for periods prior to Covidien’s 2007 separation from Tyco International (2007 separation). Covidien, Tyco International and TE Connectivity share 42 percent , 27 percent , and 31 percent , respectively, of U.S. income tax liabilities that arise from adjustments made by tax authorities to Covidien's, Tyco International’s and TE Connectivity’s U.S. income tax returns, certain income tax liabilities arising from adjustments made by tax authorities to intercompany transactions or similar adjustments, and certain taxes attributable to internal transactions undertaken in anticipation of the 2007 separation. If Tyco International and TE Connectivity default on their obligations to the Company under the Tax Sharing Agreement, the Company would be liable for the entire amount of these liabilities. All costs and expenses associated with the management of these tax liabilities are being shared equally among the parties. In connection with the 2007 separation, all tax liabilities associated with Covidien business became Covidien’s tax liabilities. Following Covidien’s spin-off of its Pharmaceuticals business to Covidien shareholders through a distribution of all the outstanding ordinary shares of Mallinkrodt (2013 separation), Mallinckrodt became the primary obligor to the taxing authorities for the tax liabilities attributable to its subsidiaries, a significant portion of which relate to periods prior to the 2007 separation. However, Covidien remains the sole party subject to the Tax Sharing Agreement. Accordingly, Mallinckrodt does not share in the Company’s liability to Tyco International and TE Connectivity, nor in the receivable that the Company has from Tyco International and TE Connectivity. If any party to the Tax Sharing Agreement were to default in its obligation to another party to pay its share of the distribution taxes that arise as a result of no party’s fault, each non-defaulting party would be required to pay, equally with any other non-defaulting party, the amounts in default. In addition, if another party to the Tax Sharing Agreement that is responsible for all or a portion of an income tax liability were to default in its payment of such liability to a taxing authority, the Company could be legally liable under applicable tax law for such liabilities and be required to make additional tax payments. Accordingly, under certain circumstances, the Company may be obligated to pay amounts in excess of the Company’s agreed upon share of Covidien's, Tyco International’s and TE Connectivity’s tax liabilities. The Company has used available information to develop its best estimates for certain assets and liabilities related to periods prior to the 2007 separation, including amounts subject to or impacted by the provisions of the Tax Sharing Agreement. The actual amounts that the Company may be required to ultimately accrue or pay under the Tax Sharing Agreement, however, could vary depending upon the outcome of the unresolved tax matters. Final determination of the balances will be made in subsequent periods, primarily related to certain pre-2007 separation tax liabilities and tax years open for examination. These balances will also be impacted by the filing of final or amended income tax returns in certain jurisdictions where those returns include a combination of Tyco International, Covidien and/or TE Connectivity legal entities for periods prior to the 2007 separation. The resolutions with the U.S. Tax Court and IRS Appeals for fiscal years 1997 through 2007 were finalized during May 2016. However, the Tax Sharing Agreement remains in place with respect to income tax liabilities that are not the subject of such resolution. In conjunction with the 2013 separation, Mallinckrodt assumed the tax liabilities that are attributable to its subsidiaries, and Covidien indemnified Mallinckrodt to the extent that such tax liabilities arising from periods prior to 2013 exceed $200 million , net of certain tax benefits realized. In addition, in connection with the 2013 separation, Covidien entered into certain other guarantee commitments and indemnifications with Mallinckrodt. See Note 1 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 28, 2017 for additional information. As part of the Company’s Minimally Invasive Therapies Group sale of the Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses to Cardinal on July 29, 2017, the Company has indemnified Cardinal for certain contingent tax liabilities related to the divested businesses that existed prior to the date of divestiture. The actual amounts that the Company may be required to ultimately accrue or pay could vary depending upon the outcome of the unresolved tax matters. Final determination of the balances will be made in subsequent periods, the majority of which the Company expects to be resolved within fiscal year 2018. In the normal course of business, the Company and/or its affiliates periodically enter into agreements that require one or more of the Company and/or its affiliates to indemnify customers or suppliers for specific risks, such as claims for injury or property damage arising as a result of the Company or its affiliates’ products, the negligence of the Company's personnel, or claims alleging that the Company's products infringe on third-party patents or other intellectual property. The Company also offers warranties on various products. The Company’s maximum exposure under these guarantees is unable to be estimated. Historically, the Company has not experienced significant losses on these types of guarantees. The Company believes the ultimate resolution of the above guarantees is not expected to have a material effect on the Company’s consolidated earnings, financial position, or cash flows.

Segment and Geographic Informat

Segment and Geographic Information	9 Months Ended
	Jan. 26, 2018
Segment Reporting [Abstract]
Segment and Geographic Information	Segment and Geographic Information Segment Information The Company’s management evaluates segment performance and allocates resources based on net sales and earnings before interest expense, net, income tax provision, and amortization of intangible assets, not including centralized distribution costs and corporate charges, as presented in the table below. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies in Note 1 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 28, 2017 . The financial information that is regularly reviewed by the Company's chief operating decision maker to assess performance and allocate resources changed during fiscal year 2017. As a result, the Company has revised the disclosure for the prior period to align with current presentation. Net sales of the Company’s reportable segments include end-customer revenues from the sale of products each reportable segment develops and manufactures or distributes. Segment disclosures are on a performance basis consistent with internal management reporting. Certain corporate and centralized expenses are not allocated to the segments. Net sales and earnings before interest expense, net, income tax provision, and amortization of intangible assets, not including centralized distribution costs and corporate charges by reportable segment are as follows: Three months ended Nine months ended (in millions) January 26, 2018 January 27, 2017 January 26, 2018 January 27, 2017 Cardiac and Vascular Group $ 2,800 $ 2,548 $ 8,219 $ 7,650 Minimally Invasive Therapies Group 2,041 2,417 6,479 7,314 Restorative Therapies Group 1,944 1,817 5,616 5,415 Diabetes Group 584 501 1,495 1,415 Net Sales $ 7,369 $ 7,283 $ 21,809 $ 21,794 Three months ended Nine months ended (in millions) January 26, 2018 January 27, 2017 January 26, 2018 January 27, 2017 Cardiac and Vascular Group $ 1,082 $ 965 $ 3,197 $ 2,936 Minimally Invasive Therapies Group 797 820 2,433 2,530 Restorative Therapies Group 756 717 2,186 2,087 Diabetes Group 187 185 389 502 Reportable segments' EBITA before other adjustments 2,822 2,687 8,205 8,055 Amortization of intangible assets (461 ) (497 ) (1,375 ) (1,484 ) Restructuring and associated costs (30 ) (21 ) (62 ) (172 ) Acquisition-related items (30 ) (68 ) (101 ) (148 ) Certain litigation charges (61 ) (218 ) (61 ) (300 ) IPR&D impairment (46 ) — (46 ) — Divestiture-related items — — (115 ) — Gain on sale of businesses — — 697 — Special charge — (100 ) (80 ) (100 ) Hurricane Maria — — (34 ) — Impact of inventory step-up — — — (38 ) Centralized distribution costs (471 ) (364 ) (1,399 ) (1,211 ) Interest expense, net (172 ) (180 ) (539 ) (532 ) Corporate (524 ) (272 ) (1,140 ) (903 ) Income before income taxes $ 1,027 $ 967 $ 3,950 $ 3,167 Geographic Information Net sales to external customers by geography are as follows: Three months ended Nine months ended (in millions) January 26, 2018 January 27, 2017 January 26, 2018 January 27, 2017 Americas (1) $ 4,202 $ 4,417 $ 12,659 $ 13,185 EMEA (2) 1,895 1,652 5,319 4,895 Asia-Pacific 815 818 2,506 2,530 Greater China 457 396 1,325 1,184 Net Sales $ 7,369 $ 7,283 $ 21,809 $ 21,794 (1) The U.S., which is included in the Americas, had net sales to external customers of $3.9 billion and $11.7 billion for the three and nine months ended January 26, 2018 , respectively, compared to $4.1 billion and $12.3 billion for the three and nine months ended January 27, 2017 , respectively. (2) EMEA consists of Europe, Middle East, and Africa. Sales to Ireland were insignificant during all periods presented.

Guarantor Financial Information

Guarantor Financial Information	9 Months Ended
	Jan. 26, 2018
Condensed Financial Information of Parent Company Only Disclosure [Abstract]
Guarantor Financial Information	Guarantor Financial Information Medtronic plc and Medtronic Global Holdings S.C.A. (Medtronic Luxco), a wholly-owned subsidiary guarantor, each have provided full and unconditional guarantees of the obligations of Medtronic, Inc., a wholly-owned subsidiary issuer, under the Senior Notes (Medtronic Senior Notes) and full and unconditional guarantees of the obligations of Covidien International Finance S.A. (CIFSA), a wholly-owned subsidiary issuer, under the Senior Notes (CIFSA Senior Notes). The guarantees of the CIFSA Senior Notes are in addition to the guarantees of the CIFSA Senior Notes by Covidien Ltd. and Covidien Group Holdings Ltd., both of which are wholly-owned subsidiary guarantors of the CIFSA Senior Notes. Effective March 28, 2017, Medtronic plc and Medtronic, Inc. each have provided a full and unconditional guarantee of the obligations of Medtronic Luxco under the Medtronic Luxco Senior Notes. The following is a summary of these guarantees: Guarantees of Medtronic Senior Notes • Parent Company Guarantor - Medtronic plc • Subsidiary Issuer - Medtronic, Inc. • Subsidiary Guarantor - Medtronic Luxco Guarantees of Medtronic Luxco Senior Notes • Parent Company Guarantor - Medtronic plc • Subsidiary Issuer - Medtronic Luxco • Subsidiary Guarantor - Medtronic, Inc. Guarantees of CIFSA Senior Notes • Parent Company Guarantor - Medtronic plc • Subsidiary Issuer - CIFSA • Subsidiary Guarantors - Medtronic Luxco, Covidien Ltd., and Covidien Group Holdings Ltd. (CIFSA Subsidiary Guarantors) The following presents the Company’s consolidating statements of comprehensive income for the three and nine months ended January 26, 2018 and January 27, 2017 , condensed consolidating balance sheets at January 26, 2018 and April 28, 2017 , and condensed consolidating statements of cash flows for the nine months ended January 26, 2018 and January 27, 2017 . The guarantees provided by the parent company guarantor and subsidiary guarantors are joint and several. Condensed consolidating financial information for Medtronic plc, Medtronic Luxco, Medtronic, Inc., CIFSA, and CIFSA Subsidiary Guarantors, on a stand-alone basis, is presented using the equity method of accounting for subsidiaries. The Company has presented the provisional tax impacts related to the Tax Act within the condensed consolidating financial statements for the three and nine months ended January 26, 2018 , at the subsidiary which the Company reasonably expects to be affected by the Tax Act. Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year. The Company made revisions to its condensed consolidating balance sheets of the guarantees of the Medtronic Senior Notes, Medtronic Luxco Senior Notes and the CIFSA Senior Notes, as previously presented in Note 23 in the Company’s Annual Report on Form 10-K for the year ended April 28, 2017. An approximate $16.0 billion revision was made to decrease the investment in subsidiaries and shareholders' equity balances in the Medtronic, Inc. column for the Medtronic Senior Notes and Medtronic Luxco Senior Notes, as well as an approximate $16.0 billion revision to increase the investment in subsidiaries and shareholders' equity balances in the CIFSA column for the CIFSA Senior Notes. Both revisions were primarily related to an incorrect presentation of an intercompany asset sale. There is no impact to the consolidated financial statements of Medtronic plc as previously filed in the 2017 Annual Report on Form 10-K or Quarterly Reports on Form 10-Q. During the third quarter of fiscal year 2018, the Company undertook certain steps to reorganize ownership of various subsidiaries. The transactions were entirely among subsidiaries under the common control of Medtronic. This reorganization has been reflected as of the beginning of the earliest period presented. Consolidating Statement of Comprehensive Income Three Months Ended January 26, 2018 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total Net sales $ — $ 275 $ — $ 7,369 $ (275 ) $ 7,369 Costs and expenses: Cost of products sold — 243 — 2,126 (178 ) 2,191 Research and development expense — 165 — 393 — 558 Selling, general, and administrative expense 4 346 — 2,149 — 2,499 Amortization of intangible assets — 2 — 459 — 461 Restructuring charges, net — — — 7 — 7 Acquisition-related items — 27 — (1 ) — 26 Certain litigation charges — 24 — 37 — 61 Other (income) expense, net 10 (768 ) — 1,006 (108 ) 140 Operating profit (loss) (14 ) 236 — 1,193 11 1,426 Investment loss — 172 — 55 — 227 Interest income — (90 ) (133 ) (410 ) 535 (98 ) Interest expense 63 464 73 205 (535 ) 270 Interest expense, net 63 374 (60 ) (205 ) — 172 Equity in net (income) loss of subsidiaries 1,314 1,161 1,374 — (3,849 ) — Income (loss) before income taxes (1,391 ) (1,471 ) (1,314 ) 1,343 3,860 1,027 Income tax (benefit) provision (2 ) 316 — 2,105 — 2,419 Net income (loss) (1,389 ) (1,787 ) (1,314 ) (762 ) 3,860 (1,392 ) Net loss attributable to noncontrolling interests — — — 3 — 3 Net income (loss) attributable to Medtronic (1,389 ) (1,787 ) (1,314 ) (759 ) 3,860 (1,389 ) Other comprehensive income (loss), net of tax 678 428 678 664 (1,770 ) 678 Other comprehensive loss attributable to noncontrolling interests — — — 3 — 3 Total comprehensive income (loss) $ (711 ) $ (1,359 ) $ (636 ) $ (95 ) $ 2,090 $ (711 ) Consolidating Statement of Comprehensive Income Nine Months Ended January 26, 2018 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total Net sales $ — $ 879 $ — $ 21,807 $ (877 ) $ 21,809 Costs and expenses: Cost of products sold — 693 — 6,548 (581 ) 6,660 Research and development expense — 492 — 1,169 — 1,661 Selling, general, and administrative expense 9 1,020 — 6,393 — 7,422 Amortization of intangible assets — 6 — 1,369 — 1,375 Restructuring charges, net — 2 — 21 — 23 Acquisition-related items — 45 — 32 — 77 Certain litigation charges — 24 — 37 — 61 Divestiture-related items — 15 — 99 — 114 Gain on sale of businesses — — — (697 ) — (697 ) Special charge — 80 — — — 80 Other (income) expense, net 35 (1,397 ) — 2,001 (322 ) 317 Operating profit (loss) (44 ) (101 ) — 4,835 26 4,716 Investment loss — 172 — 55 — 227 Interest income — (225 ) (344 ) (1,091 ) 1,370 (290 ) Interest expense 172 1,330 155 542 (1,370 ) 829 Interest expense, net 172 1,105 (189 ) (549 ) — 539 Equity in net (income) loss of subsidiaries (1,855 ) (1,599 ) (1,666 ) — 5,120 — Income (loss) before income taxes 1,639 221 1,855 5,329 (5,094 ) 3,950 Income tax (benefit) provision (5 ) 3 — 2,322 — 2,320 Net income (loss) 1,644 218 1,855 3,007 (5,094 ) 1,630 Net loss attributable to noncontrolling interests — — — 14 — 14 Net income (loss) attributable to Medtronic 1,644 218 1,855 3,021 (5,094 ) 1,644 Other comprehensive income (loss), net of tax 1,231 948 1,231 1,194 (3,373 ) 1,231 Other comprehensive loss attributable to noncontrolling interests — — — 14 — 14 Total comprehensive income (loss) $ 2,875 $ 1,166 $ 3,086 $ 4,215 $ (8,467 ) $ 2,875 Consolidating Statement of Comprehensive Income Three Months Ended January 27, 2017 Medtronic Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total Net sales $ — $ 237 $ — $ 7,283 $ (237 ) $ 7,283 Costs and expenses: Cost of products sold — 214 — 2,207 (153 ) 2,268 Research and development expense — 147 — 383 — 530 Selling, general, and administrative expense 4 264 — 2,120 — 2,388 Amortization of intangible assets — 3 — 494 — 497 Restructuring charges, net — 22 — (1 ) — 21 Acquisition-related items — 36 — 32 — 68 Certain litigation charges — — — 218 — 218 Special charge — 100 — — — 100 Other (income) expense, net 80 (462 ) — 526 (98 ) 46 Operating profit (loss) (84 ) (87 ) — 1,304 14 1,147 Interest income — (62 ) (157 ) (294 ) 425 (88 ) Interest expense 32 397 18 246 (425 ) 268 Interest expense, net 32 335 (139 ) (48 ) — 180 Equity in net (income) loss of subsidiaries (937 ) (594 ) (798 ) — 2,329 — Income (loss) before income taxes 821 172 937 1,352 (2,315 ) 967 Income tax (benefit) provision — (105 ) — 252 — 147 Net income (loss) 821 277 937 1,100 (2,315 ) 820 Net loss attributable to noncontrolling interests — — — 1 — 1 Net income (loss) attributable to Medtronic 821 277 937 1,101 (2,315 ) 821 Other comprehensive income (loss), net of tax (551 ) (183 ) (551 ) (584 ) 1,318 (551 ) Other comprehensive loss attributable to noncontrolling interests — — — 1 — 1 Total comprehensive income (loss) $ 270 $ 94 $ 386 $ 517 $ (997 ) $ 270 Consolidating Statement of Comprehensive Income Nine Months Ended January 27, 2017 Medtronic Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total Net sales $ — $ 919 $ — $ 21,793 $ (918 ) $ 21,794 Costs and expenses: Cost of products sold — 706 — 6,775 (626 ) 6,855 Research and development expense — 469 — 1,171 — 1,640 Selling, general, and administrative expense 9 828 — 6,395 — 7,232 Amortization of intangible assets — 9 — 1,475 — 1,484 Restructuring charges, net — 40 — 122 — 162 Acquisition-related items — 96 — 52 — 148 Certain litigation charges — — — 300 — 300 Special charge — 100 — — — 100 Other (income) expense, net 5 (1,431 ) — 1,906 (306 ) 174 Operating profit (loss) (14 ) 102 — 3,597 14 3,699 Interest income — (183 ) (477 ) (719 ) 1,107 (272 ) Interest expense 74 1,203 31 603 (1,107 ) 804 Interest expense, net 74 1,020 (446 ) (116 ) — 532 Equity in net (income) loss of subsidiaries (2,949 ) (2,785 ) (2,503 ) — 8,237 — Income (loss) before income taxes 2,861 1,867 2,949 3,713 (8,223 ) 3,167 Income tax (benefit) provision (4 ) (179 ) — 490 — 307 Net income (loss) 2,865 2,046 2,949 3,223 (8,223 ) 2,860 Net loss attributable to noncontrolling interests — — — 5 — 5 Net income (loss) attributable to Medtronic 2,865 2,046 2,949 3,228 (8,223 ) 2,865 Other comprehensive income (loss), net of tax (1,011 ) (472 ) (1,011 ) (1,085 ) 2,568 (1,011 ) Other comprehensive loss attributable to noncontrolling interests — — — 5 — 5 Total comprehensive income (loss) $ 1,854 $ 1,574 $ 1,938 $ 2,143 $ (5,655 ) $ 1,854 Condensed Consolidating Balance Sheet January 26, 2018 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total ASSETS Current assets: Cash and cash equivalents $ — $ 38 $ 61 $ 6,259 $ — $ 6,358 Investments — — — 8,078 — 8,078 Accounts receivable, net — — — 5,775 — 5,775 Inventories, net — 166 — 3,739 (154 ) 3,751 Intercompany receivable 40 14,773 — 33,103 (47,916 ) — Other current assets 5 313 — 2,327 — 2,645 Total current assets 45 15,290 61 59,281 (48,070 ) 26,607 Property, plant, and equipment, net — 1,378 — 3,139 — 4,517 Goodwill — — — 39,795 — 39,795 Other intangible assets, net — 13 — 22,165 — 22,178 Tax assets — 564 — 973 — 1,537 Investment in subsidiaries 59,130 58,914 59,923 — (177,967 ) — Intercompany loans receivable 3,000 6,520 18,357 32,510 (60,387 ) — Other assets — 267 — 899 — 1,166 Total assets $ 62,175 $ 82,946 $ 78,341 $ 158,762 $ (286,424 ) $ 95,800 LIABILITIES AND EQUITY Current liabilities: Current debt obligations $ — $ 2,000 $ 504 $ 398 $ — $ 2,902 Accounts payable — 368 — 1,441 — 1,809 Intercompany payable — 25,285 7,833 14,798 (47,916 ) — Accrued compensation 18 624 — 1,003 — 1,645 Accrued income taxes 14 — — 911 — 925 Other accrued expenses 2 640 15 2,995 — 3,652 Total current liabilities 34 28,917 8,352 21,546 (47,916 ) 10,933 Long-term debt — 21,771 1,843 2,304 — 25,918 Accrued compensation and retirement benefits — 988 — 536 — 1,524 Accrued income taxes 10 1,710 — 3,038 — 4,758 Intercompany loans payable 11,897 14,885 16,023 17,582 (60,387 ) — Deferred tax liabilities — — — 1,363 — 1,363 Other liabilities — 64 — 900 — 964 Total liabilities 11,941 68,335 26,218 47,269 (108,303 ) 45,460 Shareholders’ equity 50,234 14,611 52,123 111,387 (178,121 ) 50,234 Noncontrolling interests — — — 106 — 106 Total equity 50,234 14,611 52,123 111,493 (178,121 ) 50,340 Total liabilities and equity $ 62,175 $ 82,946 $ 78,341 $ 158,762 $ (286,424 ) $ 95,800 Condensed Consolidating Balance Sheet April 28, 2017 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Adjustments Total ASSETS Current assets: Cash and cash equivalents $ — $ 45 $ 5 $ 4,917 $ — $ 4,967 Investments — — — 8,741 — 8,741 Accounts receivable, net — — — 5,591 — 5,591 Inventories, net — 155 — 3,361 (178 ) 3,338 Intercompany receivable 51 16,301 — 30,475 (46,827 ) — Other current assets 10 227 — 1,628 — 1,865 Current assets held for sale — — — 371 — 371 Total current assets 61 16,728 5 55,084 (47,005 ) 24,873 Property, plant, and equipment, net — 1,311 — 3,050 — 4,361 Goodwill — — — 38,515 — 38,515 Other intangible assets, net — 20 — 23,387 — 23,407 Tax assets — 727 — 782 — 1,509 Investment in subsidiaries 55,833 55,811 52,618 — (164,262 ) — Intercompany loans receivable 3,000 6,530 16,114 25,621 (51,265 ) — Other assets — 434 — 798 — 1,232 Noncurrent assets held for sale — — — 5,919 — 5,919 Total assets $ 58,894 $ 81,561 $ 68,737 $ 153,156 $ (262,532 ) $ 99,816 LIABILITIES AND EQUITY Current liabilities: Current debt obligations $ — $ 5,000 $ 901 $ 1,619 $ — $ 7,520 Accounts payable — 304 — 1,427 — 1,731 Intercompany payable — 23,380 7,111 16,336 (46,827 ) — Accrued compensation 9 734 — 1,117 — 1,860 Accrued income taxes 13 — — 620 — 633 Other accrued expenses — 352 4 2,086 — 2,442 Current liabilities held for sale — — — 34 — 34 Total current liabilities 22 29,770 8,016 23,239 (46,827 ) 14,220 Long-term debt — 21,782 1,842 2,297 — 25,921 Accrued compensation and retirement benefits — 1,120 — 521 — 1,641 Accrued income taxes 10 1,658 — 737 — 2,405 Intercompany loans payable 8,568 13,109 10,049 19,539 (51,265 ) — Deferred tax liabilities — — — 2,978 — 2,978 Other liabilities — 153 — 1,362 — 1,515 Noncurrent liabilities held for sale — — — 720 — 720 Total liabilities 8,600 67,592 19,907 51,393 (98,092 ) 49,400 Shareholders' equity 50,294 13,969 48,830 101,641 (164,440 ) 50,294 Noncontrolling interests — — — 122 — 122 Total equity 50,294 13,969 48,830 101,763 (164,440 ) 50,416 Total liabilities and equity $ 58,894 $ 81,561 $ 68,737 $ 153,156 $ (262,532 ) $ 99,816 Condensed Consolidating Statement of Cash Flows Nine Months Ended January 26, 2018 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total Operating Activities: Net cash provided by (used in) operating activities $ 172 $ (958 ) $ 200 $ 4,232 $ — $ 3,646 Investing Activities: Acquisitions, net of cash acquired — — — (111 ) — (111 ) Proceeds from sale of businesses — — — 6,058 — 6,058 Additions to property, plant, and equipment — (234 ) — (542 ) — (776 ) Purchases of investments — — — (2,479 ) — (2,479 ) Sales and maturities of investments — — — 3,060 — 3,060 Capital contribution paid — (59 ) (4,200 ) — 4,259 — Other investing activities, net — — — (5 ) — (5 ) Net cash provided by (used in) investing activities — (293 ) (4,200 ) 5,981 4,259 5,747 Financing Activities: Acquisition-related contingent consideration — — — (43 ) — (43 ) Change in current debt obligations, net — — (397 ) 6 — (391 ) Repayment of short-term borrowings (maturities greater than 90 days) — — — (44 ) — (44 ) Proceeds from short-term borrowings (maturities greater than 90 days) — — — 1 — 1 Issuance of long-term debt — — — 21 — 21 Payments on long-term debt — (3,000 ) — (1,167 ) — (4,167 ) Dividends to shareholders (1,870 ) — — — — (1,870 ) Issuance of ordinary shares 333 — — — — 333 Repurchase of ordinary shares (1,964 ) — — — — (1,964 ) Net intercompany loan borrowings (repayments) 3,329 4,244 4,453 (12,026 ) — — Capital contribution received — — — 4,259 (4,259 ) — Other financing activities — — — (2 ) — (2 ) Net cash provided by (used in) financing activities (172 ) 1,244 4,056 (8,995 ) (4,259 ) (8,126 ) Effect of exchange rate changes on cash and cash equivalents — — — 124 — 124 Net change in cash and cash equivalents — (7 ) 56 1,342 — 1,391 Cash and cash equivalents at beginning of period — 45 5 4,917 — 4,967 Cash and cash equivalents at end of period $ — $ 38 $ 61 $ 6,259 $ — $ 6,358 Condensed Consolidating Statement of Cash Flows Nine Months Ended January 27, 2017 Medtronic Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Adjustments Total Operating Activities: Net cash provided by (used in) operating activities $ 834 $ 933 $ 161 $ 3,179 $ — $ 5,107 Investing Activities: Acquisitions, net of cash acquired — (940 ) — (388 ) — (1,328 ) Additions to property, plant, and equipment — (257 ) — (667 ) — (924 ) Purchases of investments — — — (3,516 ) 162 (3,354 ) Sales and maturities of investments — 210 — 4,238 (162 ) 4,286 Capital contribution paid — (241 ) — — 241 — Other investing activities, net — — — 21 — 21 Net cash provided by (used in) investing activities — (1,228 ) — (312 ) 241 (1,299 ) Financing Activities: Acquisition-related contingent consideration — — — (58 ) — (58 ) Change in current debt obligations, net — — 1,099 19 — 1,118 Repayment of short-term borrowings (maturities greater than 90 days) — — — (2 ) — (2 ) Proceeds from short-term borrowings (maturities greater than 90 days) — — — 4 — 4 Issuance of long-term debt — — — 131 — 131 Payments on long-term debt — (29 ) — (332 ) — (361 ) Dividends to shareholders (1,782 ) — — — — (1,782 ) Issuance of ordinary shares 309 — — — — 309 Repurchase of ordinary shares (3,409 ) — — — — (3,409 ) Net intercompany loan borrowings (repayments) 4,048 275 (1,260 ) (3,063 ) — — Capital contribution received — — — 241 (241 ) — Other financing activities — 34 — 46 — 80 Net cash provided by (used in) financing activities (834 ) 280 (161 ) (3,014 ) (241 ) (3,970 ) Effect of exchange rate changes on cash and cash equivalents — — — 54 — 54 Net change in cash and cash equivalents — (15 ) — (93 ) — (108 ) Cash and cash equivalents at beginning of period — 55 — 2,821 — 2,876 Cash and cash equivalents at end of period $ — $ 40 $ — $ 2,728 $ — $ 2,768 Consolidating Statement of Comprehensive Income Three Months Ended January 26, 2018 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total Net sales $ — $ — $ — $ 7,369 $ — $ 7,369 Costs and expenses: Cost of products sold — — — 2,191 — 2,191 Research and development expense — — — 558 — 558 Selling, general, and administrative expense 4 — — 2,495 — 2,499 Amortization of intangible assets — — — 461 — 461 Restructuring charges, net — — — 7 — 7 Acquisition-related items — — — 26 — 26 Certain litigation charges — — — 61 — 61 Other (income) expense, net 10 — — 130 — 140 Operating profit (loss) (14 ) — — 1,440 — 1,426 Investment loss — — — 227 — 227 Interest income — (13 ) (137 ) (154 ) 206 (98 ) Interest expense 63 19 73 321 (206 ) 270 Interest expense, net 63 6 (64 ) 167 — 172 Equity in net (income) loss of subsidiaries 1,314 (765 ) 1,378 — (1,927 ) — Income (loss) before income taxes (1,391 ) 759 (1,314 ) 1,046 1,927 1,027 Income tax (benefit) provision (2 ) — — 2,421 — 2,419 Net income (loss) (1,389 ) 759 (1,314 ) (1,375 ) 1,927 (1,392 ) Net loss attributable to noncontrolling interests — — — 3 — 3 Net income (loss) attributable to Medtronic (1,389 ) 759 (1,314 ) (1,372 ) 1,927 (1,389 ) Other comprehensive income (loss), net of tax 678 245 678 678 (1,601 ) 678 Other comprehensive loss attributable to non-controlling interests — — — 3 — 3 Total comprehensive income (loss) $ (711 ) $ 1,004 $ (636 ) $ (694 ) $ 326 $ (711 ) Consolidating Statement of Comprehensive Income Nine Months Ended January 26, 2018 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Total Net sales $ — $ — $ — $ 21,809 $ — $ 21,809 Costs and expenses: Cost of products sold — — — 6,660 — 6,660 Research and development expense — — — 1,661 — 1,661 Selling, general, and administrative expense 9 — 1 7,412 — 7,422 Amortization of intangible assets — — — 1,375 — 1,375 Restructuring charges, net — — — 23 — 23 Acquisition-related items — — — 77 — 77 Certain litigation charges — — — 61 — 61 Divestiture-related items — — — 114 — 114 Gain on sale of businesses — — — (697 ) — (697 ) Special charge — — — 80 — 80 Other (income) expense, net 35 1 — 281 — 317 Operating profit (loss) (44 ) (1 ) (1 ) 4,762 — 4,716 Investment loss — — — 227 — 227 Interest income — (45 ) (355 ) (392 ) 502 (290 ) Interest expense 172 63 156 940 (502 ) 829 Interest expense, net 172 18 (199 ) 548 — 539 Equity in net (income) loss of subsidiaries (1,855 ) (1,938 ) (1,657 ) — 5,450 — Income (loss) before income taxes 1,639 1,919 1,855 3,987 (5,450 ) 3,950 Income tax (benefit) provision (5 ) — — 2,325 — 2,320 Net income (loss) 1,644 1,919 1,855 1,662 (5,450 ) 1,630 Net loss attributable to noncontrolling interests — — — 14 — 14 Net income (loss) attributable to Medtronic 1,644 1,919 1,855 1,676 (5,450 ) 1,644 Other comprehensive income (loss), net of tax 1,231 314 1,231 1,231 (2,776 ) 1,231 Other comprehensive loss attributable to noncontrolling interests — — — 14 — 14 Total comprehensive income (loss) $ 2,875 $ 2,233 $ 3,086 $ 2,907 $ (8,226 ) $ 2,875 Consolidating Statement of Comprehensive Income Three Months Ended January 27, 2017 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Total Net sales $ — $ — $ — $ 7,283 $ — $ 7,283 Costs and expenses: Cost of products sold — — — 2,268 — 2,268 Research and development expense — — — 530 — 530 Selling, general, and administrative expense 4 — — 2,384 — 2,388 Amortization of intangible assets — — — 497 — 497 Restructuring charges, net — — — 21 — 21 Acquisition-related items — — — 68 — 68 Certain litigation charges — — — 218 — 218 Special charge — — — 100 — 100 Other (income) expense, net 80 — — (34 ) — 46 Operating profit (loss) (84 ) — — 1,231 — 1,147 Interest income — (23 ) (158 ) (108 ) 201 (88 ) Interest expense 32 26 18 393 (201 ) 268 Interest expense, net 32 3 (140 ) 285 — 180 Equity in net (income) loss of subsidiaries (937 ) (434 ) (797 ) — 2,168 — Income (loss) before income taxes 821 431 937 946 (2,168 ) 967 Income tax (benefit) provision — — — 147 — 147 Net income (loss) 821 431 937 799 (2,168 ) 820 Net loss attributable to noncontrolling interests — — — 1 — 1 Net income (loss) attributable to Medtronic 821 431 937 800 (2,168 ) 821 Other comprehensive income (loss), net of tax (551 ) (358 ) (551 ) (551 ) 1,460 (551 ) Other comprehensive loss attributable to — — — 1 — 1 Total comprehensive income (loss) $ 270 $ 73 $ 386 $ 249 $ (708 ) $ 270 Consolidating Statement of Comprehensive Income Nine Months Ended January 27, 2017 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Total Net sales $ — $ — $ — $ 21,794 $ — $ 21,794 Costs and expenses: Cost of products sold — — — 6,855 — 6,855 Research and development expense — — — 1,640 — 1,640 Selling, general, and administrative expense 9 1 2 7,220 — 7,232 Amortization of intangible assets — — — 1,484 — 1,484 Restructuring charges, net — — — 162 — 162 Acquisition-related items — — — 148 — 148 Certain litigation charges — — — 300 — 300 Special charge — — — 100 — 100 Other (income) expense, net 5 1 — 168 — 174 Operating profit (loss) (14 ) (2 ) (2 ) 3,717 — 3,699 Interest income — (71 ) (482 ) (315 ) 596 (272 ) Interest expense 74 81 30 1,215 (596 ) 804 Interest expense, net 74 10 (452 ) 900 — 532 Equity in net (income) loss of subsidiaries (2,949 ) (1,462 ) (2,499 ) — 6,910 — Income (loss) before income taxes 2,861 1,450 2,949 2,817 (6,910 ) 3,167 Income tax (benefit) provision (4 ) — — 311 — 307 Net income (loss) 2,865 1,450 2,949 2,506 (6,910 ) 2,860 Net loss attributable to noncontrolling interests — — — 5 — 5 Net income (loss) attributable to Medtronic 2,865 1,450 2,949 2,511 (6,910 ) 2,865 Other comprehensive income (loss), net of tax (1,011 ) (385 ) (1,011 ) (1,011 ) 2,407 (1,011 ) Other comprehensive loss attributable to — — — 5 — 5 Total comprehensive income (loss) $ 1,854 $ 1,065 $ 1,938 $ 1,500 $ (4,503 ) $ 1,854 Condensed Consolidating Balance Sheet January 26, 2018 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Total ASSETS Current assets: Cash and cash equivalents $ — $ — $ 61 $ 6,297 $ — $ 6,358 Investments — — — 8,078 — 8,078 Accounts receivable, net — — — 5,775 — 5,775 Inventories, net — — — 3,751 — 3,751 Intercompany receivable 40 — 1,338 7,855 (9,233 ) — Other current assets 5 — — 2,640 — 2,645 Total current assets 45 — 1,399 34,396 (9,233 ) 26,607 Property, plant, and equipment, net — — — 4,517 — 4,517 Goodwill — — — 39,795 — 39,795 Other intangible assets, net — — — 22,178 — 22,178 Tax assets — — — 1,537 — 1,537 Investment in subsidiaries 59,130 53,153 58,590 — (170,873 ) — Intercompany loans receivable 3,000 2,316 18,357 16,123 (39,796 ) — Other assets — — — 1,166 — 1,166 Total assets $ 62,175 $ 55,469 $ 78,346 $ 119,712 $ (219,902 ) $ 95,800 LIABILITIES AND EQUITY Current liabilities: Current debt obligations $ — $ — $ 504 $ 2,398 $ — $ 2,902 Accounts payable — — — 1,809 — 1,809 Intercompany payable — 1,278 7,833 122 (9,233 ) — Accrued compensation 18 — — 1,627 — 1,645 Accrued income taxes 14 — — 911 — 925 Other accrued expenses 2 12 19 3,619 — 3,652 Total current liabilities 34 1,290 8,356 10,486 (9,233 ) 10,933 Long-term debt — 2,117 1,843 21,958 — 25,918 Accrued compensation and retirement benefits — — — 1,524 — 1,524 Accrued income taxes 10 — — 4,748 — 4,758 Intercompany loans payable 11,897 100 16,023 11,776 (39,796 ) — Deferred tax liabilities — — — 1,363 — 1,363 Other liabilities — — 1 963 — 964 Total liabilities 11,941 3,507 26,223 52,818 (49,029 ) 45,460 Shareholders’ equity 50,234 51,962 52,123 66,788 (170,873 ) 50,234 Noncontrolling interests — — — 106 — 106 Total equity 50,234 51,962 52,123 66,894 (170,873 ) 50,340 Total liabilities and equity $ 62,175 $ 55,469 $ 78,346 $ 119,712 $ (219,902 ) $ 95,800 Condensed Consolidating Balance Sheet April 28, 2017 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total ASSETS Current assets: Cash and cash equivalents $ — $ 33 $ 5 $ 4,929 $ — $ 4,967 Investments — — — 8,741 — 8,741 Accounts receivable, net — — — 5,591 — 5,591 Inventories, net — — — 3,338 — 3,338 Intercompany receivable 51 — 1,329 7,111 (8,491 ) — Other current assets 10 — — 1,855 — 1,865 Current assets held for sale — — — 371 — 371 Total current assets 61 33 1,334 31,936 (8,491 ) 24,873 Property, plant, and equipment, net — — — 4,361 — 4,361 Goodwill — — — 38,515 — 38,515 Other intangible assets, net — — — 23,407 — 23,407 Tax assets — — — 1,509 — 1,509 Investment in subsidiaries 55,833 47,248 51,294 — (154,375 ) — Intercompany loans receivable 3,000 2,978 16,114 10,149 (32,241 ) — Other assets — — — 1,232 — 1,232 Noncurrent assets held for sale — — — 5,919 — 5,919 Total assets $ 58,894 $ 50,259 $ 68,742 $ 117,028 $ (195,107 ) $ 99,816 LIABILITIES AND EQUITY Current liabilities: Current debt obligations $ — $ 1,176 $ 901 $ 5,443 $ — $ 7,520 Accounts payable — — — 1,731 — 1,731 Intercompany payable — 1,269 7,111 111 (8,491 ) — Accrued compensation 9 — — 1,851 — 1,860 Accrued income taxes 13 — — 620 — 633 Other accrued expenses — 23 8 2,411 — 2,442 Current liabilities held for sale — — — 34 — 34 Total current liabilities 22 2,468 8,020 12,201 (8,491 ) 14,220 Long-term debt — 2,133 1,842 21,946 — 25,921 Accrued compensation and retirement benefits — — — 1,641 — 1,641 Accrued income taxes 10 — — 2,395 — 2,405 Intercompany loans payable 8,568 100 10,050 13,523 (32,241 ) — Deferred tax liabilities — — — 2,978 — 2,978 Other liabilities — — — 1,515 — 1,515 Noncurrent liabilities held for sale — — — 720 — 720 Total liabilities 8,600 4,701 19,912 56,919 (40,732 ) 49,400 Shareholders' equity 50,294 45,558 48,830 59,987 (154,375 ) 50,294 Noncontrolling interests — — — 122 — 122 Total Equity 50,294 45,558 48,830 60,109 (154,375 ) 50,416 Total liabilities and equity $ 58,894 $ 50,259 $ 68,742 $ 117,028 $ (195,107 ) $ 99,816 Condensed Consolidating Statement of Cash Flows Nine Months Ended January 26, 2018 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total Operating Activities: Net cash provided by (used in) operating activities $ 172 $ 978 $ 210 $ 3,334 $ (1,048 ) $ 3,646 Investing Activities: Acquisitions, net of cash acquired — — — (111 ) — (111 ) Proceeds from sale of businesses — — — 6,058 — 6,058 Additions to property, plant, and equipment — — — (776 ) — (776 ) Purchases of investments — — — (2,479 ) — (2,479 ) Sales and maturities of investments — — — 3,060 — 3,060 Capital contribution paid — (531 ) (4,200 ) — 4,731 — Other investing activities, net — — — (5 ) — (5 ) Net cash provided by (used in) investing activities — (531 ) (4,200 ) 5,747 4,731 5,747 Financing Activities: Acquisition-related contingent consideration — — — (43 ) — (43 ) Change in current debt obligations, net — — (397 ) 6 — (391 ) Repayment of short-term borrowings (maturities greater than 90 days) — — — (44 ) — (44 ) Proceeds from short-term borrowings (maturities greater than 90 days) — — — 1 — 1 Issuance of long-term debt — — — 21 — 21 Payments on long-term debt — (1,150 ) — (3,017 ) — (4,167 ) Dividends to shareholders (1,870 ) — — — — (1,870 ) Issuance of ordinary shares 333 — — — — 333 Repurchase of ordinary shares (1,964 ) — — — — (1,964 ) Net intercompany loan borrowings (repayments) 3,329 670 4,443 (8,442 ) — — Intercompany dividend paid — — — (1,048 ) 1,048 — Capital contribution received — — — 4,731 (4,731 ) — Other financing activities — — — (2 ) — (2 ) Net cash provided by (used in) financing activities (172 ) (480 ) 4,046 (7,837 ) (3,683 ) (8,126 ) Effect of exchange rate changes on cash and cash equivalents — — — 124 — 124 Net change in cash and cash equivalents — (33 ) 56 1,368 — 1,391 Cash and cash equivalents at beginning of period — 33 5 4,929 — 4,967 Cash and cash equivalents at end of period $ — $ — $ 61 $ 6,297 $ — $ 6,358 Condensed Consolidating Statement of Cash Flows Nine Months Ended January 27, 2017 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total Operating Activities: Net cash provided by (used in) operating activities $ 834 $ 867 $ 15 $ 4,311 $ (920 ) $ 5,107 Investing Activities: Acquisitions, net of cash acquired — — — (1,328 ) — (1,328 ) Additions to property, plant, and equipment — — — (924 ) — (924 ) Purchases of investments — — — (3,354 ) — (3,354 ) Sales and maturities of investments — — — 4,286 — 4,286 Capital contributions paid — (537 ) — — 537 — Other investing activities, net — — — 21 — 21 Net cash provided by (used in) investing activities — (537 ) — (1,299 ) 537 (1,299 ) Financing Activities: Acquisition-related contingent consideration — — — (58 ) — (58 ) Change in current debt obligations, net — — 1,099 19 — 1,118 Repayment of short-term borrowings (maturities greater than 90 days) — — — (2 ) — (2 ) Proceeds from short-term borrowings (maturities greater than 90 days) — — — 4 — 4 Issuance of long-term debt — — — 131 — 131 Payments on long-term debt — — — (361 ) — (361 ) Dividends to shareholders (1,782 ) — — — — (1,782 ) Issuance of ordinary shares 309 — — — — 309 Repurchase of ordinary shares (3,409 ) — — — — (3,409 ) Net intercompany loan borrowings (repayments) 4,048 (457 ) (1,114 ) (2,477 ) — — Intercompany dividend paid — — — (920 ) 920 — Capital contributions received — — — 537 (537 ) — Other financing activities — — — 80 — 80 Net cash provided by (used in) financing activities (834 ) (457 ) (15 ) (3,047 ) 383 (3,970 ) Effect of exchange rate changes on cash and cash equivalents — — — 54 — 54 Net change in cash and cash equivalents — (127 ) — 19 — (108 ) Cash and cash equivalents at beginning of period — 208 — 2,668 — 2,876 Cash and cash equivalents at end of period $ — $ 81 $ — $ 2,687 $ — $ 2,768

Basis of Presentation (Policies

Basis of Presentation (Policies)	9 Months Ended
	Jan. 26, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	The accompanying unaudited consolidated financial statements of Medtronic plc and its subsidiaries (Medtronic plc, Medtronic, or the Company) have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S.) (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, the consolidated financial statements include all of the adjustments necessary for a fair statement in conformity with U.S. GAAP. Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates.
Consolidation	The accompanying unaudited consolidated financial statements include the accounts of Medtronic plc, its wholly-owned subsidiaries, entities for which the Company has a controlling financial interest, and variable interest entities for which the Company is the primary beneficiary. Intercompany transactions and balances have been fully eliminated in consolidation.
Fiscal Period	The Company’s fiscal years 2018 , 2017 , and 2016 will end or ended on April 27, 2018 , April 28, 2017 , and April 29, 2016 , respectively.
New Accounting Pronouncements	Recently Adopted In March 2016, the Financial Accounting Standards Board (FASB) issued guidance to simplify the accounting for share-based payment transactions by requiring all excess tax benefits and deficiencies to be recognized in income tax expense or benefit in earnings; eliminating the requirement to classify the excess tax benefits and deficiencies as additional paid-in capital. Cash flows related to excess tax benefits are to be classified in operating activities in the statement of cash flows rather than financing. Under the new guidance, an entity makes an accounting policy election to either estimate the expected forfeiture awards or account for forfeitures as they occur. The standard also allows an entity to withhold up to the maximum statutory tax rate and classify the awards as equity. The Company prospectively adopted this guidance in the first quarter of fiscal year 2018. The Company has elected to continue to estimate forfeitures. The adoption of this guidance resulted in no cumulative adjustment to retained earnings and, including the impacts of U.S. Tax Reform, decreases to net loss and diluted loss per share of $9 million and $0.01 , respectively, for the three months ended January 26, 2018 , and increases to net income and diluted earnings per share of $50 million and $0.04 , respectively, for the nine months ended January 26, 2018 . In October 2016, the FASB issued guidance that requires the tax effect of intra-entity transactions, other than sales of inventory, to be recognized when the transaction occurs. Previously, U.S. GAAP prohibited the recognition of current and deferred income taxes associated with an intra-entity asset transfer until an asset had been sold to a third-party. This update requires an entity to recognize the income tax consequences of an intra-entity transfer of an asset, such as equipment or intangibles, when the transfer occurs. The adoption of this guidance is to be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. The Company has early adopted this guidance, as permitted, in the first quarter of fiscal year 2018. As a result of this adoption, the Company increased its beginning retained earnings by $296 million . The adoption of this guidance, not considering the impacts of U.S. Tax Reform, resulted in an increase to net loss of $5 million and no change to diluted loss per share for the three months ended January 26, 2018 , and increases to net income and diluted earnings per share of $552 million and $0.40 , respectively, for the nine months ended January 26, 2018 . Not Yet Adopted In May 2014, the FASB issued amended revenue recognition guidance to clarify the principles for recognizing revenue from contracts with customers. The guidance requires an entity to recognize revenue in an amount that reflects the consideration to which an entity expects to be entitled in exchange for the transfer of goods or services. The guidance also requires expanded disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. This accounting guidance is effective for the Company beginning in the first quarter of fiscal year 2019, and may be applied either retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of the change recognized at the date of initial application (modified retrospective method). The Company intends to adopt this guidance under the modified retrospective method. Based on the Company's current evaluation of the amended revenue recognition guidance, the Company does not expect the adoption of the amended guidance to have a material impact on the Company's consolidated financial statements. The Company is continuing to evaluate the impact of the amended guidance as it pertains to presentation and disclosure. The Company will continue to monitor any modifications, clarifications, and interpretations communicated by the FASB that may impact its conclusions. In January 2016, the FASB issued guidance which requires equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income. The guidance also includes a simplified impairment assessment of equity investments without readily determinable fair values and presentation and disclosure changes. This accounting guidance is effective for the Company beginning in the first quarter of fiscal year 2019. The Company is unable to estimate the impact of the future adoption of this guidance on its financial statements as it will depend on the equity investments at the adoption date. In February 2016, the FASB issued guidance which requires lessees to recognize right-of-use assets and lease liabilities on the balance sheet. The guidance is to be applied using a modified retrospective approach at the beginning of the earliest comparative period in the financial statements and is effective for the Company beginning in the first quarter of fiscal year 2020. Early adoption is permitted. The Company is evaluating the impact of the lease guidance on the Company's consolidated financial statements and anticipates recording additional assets and corresponding liabilities on its consolidated balance sheets related to operating leases within its lease portfolio upon adoption of the guidance. In January 2017, the FASB issued guidance which simplifies the accounting for goodwill impairment. The guidance requires a goodwill impairment to be measured as the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The Company is required to adopt this guidance beginning in the first quarter of fiscal year 2021. Early adoption is permitted, and the guidance must be applied prospectively. The Company is unable to estimate the impact of the future adoption of this guidance on its financial statements, as it is dependent on the specific facts and circumstances of any future impairments, if applicable.

Acquisitions and Acquisition-27

Acquisitions and Acquisition-Related Items (Tables)	9 Months Ended
	Jan. 26, 2018
Business Combinations [Abstract]
Fair Value of Assets Acquired and Liabilities Assumed	The acquisition date fair values of the assets and liabilities acquired were as follows: (in millions) HeartWare International, Inc. All Other Other current assets $ 351 $ 3 Property, plant, and equipment 14 6 Other intangible assets 625 93 Goodwill 481 27 Other assets 84 — Total assets acquired 1,555 129 Current liabilities 143 2 Deferred tax liabilities 6 3 Long-term debt 245 — Other liabilities 89 — Total liabilities assumed 483 5 Net assets acquired $ 1,072 $ 124
Fair Value Measurements, Contingent Consideration, Significant Unobservable Inputs	The recurring Level 3 fair value measurements of contingent consideration include the following significant unobservable inputs: Fair Value at (in millions) January 26, 2018 Valuation Technique Unobservable Input Range Discount rate 11% - 32.5% Revenue-based payments $88 Discounted cash flow Probability of payment 30% - 100% Projected fiscal year of payment 2018 - 2026 Discount rate 5.5% Product development and other milestone-based payments $83 Discounted cash flow Probability of payment 75% - 100% Projected fiscal year of payment 2018 - 2025
Reconciliation of Beginning and Ending Balances of Contingent Consideration Associated with Acquisitions	The following table provides a reconciliation of the beginning and ending balances of contingent consideration: Three months ended Nine months ended (in millions) January 26, 2018 January 27, 2017 January 26, 2018 January 27, 2017 Beginning Balance $ 190 $ 285 $ 246 $ 377 Purchase price contingent consideration 13 (4 ) 28 28 Payments (20 ) (23 ) (66 ) (62 ) Change in fair value (12 ) 4 (37 ) (81 ) Ending Balance $ 171 $ 262 $ 171 $ 262

Divestiture and Divestiture-R28

Divestiture and Divestiture-Related Items (Tables)	9 Months Ended
	Jan. 26, 2018
Discontinued Operations and Disposal Groups [Abstract]
Assets and Liabilities Classified as Held for Sale	The following table presents information related to the assets and liabilities that were classified as held for sale in the consolidated balance sheets: (in millions) April 28, 2017 Inventories, net $ 371 Property, plant, and equipment, net 689 Goodwill 2,910 Other intangible assets, net 2,320 Total assets held for sale $ 6,290 Other accrued expenses $ 34 Accrued compensation and retirement benefits 12 Deferred tax liabilities 707 Other liabilities 1 Total liabilities held for sale $ 754

Restructuring (Tables)

Restructuring (Tables)	9 Months Ended
	Jan. 26, 2018
Enterprise Excellence
Restructuring Cost and Reserve [Line Items]
Restructuring and related costs	The following table summarizes the activity related to employee termination benefits liability and the associated costs for the nine months ended January 26, 2018 : (in millions) Employee Termination Benefits Associated Costs (1) Total April 28, 2017 $ — $ — $ — Charges 9 23 32 Cash payments — (23 ) (23 ) January 26, 2018 $ 9 $ — $ 9 (1) Associated costs include costs incurred as a direct result of the restructuring program, such as salaries for employees supporting the program and consulting expenses. For the three months ended January 26, 2018 , $13 million was recognized within cost of products sold and $10 million was recognized within selling, general and administrative expense in the consolidated statements of income.
Cost Synergies
Restructuring Cost and Reserve [Line Items]
Restructuring and related costs	A summary of the restructuring accrual and related activity is presented below: (in millions) Employee Termination Benefits Other Costs Total April 28, 2017 $ 261 $ 30 $ 291 Charges 25 20 45 Cash payments (119 ) (30 ) (149 ) Accrual adjustments (17 ) 2 (15 ) January 26, 2018 $ 150 $ 22 $ 172

Financial Instruments (Tables)

Financial Instruments (Tables)	9 Months Ended
	Jan. 26, 2018
Investments [Abstract]
Investments by Category and Related Balance Sheet Classification	The following table summarizes the Company's investments by significant investment category and the related consolidated balance sheet classification at January 26, 2018 : Valuation Balance Sheet Classification (in millions) Cost Unrealized Gains Unrealized Losses Fair Value Investments Other Assets Available-for-sale securities: Level 1: U.S. government and agency securities $ 618 $ — $ (16 ) $ 602 $ 602 $ — Marketable equity securities 69 126 (2 ) 193 — 193 Total Level 1 687 126 (18 ) 795 602 193 Level 2: Corporate debt securities 4,254 42 (30 ) 4,266 4,266 — U.S. government and agency securities 882 — (18 ) 864 864 — Mortgage-backed securities 753 3 (26 ) 730 730 — Foreign government and agency securities 66 — (1 ) 65 65 — Other asset-backed securities 337 1 (2 ) 336 336 — Debt funds 939 7 (126 ) 820 820 — Total Level 2 7,231 53 (203 ) 7,081 7,081 — Level 3: Corporate debt securities 1 — — 1 — 1 Auction rate securities 47 — (3 ) 44 — 44 Total Level 3 48 — (3 ) 45 — 45 Investments measured at net asset value (1) : Debt funds 400 — (5 ) 395 395 — Total available-for-sale securities 8,366 179 (229 ) 8,316 8,078 238 Cost method, equity method, and other investments: Level 3: Cost method, equity method, and other investments 407 — — N/A — 407 Total Level 3 407 — — N/A — 407 Total cost method, equity method, and other investments 407 — — N/A — 407 Total investments $ 8,773 $ 179 $ (229 ) $ 8,316 $ 8,078 $ 645 (1) Certain investments that are measured at the net asset value per share (or its equivalent) as a practical expedient are excluded from the fair value hierarchy. The fair value amounts presented herein are intended to permit reconciliation to the consolidated balance sheets. The following table summarizes the Company's investments by significant investment category and the related consolidated balance sheet classification at April 28, 2017 : Valuation Balance Sheet Classification (in millions) Cost Unrealized Gains Unrealized Losses Fair Value Investments Other Assets Available-for-sale securities: Level 1: U.S. government and agency securities $ 613 $ 2 $ (5 ) $ 610 $ 610 $ — Marketable equity securities 58 49 (4 ) 103 — 103 Total Level 1 671 51 (9 ) 713 610 103 Level 2: Corporate debt securities 4,643 62 (23 ) 4,682 4,682 — U.S. government and agency securities 860 — (10 ) 850 850 — Mortgage-backed securities 766 9 (16 ) 759 759 — Foreign government and agency securities 49 — — 49 49 — Other asset-backed securities 228 1 (1 ) 228 228 — Debt funds 1,246 4 (178 ) 1,072 1,072 — Total Level 2 7,792 76 (228 ) 7,640 7,640 — Level 3: Corporate debt securities 1 — — 1 — 1 Auction rate securities 47 — (3 ) 44 — 44 Total Level 3 48 — (3 ) 45 — 45 Investments measured at net asset value (1) : Debt funds 497 — (6 ) 491 491 — Total available-for-sale securities 9,008 127 (246 ) 8,889 8,741 148 Cost method, equity method, and other investments: Level 3: Cost method, equity method, and other investments 589 — — N/A — 589 Total Level 3 589 — — N/A — 589 Total cost method, equity method, and other investments 589 — — N/A — 589 Total investments $ 9,597 $ 127 $ (246 ) $ 8,889 $ 8,741 $ 737 (1) Certain investments that are measured at the net asset value per share (or its equivalent) as a practical expedient are excluded from the fair value hierarchy. The fair value amounts presented herein are intended to permit reconciliation to the consolidated balance sheets.
Available-For-Sale Securities in Continuous Unrealized Loss Position	The following tables present the gross unrealized losses and fair values of the Company’s available-for-sale securities that have been in a continuous unrealized loss position deemed to be temporary, aggregated by investment category at January 26, 2018 and April 28, 2017 : January 26, 2018 Less than 12 months More than 12 months (in millions) Fair Value Unrealized Losses Fair Value Unrealized Losses Corporate debt securities $ 1,675 $ (19 ) $ 295 $ (11 ) Auction rate securities — — 44 (3 ) Mortgage-backed securities 435 (9 ) 107 (17 ) U.S. government and agency securities 658 (20 ) 454 (14 ) Foreign government and agency securities — — 36 (1 ) Debt funds — — 1,001 (131 ) Other asset-backed securities 184 (1 ) 61 (1 ) Marketable equity securities — — 1 (2 ) Total $ 2,952 $ (49 ) $ 1,999 $ (180 ) April 28, 2017 Less than 12 months More than 12 months (in millions) Fair Value Unrealized Losses Fair Value Unrealized Losses Corporate debt securities $ 1,263 $ (19 ) $ 46 $ (4 ) Auction rate securities — — 44 (3 ) Mortgage-backed securities 276 (4 ) 95 (12 ) U.S. government and agency securities 896 (15 ) — — Other asset-backed securities 127 (1 ) — — Debt funds 173 (1 ) 1,125 (183 ) Marketable equity securities 14 (3 ) 2 (1 ) Total $ 2,749 $ (43 ) $ 1,312 $ (203 )
Unobservable Inputs Utilized in the Fair Value Measurement of Auction Rate Securities Classified as Level 3	The following table presents the unobservable inputs utilized in the fair value measurement of the auction rate securities classified as Level 3 at January 26, 2018 : Valuation Technique Unobservable Input Range (Weighted Average) Auction rate securities Discounted cash flow Years to principal recovery 2 yrs. - 12 yrs. (3 yrs.) Illiquidity premium 6%
Activity Related to the Company's Investment Portfolio	Activity related to the Company’s investment portfolio is as follows: Three months ended January 26, 2018 January 27, 2017 (in millions) Debt (1) Equity (2) Debt (1) Equity (2) Proceeds from sales $ 667 $ 39 $ 661 $ 1 Gross realized gains 3 8 10 — Gross realized losses (2 ) — (7 ) — Impairment losses recognized — (227 ) — (10 ) Nine months ended January 26, 2018 January 27, 2017 (in millions) Debt (1) Equity (2) Debt (1) Equity (2) Proceeds from sales $ 3,021 $ 39 $ 4,203 $ 83 Gross realized gains 22 15 74 29 Gross realized losses (17 ) — (56 ) — Impairment losses recognized — (228 ) — (20 ) (1) Includes available-for-sale debt securities and debt funds. (2) Includes marketable equity securities and cost and equity method investments.
Available-for-sale Debt Securities Contractual Maturities	The January 26, 2018 balance of available-for-sale debt securities, excluding debt funds which have no single maturity date, by contractual maturity is shown in the following table. Within the table, maturities of mortgage-backed securities have been allocated based upon timing of estimated cash flows assuming no change in the current interest rate environment. Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties. (in millions) January 26, 2018 Due in one year or less $ 885 Due after one year through five years 2,748 Due after five years through ten years 3,161 Due after ten years 114 Total $ 6,908

Financing Arrangements (Tables)

Financing Arrangements (Tables)	9 Months Ended
	Jan. 26, 2018
Debt Disclosure [Abstract]
Long-term Debt	The Company's debt obligations consisted of the following: (in millions, except interest rates) Maturity by Fiscal Year January 26, 2018 April 28, 2017 Current debt obligations 2018 - 2019 $ 2,902 $ 7,520 Long-term debt 5.600 percent ten-year 2009 senior notes 2019 400 400 1.700 percent two-year 2017 senior notes 2019 1,000 1,000 4.450 percent ten-year 2010 senior notes 2020 766 766 2.500 percent five-year 2015 senior notes 2020 2,500 2,500 Floating rate five-year 2015 senior notes 2020 500 500 4.200 percent ten-year 2010 CIFSA senior notes 2021 600 600 4.125 percent ten-year 2011 senior notes 2021 500 500 3.125 percent ten-year 2012 senior notes 2022 675 675 3.150 percent seven-year 2015 senior notes 2022 2,500 2,500 3.200 percent ten-year 2012 CIFSA senior notes 2023 650 650 2.750 percent ten-year 2013 senior notes 2023 530 530 2.950 percent ten-year 2013 CIFSA senior notes 2024 310 310 3.625 percent ten-year 2014 senior notes 2024 850 850 3.500 percent ten-year 2015 senior notes 2025 4,000 4,000 3.350 percent ten-year 2017 senior notes 2027 850 850 4.375 percent twenty-year 2015 senior notes 2035 2,382 2,382 6.550 percent thirty-year 2008 CIFSA senior notes 2038 374 374 6.500 percent thirty-year 2009 senior notes 2039 300 300 5.550 percent thirty-year 2010 senior notes 2040 500 500 4.500 percent thirty-year 2012 senior notes 2042 400 400 4.000 percent thirty-year 2013 senior notes 2043 325 325 4.625 percent thirty-year 2014 senior notes 2044 650 650 4.625 percent thirty-year 2015 senior notes 2045 4,150 4,150 Interest rate swaps (Note 9) 2021 - 2022 10 40 Capital lease obligations 2019 - 2025 22 23 Bank borrowings 2019 - 2021 165 139 Debt premium, net 2019 - 2045 123 135 Deferred financing costs 2019 - 2045 (114 ) (128 ) Long-term debt $ 25,918 $ 25,921

Derivatives and Currency Exch32

Derivatives and Currency Exchange Risk Management (Tables)	9 Months Ended
	Jan. 26, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Amount and Location of Gains (Losses) in Statements of Income, Derivative Instruments Not Designated as Hedging Instruments	The amounts and classification of the gains (losses) in the consolidated statements of income related to derivative instruments, not designated as hedging instruments, for the three and nine months ended January 26, 2018 and January 27, 2017 were as follows: Three months ended Nine months ended (in millions) Classification January 26, 2018 January 27, 2017 January 26, 2018 January 27, 2017 Currency exchange rate contract (losses) gains Other expense, net $ (181 ) $ 67 $ (318 ) $ 27
Amount and Location of Gains (Losses) in Statements of Income and OCI, Derivative Instruments Designated as Cash Flow Hedges	The amount of gross gains (losses), classification of the gains (losses) in the consolidated statements of income, and the accumulated other comprehensive income (loss) (AOCI) related to the effective portion of currency exchange rate contract derivative instruments designated as cash flow hedges for the three and nine months ended January 26, 2018 and January 27, 2017 were as follows: Three months ended January 26, 2018 Recognized in AOCI Recognized in Income (in millions) Amount Classification Amount Currency exchange rate contracts $ (287 ) Other expense, net $ (11 ) Three months ended January 27, 2017 Recognized in AOCI Recognized in Income (in millions) Amount Classification Amount Currency exchange rate contracts $ 190 Other expense, net $ 68 Nine months ended January 26, 2018 Recognized in AOCI Recognized in Income (in millions) Amount Classification Amount Currency exchange rate contracts $ (507 ) Other expense, net $ 1 Nine months ended January 27, 2017 Recognized in AOCI Recognized in Income (in millions) Amount Classification Amount Currency exchange rate contracts $ 378 Other expense, net $ 89
Classification and Fair Value Amounts of Derivative Instruments in Balance Sheets	The following tables summarize the balance sheet classification and fair value of derivative instruments included in the consolidated balance sheets at January 26, 2018 and April 28, 2017 . The fair value amounts are presented on a gross basis and are segregated between derivatives that are designated and qualify as hedging instruments and those that are not designated and do not qualify as hedging instruments and are further segregated by type of contract within those two categories. January 26, 2018 Derivative Assets Derivative Liabilities (in millions) Balance Sheet Classification Fair Value Balance Sheet Classification Fair Value Derivatives designated as hedging instruments Currency exchange rate contracts Other current assets $ 23 Other accrued expenses $ 249 Interest rate contracts Other assets 15 Other liabilities 5 Currency exchange rate contracts Other assets 8 Other liabilities 113 Total derivatives designated as hedging instruments $ 46 $ 367 Derivatives not designated as hedging instruments Currency exchange rate contracts Other current assets $ 52 Other accrued expenses $ 73 Total return swap Other current assets 22 Other accrued expenses — Stock warrants Other assets 29 Other liabilities — Cross currency interest rate contracts Other assets 6 Other liabilities 8 Total derivatives not designated as hedging instruments $ 109 $ 81 Total derivatives $ 155 $ 448 April 28, 2017 Derivative Assets Derivative Liabilities (in millions) Balance Sheet Classification Fair Value Balance Sheet Classification Fair Value Derivatives designated as hedging instruments Currency exchange rate contracts Other current assets $ 152 Other accrued expenses $ 43 Interest rate contracts Other assets 41 Other liabilities — Currency exchange rate contracts Other assets 48 Other liabilities 14 Total derivatives designated as hedging instruments $ 241 $ 57 Derivatives not designated as hedging instruments Currency exchange rate contracts Other current assets 16 Other accrued expenses 36 Cross currency interest rate contracts Other assets 5 Other liabilities 11 Total derivatives not designated as hedging instruments $ 21 $ 47 Total derivatives $ 262 $ 104
Derivative Assets and Liabilities Measured at Fair Value on a Recurring Basis	The following table provides information by level for the derivative assets and liabilities that are measured at fair value on a recurring basis. January 26, 2018 April 28, 2017 (in millions) Level 1 Level 2 Level 1 Level 2 Derivative assets $ 83 $ 72 $ 216 $ 46 Derivative liabilities 435 13 93 11
Offsetting Assets	The following table provides information as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria as stipulated by the terms of the master netting arrangements with each of the counterparties. Derivatives not subject to master netting arrangements are not eligible for net presentation. January 26, 2018 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recorded Assets (Liabilities) Financial Instruments Collateral (Received) Posted Net Amount Derivative assets: Currency exchange rate contracts $ 83 $ (56 ) $ — $ 27 Interest rate contracts 15 (12 ) — 3 Cross currency interest rate contracts 6 (2 ) — 4 Stock warrants 29 — — 29 Total return swap 22 — — 22 $ 155 $ (70 ) $ — $ 85 Derivative liabilities: Currency exchange rate contracts $ (435 ) $ 66 $ 98 $ (271 ) Interest rate contracts (5 ) 2 1 (2 ) Cross currency interest rate contracts (8 ) 2 — (6 ) $ (448 ) $ 70 $ 99 $ (279 ) Total $ (293 ) $ — $ 99 $ (194 ) April 28, 2017 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recorded Assets (Liabilities) Financial Instruments Collateral (Received) Posted Net Amount Derivative assets: Currency exchange rate contracts $ 216 $ (58 ) $ (55 ) $ 103 Interest rate contracts 41 (15 ) (5 ) 21 Cross currency interest rate contracts 5 (2 ) — 3 $ 262 $ (75 ) $ (60 ) $ 127 Derivative liabilities: Currency exchange rate contracts $ (93 ) $ 73 $ — $ (20 ) Cross currency interest rate contracts (11 ) 2 — (9 ) $ (104 ) $ 75 $ — $ (29 ) Total $ 158 $ — $ (60 ) $ 98
Offsetting Liabilities	The following table provides information as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria as stipulated by the terms of the master netting arrangements with each of the counterparties. Derivatives not subject to master netting arrangements are not eligible for net presentation. January 26, 2018 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recorded Assets (Liabilities) Financial Instruments Collateral (Received) Posted Net Amount Derivative assets: Currency exchange rate contracts $ 83 $ (56 ) $ — $ 27 Interest rate contracts 15 (12 ) — 3 Cross currency interest rate contracts 6 (2 ) — 4 Stock warrants 29 — — 29 Total return swap 22 — — 22 $ 155 $ (70 ) $ — $ 85 Derivative liabilities: Currency exchange rate contracts $ (435 ) $ 66 $ 98 $ (271 ) Interest rate contracts (5 ) 2 1 (2 ) Cross currency interest rate contracts (8 ) 2 — (6 ) $ (448 ) $ 70 $ 99 $ (279 ) Total $ (293 ) $ — $ 99 $ (194 ) April 28, 2017 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recorded Assets (Liabilities) Financial Instruments Collateral (Received) Posted Net Amount Derivative assets: Currency exchange rate contracts $ 216 $ (58 ) $ (55 ) $ 103 Interest rate contracts 41 (15 ) (5 ) 21 Cross currency interest rate contracts 5 (2 ) — 3 $ 262 $ (75 ) $ (60 ) $ 127 Derivative liabilities: Currency exchange rate contracts $ (93 ) $ 73 $ — $ (20 ) Cross currency interest rate contracts (11 ) 2 — (9 ) $ (104 ) $ 75 $ — $ (29 ) Total $ 158 $ — $ (60 ) $ 98

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Jan. 26, 2018
Inventory Disclosure [Abstract]
Inventory Balances	Inventory balances, net of reserves, were as follows: (in millions) January 26, 2018 April 28, 2017 Finished goods $ 2,472 $ 2,211 Work in-process 523 458 Raw materials 756 669 Total $ 3,751 $ 3,338

Goodwill and Other Intangible34

Goodwill and Other Intangible Assets (Tables)	9 Months Ended
	Jan. 26, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Changes in the Carrying Amount of Goodwill	The following table presents the changes in the carrying amount of goodwill by reportable segment: (in millions) Cardiac and Vascular Group Minimally Invasive Therapies Group Restorative Therapies Group Diabetes Group Total April 28, 2017 $ 6,651 $ 20,411 $ 9,600 $ 1,853 $ 38,515 Goodwill as a result of acquisitions — 11 9 7 27 Purchase accounting adjustments 54 — — — 54 Currency translation 110 959 130 — 1,199 January 26, 2018 $ 6,815 $ 21,381 $ 9,739 $ 1,860 $ 39,795
Gross Carrying Amount of Indefinite-Lived Intangible Assets	The following table presents the gross carrying amount and accumulated amortization of intangible assets: January 26, 2018 April 28, 2017 (in millions) Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Definite-lived: Customer-related $ 16,989 $ (2,901 ) $ 16,862 $ (2,166 ) Purchased technology and patents 11,548 (4,248 ) 11,461 (3,690 ) Trademarks and tradenames 822 (562 ) 772 (461 ) Other 84 (48 ) 77 (42 ) Total $ 29,443 $ (7,759 ) $ 29,172 $ (6,359 ) Indefinite-lived: IPR&D $ 494 $ 594
Gross Carrying Amount and Accumulated Amortization of Definite-Lived Intangible Assets	The following table presents the gross carrying amount and accumulated amortization of intangible assets: January 26, 2018 April 28, 2017 (in millions) Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Definite-lived: Customer-related $ 16,989 $ (2,901 ) $ 16,862 $ (2,166 ) Purchased technology and patents 11,548 (4,248 ) 11,461 (3,690 ) Trademarks and tradenames 822 (562 ) 772 (461 ) Other 84 (48 ) 77 (42 ) Total $ 29,443 $ (7,759 ) $ 29,172 $ (6,359 ) Indefinite-lived: IPR&D $ 494 $ 594
Estimated Future Aggregate Amortization Expense, Definite-Lived Intangible Assets	Estimated aggregate amortization expense by fiscal year based on the carrying value of definite-lived intangible assets at January 26, 2018 , excluding any possible future amortization associated with acquired IPR&D which has not yet met technological feasibility, is as follows: (in millions) Amortization Expense Remaining 2018 $ 433 2019 1,684 2020 1,631 2021 1,611 2022 1,572 2023 1,494

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Jan. 26, 2018
Earnings Per Share [Abstract]
Computation of Basic and Diluted Earnings Per Share	The table below sets forth the computation of basic and diluted earnings (loss) per share: Three months ended Nine months ended (in millions, except per share data) January 26, 2018 January 27, 2017 January 26, 2018 January 27, 2017 Numerator: Net (loss) income attributable to ordinary shareholders $ (1,389 ) $ 821 $ 1,644 $ 2,865 Denominator: Basic – weighted average shares outstanding 1,354.0 1,372.2 1,357.2 1,381.9 Effect of dilutive securities: Employee stock options — 7.9 8.1 9.2 Employee restricted stock units — 3.0 3.4 3.4 Other — — 0.2 0.2 Diluted – weighted average shares outstanding 1,354.0 1,383.1 1,368.9 1,394.7 Basic (loss) earnings per share $ (1.03 ) $ 0.60 $ 1.21 $ 2.07 Diluted (loss) earnings per share $ (1.03 ) $ 0.59 $ 1.20 $ 2.05

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Jan. 26, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Components and Classification of Stock-based Compensation Expense	The following table presents the components and classification of stock-based compensation expense for stock options, restricted stock, and employee stock purchase plan shares recognized for the three and nine months ended January 26, 2018 and January 27, 2017 : Three months ended Nine months ended (in millions) January 26, 2018 January 27, 2017 January 26, 2018 January 27, 2017 Stock options $ 28 $ 37 $ 105 $ 128 Restricted stock 38 40 145 128 Employee stock purchase plan 6 5 20 16 Total stock-based compensation expense $ 72 $ 82 $ 270 $ 272 Cost of products sold $ 10 $ 12 $ 34 $ 38 Research and development expense 8 10 29 32 Selling, general, and administrative expense 53 55 187 179 Restructuring charges, net — — — 2 Acquisition-related items 1 5 4 21 Divestiture-related items — — 16 — Total stock-based compensation expense 72 82 270 272 Income tax benefits (12 ) (23 ) (69 ) (77 ) Total stock-based compensation expense, net of tax $ 60 $ 59 $ 201 $ 195

Retirement Benefit Plans (Table

Retirement Benefit Plans (Tables)	9 Months Ended
	Jan. 26, 2018
Retirement Benefits [Abstract]
Components of Net Periodic Benefit Cost	The net periodic benefit cost of the defined benefit pension plans included the following components for the three and nine months ended January 26, 2018 and January 27, 2017 : U.S. Non-U.S. Three months ended Three months ended (in millions) January 26, 2018 January 27, 2017 January 26, 2018 January 27, 2017 Service cost $ 29 $ 29 $ 17 $ 19 Interest cost 29 27 7 6 Expected return on plan assets (51 ) (47 ) (13 ) (12 ) Amortization of net actuarial loss 20 23 4 4 Plan settlement 15 — — — Net periodic benefit cost $ 42 $ 32 $ 15 $ 17 U.S. Non-U.S. Nine months ended Nine months ended (in millions) January 26, 2018 January 27, 2017 January 26, 2018 January 27, 2017 Service cost $ 87 $ 87 $ 51 $ 57 Interest cost 89 81 21 18 Expected return on plan assets (155 ) (141 ) (39 ) (36 ) Amortization of net actuarial loss 60 69 12 12 Plan settlement 15 — — — Net periodic benefit cost $ 96 $ 96 $ 45 $ 51

Accumulated Other Comprehensi38

Accumulated Other Comprehensive Income and Supplemental Equity Disclosure (Tables)	9 Months Ended
	Jan. 26, 2018
Equity [Abstract]
Changes in AOCI by Component	The following table provides changes in AOCI, net of tax, and by component. (in millions) Unrealized (Loss) Gain on Available-for-Sale Securities Cumulative Translation Adjustment Net Change in Retirement Obligations Unrealized (Loss) Gain on Derivative Financial Instruments Total Accumulated Other Comprehensive (Loss) Income April 28, 2017 $ (69 ) $ (1,452 ) $ (1,129 ) $ 37 $ (2,613 ) Other comprehensive income (loss) before reclassifications 50 1,559 (38 ) (351 ) 1,220 Reclassifications (9 ) (34 ) 49 5 11 Other comprehensive income (loss) 41 1,525 11 (346 ) 1,231 January 26, 2018 $ (28 ) $ 73 $ (1,118 ) $ (309 ) $ (1,382 ) (in millions) Unrealized (Loss) Gain on Available-for-Sale Securities Cumulative Translation Adjustment Net Change in Retirement Obligations Unrealized (Loss) Gain on Derivative Financial Instruments Total Accumulated Other Comprehensive (Loss) Income April 29, 2016 $ (107 ) $ (474 ) $ (1,197 ) $ (90 ) $ (1,868 ) Other comprehensive income (loss) before reclassifications (25 ) (1,239 ) — 255 (1,009 ) Reclassifications (15 ) — 66 (53 ) (2 ) Other comprehensive income (loss) (40 ) (1,239 ) 66 202 (1,011 ) January 27, 2017 $ (147 ) $ (1,713 ) $ (1,131 ) $ 112 $ (2,879 )
Supplemental Equity Schedule	The supplemental equity schedule below presents changes in the Company's total shareholders' equity and noncontrolling interests for the nine months ended January 26, 2018 and January 27, 2017 . (in millions) Total Shareholders' Equity Noncontrolling Interests Total Equity April 28, 2017 $ 50,294 $ 122 $ 50,416 Net income (loss) 1,644 (14 ) 1,630 Other comprehensive income 1,231 — 1,231 Dividends to shareholders (1,870 ) — (1,870 ) Issuance of shares under stock purchase and award plans 266 — 266 Repurchase of ordinary shares (1,897 ) — (1,897 ) Stock-based compensation 270 — 270 Cumulative effect of change in accounting principle 296 — 296 Additions (reductions) of noncontrolling ownership interests — (2 ) (2 ) January 26, 2018 $ 50,234 $ 106 $ 50,340 (in millions) Total Shareholders' Equity Noncontrolling Interests Total Equity April 29, 2016 $ 52,063 $ — $ 52,063 Net income (loss) 2,865 (5 ) 2,860 Other comprehensive loss (1,011 ) — (1,011 ) Dividends to shareholders (1,782 ) — (1,782 ) Issuance of shares under stock purchase and award plans 309 — 309 Repurchase of ordinary shares (3,409 ) — (3,409 ) Tax benefit from exercise of stock-based awards 80 — 80 Stock-based compensation 272 — 272 Additions (reductions) of noncontrolling ownership interests — 111 111 January 27, 2017 $ 49,387 $ 106 $ 49,493

Segment and Geographic Inform39

Segment and Geographic Information (Tables)	9 Months Ended
	Jan. 26, 2018
Segment Reporting [Abstract]
Net Sales by Segment	Net sales and earnings before interest expense, net, income tax provision, and amortization of intangible assets, not including centralized distribution costs and corporate charges by reportable segment are as follows: Three months ended Nine months ended (in millions) January 26, 2018 January 27, 2017 January 26, 2018 January 27, 2017 Cardiac and Vascular Group $ 2,800 $ 2,548 $ 8,219 $ 7,650 Minimally Invasive Therapies Group 2,041 2,417 6,479 7,314 Restorative Therapies Group 1,944 1,817 5,616 5,415 Diabetes Group 584 501 1,495 1,415 Net Sales $ 7,369 $ 7,283 $ 21,809 $ 21,794
Income From Operations Before Income Taxes by Reportable Segment and Reconciliation to Consolidated	Three months ended Nine months ended (in millions) January 26, 2018 January 27, 2017 January 26, 2018 January 27, 2017 Cardiac and Vascular Group $ 1,082 $ 965 $ 3,197 $ 2,936 Minimally Invasive Therapies Group 797 820 2,433 2,530 Restorative Therapies Group 756 717 2,186 2,087 Diabetes Group 187 185 389 502 Reportable segments' EBITA before other adjustments 2,822 2,687 8,205 8,055 Amortization of intangible assets (461 ) (497 ) (1,375 ) (1,484 ) Restructuring and associated costs (30 ) (21 ) (62 ) (172 ) Acquisition-related items (30 ) (68 ) (101 ) (148 ) Certain litigation charges (61 ) (218 ) (61 ) (300 ) IPR&D impairment (46 ) — (46 ) — Divestiture-related items — — (115 ) — Gain on sale of businesses — — 697 — Special charge — (100 ) (80 ) (100 ) Hurricane Maria — — (34 ) — Impact of inventory step-up — — — (38 ) Centralized distribution costs (471 ) (364 ) (1,399 ) (1,211 ) Interest expense, net (172 ) (180 ) (539 ) (532 ) Corporate (524 ) (272 ) (1,140 ) (903 ) Income before income taxes $ 1,027 $ 967 $ 3,950 $ 3,167
Net Sales to External Customers by Geography	Net sales to external customers by geography are as follows: Three months ended Nine months ended (in millions) January 26, 2018 January 27, 2017 January 26, 2018 January 27, 2017 Americas (1) $ 4,202 $ 4,417 $ 12,659 $ 13,185 EMEA (2) 1,895 1,652 5,319 4,895 Asia-Pacific 815 818 2,506 2,530 Greater China 457 396 1,325 1,184 Net Sales $ 7,369 $ 7,283 $ 21,809 $ 21,794 (1) The U.S., which is included in the Americas, had net sales to external customers of $3.9 billion and $11.7 billion for the three and nine months ended January 26, 2018 , respectively, compared to $4.1 billion and $12.3 billion for the three and nine months ended January 27, 2017 , respectively. (2) EMEA consists of Europe, Middle East, and Africa. Sales to Ireland were insignificant during all periods presented.

Guarantor Financial Informati40

Guarantor Financial Information (Tables)	9 Months Ended
	Jan. 26, 2018
Condensed Financial Information of Parent Company Only Disclosure [Abstract]
Consolidating Statement of Comprehensive Income	Consolidating Statement of Comprehensive Income Three Months Ended January 26, 2018 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total Net sales $ — $ 275 $ — $ 7,369 $ (275 ) $ 7,369 Costs and expenses: Cost of products sold — 243 — 2,126 (178 ) 2,191 Research and development expense — 165 — 393 — 558 Selling, general, and administrative expense 4 346 — 2,149 — 2,499 Amortization of intangible assets — 2 — 459 — 461 Restructuring charges, net — — — 7 — 7 Acquisition-related items — 27 — (1 ) — 26 Certain litigation charges — 24 — 37 — 61 Other (income) expense, net 10 (768 ) — 1,006 (108 ) 140 Operating profit (loss) (14 ) 236 — 1,193 11 1,426 Investment loss — 172 — 55 — 227 Interest income — (90 ) (133 ) (410 ) 535 (98 ) Interest expense 63 464 73 205 (535 ) 270 Interest expense, net 63 374 (60 ) (205 ) — 172 Equity in net (income) loss of subsidiaries 1,314 1,161 1,374 — (3,849 ) — Income (loss) before income taxes (1,391 ) (1,471 ) (1,314 ) 1,343 3,860 1,027 Income tax (benefit) provision (2 ) 316 — 2,105 — 2,419 Net income (loss) (1,389 ) (1,787 ) (1,314 ) (762 ) 3,860 (1,392 ) Net loss attributable to noncontrolling interests — — — 3 — 3 Net income (loss) attributable to Medtronic (1,389 ) (1,787 ) (1,314 ) (759 ) 3,860 (1,389 ) Other comprehensive income (loss), net of tax 678 428 678 664 (1,770 ) 678 Other comprehensive loss attributable to noncontrolling interests — — — 3 — 3 Total comprehensive income (loss) $ (711 ) $ (1,359 ) $ (636 ) $ (95 ) $ 2,090 $ (711 ) Consolidating Statement of Comprehensive Income Nine Months Ended January 26, 2018 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total Net sales $ — $ 879 $ — $ 21,807 $ (877 ) $ 21,809 Costs and expenses: Cost of products sold — 693 — 6,548 (581 ) 6,660 Research and development expense — 492 — 1,169 — 1,661 Selling, general, and administrative expense 9 1,020 — 6,393 — 7,422 Amortization of intangible assets — 6 — 1,369 — 1,375 Restructuring charges, net — 2 — 21 — 23 Acquisition-related items — 45 — 32 — 77 Certain litigation charges — 24 — 37 — 61 Divestiture-related items — 15 — 99 — 114 Gain on sale of businesses — — — (697 ) — (697 ) Special charge — 80 — — — 80 Other (income) expense, net 35 (1,397 ) — 2,001 (322 ) 317 Operating profit (loss) (44 ) (101 ) — 4,835 26 4,716 Investment loss — 172 — 55 — 227 Interest income — (225 ) (344 ) (1,091 ) 1,370 (290 ) Interest expense 172 1,330 155 542 (1,370 ) 829 Interest expense, net 172 1,105 (189 ) (549 ) — 539 Equity in net (income) loss of subsidiaries (1,855 ) (1,599 ) (1,666 ) — 5,120 — Income (loss) before income taxes 1,639 221 1,855 5,329 (5,094 ) 3,950 Income tax (benefit) provision (5 ) 3 — 2,322 — 2,320 Net income (loss) 1,644 218 1,855 3,007 (5,094 ) 1,630 Net loss attributable to noncontrolling interests — — — 14 — 14 Net income (loss) attributable to Medtronic 1,644 218 1,855 3,021 (5,094 ) 1,644 Other comprehensive income (loss), net of tax 1,231 948 1,231 1,194 (3,373 ) 1,231 Other comprehensive loss attributable to noncontrolling interests — — — 14 — 14 Total comprehensive income (loss) $ 2,875 $ 1,166 $ 3,086 $ 4,215 $ (8,467 ) $ 2,875 Consolidating Statement of Comprehensive Income Three Months Ended January 27, 2017 Medtronic Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total Net sales $ — $ 237 $ — $ 7,283 $ (237 ) $ 7,283 Costs and expenses: Cost of products sold — 214 — 2,207 (153 ) 2,268 Research and development expense — 147 — 383 — 530 Selling, general, and administrative expense 4 264 — 2,120 — 2,388 Amortization of intangible assets — 3 — 494 — 497 Restructuring charges, net — 22 — (1 ) — 21 Acquisition-related items — 36 — 32 — 68 Certain litigation charges — — — 218 — 218 Special charge — 100 — — — 100 Other (income) expense, net 80 (462 ) — 526 (98 ) 46 Operating profit (loss) (84 ) (87 ) — 1,304 14 1,147 Interest income — (62 ) (157 ) (294 ) 425 (88 ) Interest expense 32 397 18 246 (425 ) 268 Interest expense, net 32 335 (139 ) (48 ) — 180 Equity in net (income) loss of subsidiaries (937 ) (594 ) (798 ) — 2,329 — Income (loss) before income taxes 821 172 937 1,352 (2,315 ) 967 Income tax (benefit) provision — (105 ) — 252 — 147 Net income (loss) 821 277 937 1,100 (2,315 ) 820 Net loss attributable to noncontrolling interests — — — 1 — 1 Net income (loss) attributable to Medtronic 821 277 937 1,101 (2,315 ) 821 Other comprehensive income (loss), net of tax (551 ) (183 ) (551 ) (584 ) 1,318 (551 ) Other comprehensive loss attributable to noncontrolling interests — — — 1 — 1 Total comprehensive income (loss) $ 270 $ 94 $ 386 $ 517 $ (997 ) $ 270 Consolidating Statement of Comprehensive Income Nine Months Ended January 27, 2017 Medtronic Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total Net sales $ — $ 919 $ — $ 21,793 $ (918 ) $ 21,794 Costs and expenses: Cost of products sold — 706 — 6,775 (626 ) 6,855 Research and development expense — 469 — 1,171 — 1,640 Selling, general, and administrative expense 9 828 — 6,395 — 7,232 Amortization of intangible assets — 9 — 1,475 — 1,484 Restructuring charges, net — 40 — 122 — 162 Acquisition-related items — 96 — 52 — 148 Certain litigation charges — — — 300 — 300 Special charge — 100 — — — 100 Other (income) expense, net 5 (1,431 ) — 1,906 (306 ) 174 Operating profit (loss) (14 ) 102 — 3,597 14 3,699 Interest income — (183 ) (477 ) (719 ) 1,107 (272 ) Interest expense 74 1,203 31 603 (1,107 ) 804 Interest expense, net 74 1,020 (446 ) (116 ) — 532 Equity in net (income) loss of subsidiaries (2,949 ) (2,785 ) (2,503 ) — 8,237 — Income (loss) before income taxes 2,861 1,867 2,949 3,713 (8,223 ) 3,167 Income tax (benefit) provision (4 ) (179 ) — 490 — 307 Net income (loss) 2,865 2,046 2,949 3,223 (8,223 ) 2,860 Net loss attributable to noncontrolling interests — — — 5 — 5 Net income (loss) attributable to Medtronic 2,865 2,046 2,949 3,228 (8,223 ) 2,865 Other comprehensive income (loss), net of tax (1,011 ) (472 ) (1,011 ) (1,085 ) 2,568 (1,011 ) Other comprehensive loss attributable to noncontrolling interests — — — 5 — 5 Total comprehensive income (loss) $ 1,854 $ 1,574 $ 1,938 $ 2,143 $ (5,655 ) $ 1,854 Consolidating Statement of Comprehensive Income Three Months Ended January 26, 2018 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total Net sales $ — $ — $ — $ 7,369 $ — $ 7,369 Costs and expenses: Cost of products sold — — — 2,191 — 2,191 Research and development expense — — — 558 — 558 Selling, general, and administrative expense 4 — — 2,495 — 2,499 Amortization of intangible assets — — — 461 — 461 Restructuring charges, net — — — 7 — 7 Acquisition-related items — — — 26 — 26 Certain litigation charges — — — 61 — 61 Other (income) expense, net 10 — — 130 — 140 Operating profit (loss) (14 ) — — 1,440 — 1,426 Investment loss — — — 227 — 227 Interest income — (13 ) (137 ) (154 ) 206 (98 ) Interest expense 63 19 73 321 (206 ) 270 Interest expense, net 63 6 (64 ) 167 — 172 Equity in net (income) loss of subsidiaries 1,314 (765 ) 1,378 — (1,927 ) — Income (loss) before income taxes (1,391 ) 759 (1,314 ) 1,046 1,927 1,027 Income tax (benefit) provision (2 ) — — 2,421 — 2,419 Net income (loss) (1,389 ) 759 (1,314 ) (1,375 ) 1,927 (1,392 ) Net loss attributable to noncontrolling interests — — — 3 — 3 Net income (loss) attributable to Medtronic (1,389 ) 759 (1,314 ) (1,372 ) 1,927 (1,389 ) Other comprehensive income (loss), net of tax 678 245 678 678 (1,601 ) 678 Other comprehensive loss attributable to non-controlling interests — — — 3 — 3 Total comprehensive income (loss) $ (711 ) $ 1,004 $ (636 ) $ (694 ) $ 326 $ (711 ) Consolidating Statement of Comprehensive Income Nine Months Ended January 26, 2018 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Total Net sales $ — $ — $ — $ 21,809 $ — $ 21,809 Costs and expenses: Cost of products sold — — — 6,660 — 6,660 Research and development expense — — — 1,661 — 1,661 Selling, general, and administrative expense 9 — 1 7,412 — 7,422 Amortization of intangible assets — — — 1,375 — 1,375 Restructuring charges, net — — — 23 — 23 Acquisition-related items — — — 77 — 77 Certain litigation charges — — — 61 — 61 Divestiture-related items — — — 114 — 114 Gain on sale of businesses — — — (697 ) — (697 ) Special charge — — — 80 — 80 Other (income) expense, net 35 1 — 281 — 317 Operating profit (loss) (44 ) (1 ) (1 ) 4,762 — 4,716 Investment loss — — — 227 — 227 Interest income — (45 ) (355 ) (392 ) 502 (290 ) Interest expense 172 63 156 940 (502 ) 829 Interest expense, net 172 18 (199 ) 548 — 539 Equity in net (income) loss of subsidiaries (1,855 ) (1,938 ) (1,657 ) — 5,450 — Income (loss) before income taxes 1,639 1,919 1,855 3,987 (5,450 ) 3,950 Income tax (benefit) provision (5 ) — — 2,325 — 2,320 Net income (loss) 1,644 1,919 1,855 1,662 (5,450 ) 1,630 Net loss attributable to noncontrolling interests — — — 14 — 14 Net income (loss) attributable to Medtronic 1,644 1,919 1,855 1,676 (5,450 ) 1,644 Other comprehensive income (loss), net of tax 1,231 314 1,231 1,231 (2,776 ) 1,231 Other comprehensive loss attributable to noncontrolling interests — — — 14 — 14 Total comprehensive income (loss) $ 2,875 $ 2,233 $ 3,086 $ 2,907 $ (8,226 ) $ 2,875 Consolidating Statement of Comprehensive Income Three Months Ended January 27, 2017 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Total Net sales $ — $ — $ — $ 7,283 $ — $ 7,283 Costs and expenses: Cost of products sold — — — 2,268 — 2,268 Research and development expense — — — 530 — 530 Selling, general, and administrative expense 4 — — 2,384 — 2,388 Amortization of intangible assets — — — 497 — 497 Restructuring charges, net — — — 21 — 21 Acquisition-related items — — — 68 — 68 Certain litigation charges — — — 218 — 218 Special charge — — — 100 — 100 Other (income) expense, net 80 — — (34 ) — 46 Operating profit (loss) (84 ) — — 1,231 — 1,147 Interest income — (23 ) (158 ) (108 ) 201 (88 ) Interest expense 32 26 18 393 (201 ) 268 Interest expense, net 32 3 (140 ) 285 — 180 Equity in net (income) loss of subsidiaries (937 ) (434 ) (797 ) — 2,168 — Income (loss) before income taxes 821 431 937 946 (2,168 ) 967 Income tax (benefit) provision — — — 147 — 147 Net income (loss) 821 431 937 799 (2,168 ) 820 Net loss attributable to noncontrolling interests — — — 1 — 1 Net income (loss) attributable to Medtronic 821 431 937 800 (2,168 ) 821 Other comprehensive income (loss), net of tax (551 ) (358 ) (551 ) (551 ) 1,460 (551 ) Other comprehensive loss attributable to — — — 1 — 1 Total comprehensive income (loss) $ 270 $ 73 $ 386 $ 249 $ (708 ) $ 270 Consolidating Statement of Comprehensive Income Nine Months Ended January 27, 2017 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Total Net sales $ — $ — $ — $ 21,794 $ — $ 21,794 Costs and expenses: Cost of products sold — — — 6,855 — 6,855 Research and development expense — — — 1,640 — 1,640 Selling, general, and administrative expense 9 1 2 7,220 — 7,232 Amortization of intangible assets — — — 1,484 — 1,484 Restructuring charges, net — — — 162 — 162 Acquisition-related items — — — 148 — 148 Certain litigation charges — — — 300 — 300 Special charge — — — 100 — 100 Other (income) expense, net 5 1 — 168 — 174 Operating profit (loss) (14 ) (2 ) (2 ) 3,717 — 3,699 Interest income — (71 ) (482 ) (315 ) 596 (272 ) Interest expense 74 81 30 1,215 (596 ) 804 Interest expense, net 74 10 (452 ) 900 — 532 Equity in net (income) loss of subsidiaries (2,949 ) (1,462 ) (2,499 ) — 6,910 — Income (loss) before income taxes 2,861 1,450 2,949 2,817 (6,910 ) 3,167 Income tax (benefit) provision (4 ) — — 311 — 307 Net income (loss) 2,865 1,450 2,949 2,506 (6,910 ) 2,860 Net loss attributable to noncontrolling interests — — — 5 — 5 Net income (loss) attributable to Medtronic 2,865 1,450 2,949 2,511 (6,910 ) 2,865 Other comprehensive income (loss), net of tax (1,011 ) (385 ) (1,011 ) (1,011 ) 2,407 (1,011 ) Other comprehensive loss attributable to — — — 5 — 5 Total comprehensive income (loss) $ 1,854 $ 1,065 $ 1,938 $ 1,500 $ (4,503 ) $ 1,854
Condensed Consolidating Balance Sheet	Condensed Consolidating Balance Sheet January 26, 2018 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total ASSETS Current assets: Cash and cash equivalents $ — $ 38 $ 61 $ 6,259 $ — $ 6,358 Investments — — — 8,078 — 8,078 Accounts receivable, net — — — 5,775 — 5,775 Inventories, net — 166 — 3,739 (154 ) 3,751 Intercompany receivable 40 14,773 — 33,103 (47,916 ) — Other current assets 5 313 — 2,327 — 2,645 Total current assets 45 15,290 61 59,281 (48,070 ) 26,607 Property, plant, and equipment, net — 1,378 — 3,139 — 4,517 Goodwill — — — 39,795 — 39,795 Other intangible assets, net — 13 — 22,165 — 22,178 Tax assets — 564 — 973 — 1,537 Investment in subsidiaries 59,130 58,914 59,923 — (177,967 ) — Intercompany loans receivable 3,000 6,520 18,357 32,510 (60,387 ) — Other assets — 267 — 899 — 1,166 Total assets $ 62,175 $ 82,946 $ 78,341 $ 158,762 $ (286,424 ) $ 95,800 LIABILITIES AND EQUITY Current liabilities: Current debt obligations $ — $ 2,000 $ 504 $ 398 $ — $ 2,902 Accounts payable — 368 — 1,441 — 1,809 Intercompany payable — 25,285 7,833 14,798 (47,916 ) — Accrued compensation 18 624 — 1,003 — 1,645 Accrued income taxes 14 — — 911 — 925 Other accrued expenses 2 640 15 2,995 — 3,652 Total current liabilities 34 28,917 8,352 21,546 (47,916 ) 10,933 Long-term debt — 21,771 1,843 2,304 — 25,918 Accrued compensation and retirement benefits — 988 — 536 — 1,524 Accrued income taxes 10 1,710 — 3,038 — 4,758 Intercompany loans payable 11,897 14,885 16,023 17,582 (60,387 ) — Deferred tax liabilities — — — 1,363 — 1,363 Other liabilities — 64 — 900 — 964 Total liabilities 11,941 68,335 26,218 47,269 (108,303 ) 45,460 Shareholders’ equity 50,234 14,611 52,123 111,387 (178,121 ) 50,234 Noncontrolling interests — — — 106 — 106 Total equity 50,234 14,611 52,123 111,493 (178,121 ) 50,340 Total liabilities and equity $ 62,175 $ 82,946 $ 78,341 $ 158,762 $ (286,424 ) $ 95,800 Condensed Consolidating Balance Sheet April 28, 2017 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Adjustments Total ASSETS Current assets: Cash and cash equivalents $ — $ 45 $ 5 $ 4,917 $ — $ 4,967 Investments — — — 8,741 — 8,741 Accounts receivable, net — — — 5,591 — 5,591 Inventories, net — 155 — 3,361 (178 ) 3,338 Intercompany receivable 51 16,301 — 30,475 (46,827 ) — Other current assets 10 227 — 1,628 — 1,865 Current assets held for sale — — — 371 — 371 Total current assets 61 16,728 5 55,084 (47,005 ) 24,873 Property, plant, and equipment, net — 1,311 — 3,050 — 4,361 Goodwill — — — 38,515 — 38,515 Other intangible assets, net — 20 — 23,387 — 23,407 Tax assets — 727 — 782 — 1,509 Investment in subsidiaries 55,833 55,811 52,618 — (164,262 ) — Intercompany loans receivable 3,000 6,530 16,114 25,621 (51,265 ) — Other assets — 434 — 798 — 1,232 Noncurrent assets held for sale — — — 5,919 — 5,919 Total assets $ 58,894 $ 81,561 $ 68,737 $ 153,156 $ (262,532 ) $ 99,816 LIABILITIES AND EQUITY Current liabilities: Current debt obligations $ — $ 5,000 $ 901 $ 1,619 $ — $ 7,520 Accounts payable — 304 — 1,427 — 1,731 Intercompany payable — 23,380 7,111 16,336 (46,827 ) — Accrued compensation 9 734 — 1,117 — 1,860 Accrued income taxes 13 — — 620 — 633 Other accrued expenses — 352 4 2,086 — 2,442 Current liabilities held for sale — — — 34 — 34 Total current liabilities 22 29,770 8,016 23,239 (46,827 ) 14,220 Long-term debt — 21,782 1,842 2,297 — 25,921 Accrued compensation and retirement benefits — 1,120 — 521 — 1,641 Accrued income taxes 10 1,658 — 737 — 2,405 Intercompany loans payable 8,568 13,109 10,049 19,539 (51,265 ) — Deferred tax liabilities — — — 2,978 — 2,978 Other liabilities — 153 — 1,362 — 1,515 Noncurrent liabilities held for sale — — — 720 — 720 Total liabilities 8,600 67,592 19,907 51,393 (98,092 ) 49,400 Shareholders' equity 50,294 13,969 48,830 101,641 (164,440 ) 50,294 Noncontrolling interests — — — 122 — 122 Total equity 50,294 13,969 48,830 101,763 (164,440 ) 50,416 Total liabilities and equity $ 58,894 $ 81,561 $ 68,737 $ 153,156 $ (262,532 ) $ 99,816 Condensed Consolidating Balance Sheet January 26, 2018 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Total ASSETS Current assets: Cash and cash equivalents $ — $ — $ 61 $ 6,297 $ — $ 6,358 Investments — — — 8,078 — 8,078 Accounts receivable, net — — — 5,775 — 5,775 Inventories, net — — — 3,751 — 3,751 Intercompany receivable 40 — 1,338 7,855 (9,233 ) — Other current assets 5 — — 2,640 — 2,645 Total current assets 45 — 1,399 34,396 (9,233 ) 26,607 Property, plant, and equipment, net — — — 4,517 — 4,517 Goodwill — — — 39,795 — 39,795 Other intangible assets, net — — — 22,178 — 22,178 Tax assets — — — 1,537 — 1,537 Investment in subsidiaries 59,130 53,153 58,590 — (170,873 ) — Intercompany loans receivable 3,000 2,316 18,357 16,123 (39,796 ) — Other assets — — — 1,166 — 1,166 Total assets $ 62,175 $ 55,469 $ 78,346 $ 119,712 $ (219,902 ) $ 95,800 LIABILITIES AND EQUITY Current liabilities: Current debt obligations $ — $ — $ 504 $ 2,398 $ — $ 2,902 Accounts payable — — — 1,809 — 1,809 Intercompany payable — 1,278 7,833 122 (9,233 ) — Accrued compensation 18 — — 1,627 — 1,645 Accrued income taxes 14 — — 911 — 925 Other accrued expenses 2 12 19 3,619 — 3,652 Total current liabilities 34 1,290 8,356 10,486 (9,233 ) 10,933 Long-term debt — 2,117 1,843 21,958 — 25,918 Accrued compensation and retirement benefits — — — 1,524 — 1,524 Accrued income taxes 10 — — 4,748 — 4,758 Intercompany loans payable 11,897 100 16,023 11,776 (39,796 ) — Deferred tax liabilities — — — 1,363 — 1,363 Other liabilities — — 1 963 — 964 Total liabilities 11,941 3,507 26,223 52,818 (49,029 ) 45,460 Shareholders’ equity 50,234 51,962 52,123 66,788 (170,873 ) 50,234 Noncontrolling interests — — — 106 — 106 Total equity 50,234 51,962 52,123 66,894 (170,873 ) 50,340 Total liabilities and equity $ 62,175 $ 55,469 $ 78,346 $ 119,712 $ (219,902 ) $ 95,800 Condensed Consolidating Balance Sheet April 28, 2017 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total ASSETS Current assets: Cash and cash equivalents $ — $ 33 $ 5 $ 4,929 $ — $ 4,967 Investments — — — 8,741 — 8,741 Accounts receivable, net — — — 5,591 — 5,591 Inventories, net — — — 3,338 — 3,338 Intercompany receivable 51 — 1,329 7,111 (8,491 ) — Other current assets 10 — — 1,855 — 1,865 Current assets held for sale — — — 371 — 371 Total current assets 61 33 1,334 31,936 (8,491 ) 24,873 Property, plant, and equipment, net — — — 4,361 — 4,361 Goodwill — — — 38,515 — 38,515 Other intangible assets, net — — — 23,407 — 23,407 Tax assets — — — 1,509 — 1,509 Investment in subsidiaries 55,833 47,248 51,294 — (154,375 ) — Intercompany loans receivable 3,000 2,978 16,114 10,149 (32,241 ) — Other assets — — — 1,232 — 1,232 Noncurrent assets held for sale — — — 5,919 — 5,919 Total assets $ 58,894 $ 50,259 $ 68,742 $ 117,028 $ (195,107 ) $ 99,816 LIABILITIES AND EQUITY Current liabilities: Current debt obligations $ — $ 1,176 $ 901 $ 5,443 $ — $ 7,520 Accounts payable — — — 1,731 — 1,731 Intercompany payable — 1,269 7,111 111 (8,491 ) — Accrued compensation 9 — — 1,851 — 1,860 Accrued income taxes 13 — — 620 — 633 Other accrued expenses — 23 8 2,411 — 2,442 Current liabilities held for sale — — — 34 — 34 Total current liabilities 22 2,468 8,020 12,201 (8,491 ) 14,220 Long-term debt — 2,133 1,842 21,946 — 25,921 Accrued compensation and retirement benefits — — — 1,641 — 1,641 Accrued income taxes 10 — — 2,395 — 2,405 Intercompany loans payable 8,568 100 10,050 13,523 (32,241 ) — Deferred tax liabilities — — — 2,978 — 2,978 Other liabilities — — — 1,515 — 1,515 Noncurrent liabilities held for sale — — — 720 — 720 Total liabilities 8,600 4,701 19,912 56,919 (40,732 ) 49,400 Shareholders' equity 50,294 45,558 48,830 59,987 (154,375 ) 50,294 Noncontrolling interests — — — 122 — 122 Total Equity 50,294 45,558 48,830 60,109 (154,375 ) 50,416 Total liabilities and equity $ 58,894 $ 50,259 $ 68,742 $ 117,028 $ (195,107 ) $ 99,816
Condensed Consolidating Statement of Cash Flows	Condensed Consolidating Statement of Cash Flows Nine Months Ended January 26, 2018 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total Operating Activities: Net cash provided by (used in) operating activities $ 172 $ (958 ) $ 200 $ 4,232 $ — $ 3,646 Investing Activities: Acquisitions, net of cash acquired — — — (111 ) — (111 ) Proceeds from sale of businesses — — — 6,058 — 6,058 Additions to property, plant, and equipment — (234 ) — (542 ) — (776 ) Purchases of investments — — — (2,479 ) — (2,479 ) Sales and maturities of investments — — — 3,060 — 3,060 Capital contribution paid — (59 ) (4,200 ) — 4,259 — Other investing activities, net — — — (5 ) — (5 ) Net cash provided by (used in) investing activities — (293 ) (4,200 ) 5,981 4,259 5,747 Financing Activities: Acquisition-related contingent consideration — — — (43 ) — (43 ) Change in current debt obligations, net — — (397 ) 6 — (391 ) Repayment of short-term borrowings (maturities greater than 90 days) — — — (44 ) — (44 ) Proceeds from short-term borrowings (maturities greater than 90 days) — — — 1 — 1 Issuance of long-term debt — — — 21 — 21 Payments on long-term debt — (3,000 ) — (1,167 ) — (4,167 ) Dividends to shareholders (1,870 ) — — — — (1,870 ) Issuance of ordinary shares 333 — — — — 333 Repurchase of ordinary shares (1,964 ) — — — — (1,964 ) Net intercompany loan borrowings (repayments) 3,329 4,244 4,453 (12,026 ) — — Capital contribution received — — — 4,259 (4,259 ) — Other financing activities — — — (2 ) — (2 ) Net cash provided by (used in) financing activities (172 ) 1,244 4,056 (8,995 ) (4,259 ) (8,126 ) Effect of exchange rate changes on cash and cash equivalents — — — 124 — 124 Net change in cash and cash equivalents — (7 ) 56 1,342 — 1,391 Cash and cash equivalents at beginning of period — 45 5 4,917 — 4,967 Cash and cash equivalents at end of period $ — $ 38 $ 61 $ 6,259 $ — $ 6,358 Condensed Consolidating Statement of Cash Flows Nine Months Ended January 27, 2017 Medtronic Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Adjustments Total Operating Activities: Net cash provided by (used in) operating activities $ 834 $ 933 $ 161 $ 3,179 $ — $ 5,107 Investing Activities: Acquisitions, net of cash acquired — (940 ) — (388 ) — (1,328 ) Additions to property, plant, and equipment — (257 ) — (667 ) — (924 ) Purchases of investments — — — (3,516 ) 162 (3,354 ) Sales and maturities of investments — 210 — 4,238 (162 ) 4,286 Capital contribution paid — (241 ) — — 241 — Other investing activities, net — — — 21 — 21 Net cash provided by (used in) investing activities — (1,228 ) — (312 ) 241 (1,299 ) Financing Activities: Acquisition-related contingent consideration — — — (58 ) — (58 ) Change in current debt obligations, net — — 1,099 19 — 1,118 Repayment of short-term borrowings (maturities greater than 90 days) — — — (2 ) — (2 ) Proceeds from short-term borrowings (maturities greater than 90 days) — — — 4 — 4 Issuance of long-term debt — — — 131 — 131 Payments on long-term debt — (29 ) — (332 ) — (361 ) Dividends to shareholders (1,782 ) — — — — (1,782 ) Issuance of ordinary shares 309 — — — — 309 Repurchase of ordinary shares (3,409 ) — — — — (3,409 ) Net intercompany loan borrowings (repayments) 4,048 275 (1,260 ) (3,063 ) — — Capital contribution received — — — 241 (241 ) — Other financing activities — 34 — 46 — 80 Net cash provided by (used in) financing activities (834 ) 280 (161 ) (3,014 ) (241 ) (3,970 ) Effect of exchange rate changes on cash and cash equivalents — — — 54 — 54 Net change in cash and cash equivalents — (15 ) — (93 ) — (108 ) Cash and cash equivalents at beginning of period — 55 — 2,821 — 2,876 Cash and cash equivalents at end of period $ — $ 40 $ — $ 2,728 $ — $ 2,768 Condensed Consolidating Statement of Cash Flows Nine Months Ended January 26, 2018 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total Operating Activities: Net cash provided by (used in) operating activities $ 172 $ 978 $ 210 $ 3,334 $ (1,048 ) $ 3,646 Investing Activities: Acquisitions, net of cash acquired — — — (111 ) — (111 ) Proceeds from sale of businesses — — — 6,058 — 6,058 Additions to property, plant, and equipment — — — (776 ) — (776 ) Purchases of investments — — — (2,479 ) — (2,479 ) Sales and maturities of investments — — — 3,060 — 3,060 Capital contribution paid — (531 ) (4,200 ) — 4,731 — Other investing activities, net — — — (5 ) — (5 ) Net cash provided by (used in) investing activities — (531 ) (4,200 ) 5,747 4,731 5,747 Financing Activities: Acquisition-related contingent consideration — — — (43 ) — (43 ) Change in current debt obligations, net — — (397 ) 6 — (391 ) Repayment of short-term borrowings (maturities greater than 90 days) — — — (44 ) — (44 ) Proceeds from short-term borrowings (maturities greater than 90 days) — — — 1 — 1 Issuance of long-term debt — — — 21 — 21 Payments on long-term debt — (1,150 ) — (3,017 ) — (4,167 ) Dividends to shareholders (1,870 ) — — — — (1,870 ) Issuance of ordinary shares 333 — — — — 333 Repurchase of ordinary shares (1,964 ) — — — — (1,964 ) Net intercompany loan borrowings (repayments) 3,329 670 4,443 (8,442 ) — — Intercompany dividend paid — — — (1,048 ) 1,048 — Capital contribution received — — — 4,731 (4,731 ) — Other financing activities — — — (2 ) — (2 ) Net cash provided by (used in) financing activities (172 ) (480 ) 4,046 (7,837 ) (3,683 ) (8,126 ) Effect of exchange rate changes on cash and cash equivalents — — — 124 — 124 Net change in cash and cash equivalents — (33 ) 56 1,368 — 1,391 Cash and cash equivalents at beginning of period — 33 5 4,929 — 4,967 Cash and cash equivalents at end of period $ — $ — $ 61 $ 6,297 $ — $ 6,358 Condensed Consolidating Statement of Cash Flows Nine Months Ended January 27, 2017 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total Operating Activities: Net cash provided by (used in) operating activities $ 834 $ 867 $ 15 $ 4,311 $ (920 ) $ 5,107 Investing Activities: Acquisitions, net of cash acquired — — — (1,328 ) — (1,328 ) Additions to property, plant, and equipment — — — (924 ) — (924 ) Purchases of investments — — — (3,354 ) — (3,354 ) Sales and maturities of investments — — — 4,286 — 4,286 Capital contributions paid — (537 ) — — 537 — Other investing activities, net — — — 21 — 21 Net cash provided by (used in) investing activities — (537 ) — (1,299 ) 537 (1,299 ) Financing Activities: Acquisition-related contingent consideration — — — (58 ) — (58 ) Change in current debt obligations, net — — 1,099 19 — 1,118 Repayment of short-term borrowings (maturities greater than 90 days) — — — (2 ) — (2 ) Proceeds from short-term borrowings (maturities greater than 90 days) — — — 4 — 4 Issuance of long-term debt — — — 131 — 131 Payments on long-term debt — — — (361 ) — (361 ) Dividends to shareholders (1,782 ) — — — — (1,782 ) Issuance of ordinary shares 309 — — — — 309 Repurchase of ordinary shares (3,409 ) — — — — (3,409 ) Net intercompany loan borrowings (repayments) 4,048 (457 ) (1,114 ) (2,477 ) — — Intercompany dividend paid — — — (920 ) 920 — Capital contributions received — — — 537 (537 ) — Other financing activities — — — 80 — 80 Net cash provided by (used in) financing activities (834 ) (457 ) (15 ) (3,047 ) 383 (3,970 ) Effect of exchange rate changes on cash and cash equivalents — — — 54 — 54 Net change in cash and cash equivalents — (127 ) — 19 — (108 ) Cash and cash equivalents at beginning of period — 208 — 2,668 — 2,876 Cash and cash equivalents at end of period $ — $ 81 $ — $ 2,687 $ — $ 2,768

New Accounting Pronouncements (

New Accounting Pronouncements (Details) - USD ($)	3 Months Ended	9 Months Ended
	Jan. 26, 2018	Jan. 26, 2018	Jul. 28, 2017	Apr. 28, 2017
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect of change in accounting principle				$ 296,000,000
Accounting Standards Update 2016-09
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Increase (decrease) to net income	$ 9,000,000	$ 50,000,000
Increase (decrease) to diluted earnings per share (in dollars per share)	$ 0.01	$ 0.04
Accounting Standards Update 2016-09 | Retained Earnings
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect of change in accounting principle	$ 0	$ 0
Accounting Standards Update 2016-16
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Increase (decrease) to net income	$ (5,000,000)	$ 552,000,000
Increase (decrease) to diluted earnings per share (in dollars per share)	$ 0	$ 0.40
Accounting Standards Update 2016-16 | Retained Earnings
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect of change in accounting principle			$ 296,000,000

Acquisitions and Acquisition-42

Acquisitions and Acquisition-Related Items - Fair Value of Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Millions	Jan. 26, 2018	Apr. 28, 2017	Aug. 23, 2016
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Goodwill	$ 39,795	$ 38,515
Heartware International, Inc.
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Other current assets			$ 351
Property, plant, and equipment			14
Other intangible assets			625
Goodwill			481
Other assets			84
Total assets acquired			1,555
Current liabilities			143
Deferred tax liabilities			6
Long-term debt			245
Other liabilities			89
Total liabilities assumed			483
Net assets acquired			$ 1,072
All Other
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Other current assets	3
Property, plant, and equipment	6
Other intangible assets	93
Goodwill	27
Other assets	0
Total assets acquired	129
Current liabilities	2
Deferred tax liabilities	3
Long-term debt	0
Other liabilities	0
Total liabilities assumed	5
Net assets acquired	$ 124

Acquisitions and Acquisition-43

Acquisitions and Acquisition-Related Items - Fair Value Measurement, Contingent Consideration, Significant Unobservable Inputs (Details) - USD ($) $ in Millions	9 Months Ended
	Jan. 26, 2018	Oct. 27, 2017	Apr. 28, 2017	Jan. 27, 2017	Oct. 28, 2016	Apr. 29, 2016
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Contingent consideration, fair value	$ 171	$ 190	$ 246	$ 262	$ 285	$ 377
Revenue-based payments | Recurring | Level 3 | Discounted cash flow
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Contingent consideration, fair value	$ 88
Revenue-based payments | Minimum | Recurring | Level 3 | Discounted cash flow
Fair Value Inputs
Discount rate	11.00%
Probability of payment	30.00%
Revenue-based payments | Maximum | Recurring | Level 3 | Discounted cash flow
Fair Value Inputs
Discount rate	32.50%
Probability of payment	100.00%
Product development and other milestone-based payments | Recurring | Level 3 | Discounted cash flow
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Contingent consideration, fair value	$ 83
Fair Value Inputs
Discount rate	5.50%
Product development and other milestone-based payments | Minimum | Recurring | Level 3 | Discounted cash flow
Fair Value Inputs
Probability of payment	75.00%
Product development and other milestone-based payments | Maximum | Recurring | Level 3 | Discounted cash flow
Fair Value Inputs
Probability of payment	100.00%

Acquisitions and Acquisition-44

Acquisitions and Acquisition-Related Items - Reconciliation of Beginning and Ending Balances of Contingent Consideration (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jan. 26, 2018	Jan. 27, 2017	Jan. 26, 2018	Jan. 27, 2017
Reconciliation of Beginning and Ending Balances of Contingent Milestone Payments Associated with Acquisitions [Roll Forward]
Beginning Balance	$ 190	$ 285	$ 246	$ 377
Purchase price contingent consideration	13	(4)	28	28
Payments	(20)	(23)	(66)	(62)
Change in fair value	(12)	4	(37)	(81)
Ending Balance	$ 171	$ 262	$ 171	$ 262

Acquisitions and Acquisition-45

Acquisitions and Acquisition-Related Items - Narrative (Details) - USD ($) $ in Millions	Aug. 23, 2016	Jan. 26, 2018	Jan. 27, 2017	Apr. 24, 2015	Jan. 26, 2018	Jan. 27, 2017	Oct. 27, 2017	Apr. 28, 2017	Oct. 28, 2016	Aug. 31, 2016	Apr. 29, 2016
Business Acquisition [Line Items]
Goodwill		$ 39,795			$ 39,795			$ 38,515
Acquisition-related items		26	$ 68		77	$ 148
Cost of products sold		2,191	2,268		6,660	6,855
Fair value of contingent consideration		171	262		171	262	$ 190	246	$ 285		$ 377
Other liabilities
Business Acquisition [Line Items]
Fair value of contingent consideration		80			80			180
Other accrued expenses
Business Acquisition [Line Items]
Fair value of contingent consideration		91			91			$ 66
Heartware International, Inc.
Business Acquisition [Line Items]
Acquisition consideration	$ 1,100
Other intangible assets	625
Goodwill	481
Long-term debt	245
Debt redeemed										$ 203
Heartware International, Inc. | Bank borrowings | Debt due December 2017
Business Acquisition [Line Items]
Long-term debt	42
Heartware International, Inc. | Customer-related and technology-related
Business Acquisition [Line Items]
Other intangible assets	$ 602
Estimated useful lives	15 years
Heartware International, Inc. | Tradenames
Business Acquisition [Line Items]
Other intangible assets	$ 23
Estimated useful lives	5 years
Covidien plc
Business Acquisition [Line Items]
Acquisition-related items				$ 50,000
All Other
Business Acquisition [Line Items]
Other intangible assets		93			93
Goodwill		27			27
Long-term debt		0			0
Acquisition-related items		48			137
Acquisition-related items and other		30			101
Cost of products sold		$ 4			$ 24
Integration costs			51			154
Accelerated and incremental stock compensation expense			$ 5			$ 21

Divestiture and Divestiture-R46

Divestiture and Divestiture-Related Items (Details)	Jul. 29, 2017USD ($)site	Jan. 26, 2018USD ($)	Jan. 27, 2017USD ($)	Jan. 26, 2018USD ($)	Jan. 27, 2017USD ($)	Apr. 28, 2017USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of businesses				$ 6,058,000,000	$ 0
Gain on sale of businesses		$ 0	$ 0	697,000,000	0
Divestiture-related items		$ 0	$ 0	114,000,000	$ 0
Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency Business
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of businesses	$ 6,100,000,000
Gain on sale of businesses	$ 697,000,000
Sale of businesses, number of dedicated manufacturing sites | site	17
Sale of businesses, transitional agreement, manufacture and supply services, term	5 years
Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency Business | Disposal Group, Held-for-sale, Not Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Inventories, net						$ 371,000,000
Property, plant, and equipment, net						689,000,000
Goodwill						2,910,000,000
Other intangible assets, net						2,320,000,000
Total assets held for sale						6,290,000,000
Other accrued expenses						34,000,000
Accrued compensation and retirement benefits						12,000,000
Deferred tax liabilities						707,000,000
Other liabilities						1,000,000
Total liabilities held for sale						$ 754,000,000
Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency Business | Disposal group, disposed of by sale, not discontinued operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Accelerated and incremental stock compensation expense				$ 16,000,000
Maximum | Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency Business
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Sale of businesses, transitional agreement, administrative services, term	12 months

Special Charge (Details)

Special Charge (Details) - USD ($)	3 Months Ended		9 Months Ended
	Jan. 26, 2018	Jan. 27, 2017	Jan. 26, 2018	Jan. 27, 2017
Commitments and Contingencies Disclosure [Abstract]
Special charge	$ 0	$ 100,000,000	$ 80,000,000	$ 100,000,000

Restructuring - Termination Lia

Restructuring - Termination Liability and Restructuring Reserve (Details) - USD ($)	3 Months Ended		9 Months Ended
	Jan. 26, 2018	Jan. 27, 2017	Jan. 26, 2018	Jan. 27, 2017
Enterprise Excellence
Restructuring Reserve [Roll Forward]
Beginning balance			$ 0
Charges	$ 32,000,000		32,000,000
Cash payments			(23,000,000)
Ending balance	9,000,000		9,000,000
Enterprise Excellence | Employee Termination Benefits
Restructuring Reserve [Roll Forward]
Beginning balance			0
Charges			9,000,000
Cash payments			0
Ending balance	9,000,000		9,000,000
Enterprise Excellence | Associated Costs
Restructuring Reserve [Roll Forward]
Beginning balance			0
Charges			23,000,000
Cash payments			(23,000,000)
Ending balance	0		0
Cost Synergies
Restructuring Reserve [Roll Forward]
Beginning balance			291,000,000
Charges	0	$ 56,000,000	45,000,000	$ 214,000,000
Cash payments			(149,000,000)
Accrual adjustments	(2,000,000)	$ (35,000,000)	(15,000,000)	$ (42,000,000)
Ending balance	172,000,000		172,000,000
Cost Synergies | Employee Termination Benefits
Restructuring Reserve [Roll Forward]
Beginning balance			261,000,000
Charges			25,000,000
Cash payments			(119,000,000)
Accrual adjustments			(17,000,000)
Ending balance	150,000,000		150,000,000
Cost Synergies | Other Costs
Restructuring Reserve [Roll Forward]
Beginning balance			30,000,000
Charges			20,000,000
Cash payments			(30,000,000)
Accrual adjustments			2,000,000
Ending balance	22,000,000		22,000,000
Cost of products sold | Enterprise Excellence | Associated Costs
Restructuring Reserve [Roll Forward]
Charges	13,000,000		13,000,000
Cost of products sold | Cost Synergies
Restructuring Reserve [Roll Forward]
Charges			12,000,000
Selling, general, and administrative expense | Enterprise Excellence | Associated Costs
Restructuring Reserve [Roll Forward]
Charges	$ 10,000,000		10,000,000
Selling, general, and administrative expense | Cost Synergies
Restructuring Reserve [Roll Forward]
Charges			$ 4,000,000

Restructuring - Narrative (Deta

Restructuring - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended
	Jan. 26, 2018	Jan. 27, 2017	Jan. 26, 2018	Jan. 27, 2017
Enterprise Excellence
Restructuring Cost and Reserve [Line Items]
Charges	$ 32,000,000		$ 32,000,000
Restructuring reserve, payments and write-downs			23,000,000
Cost Synergies
Restructuring Cost and Reserve [Line Items]
Charges	0	$ 56,000,000	45,000,000	$ 214,000,000
Accrual (reversal of accrual) for restructuring reserves	(2,000,000)	(35,000,000)	(15,000,000)	(42,000,000)
Restructuring reserve, payments and write-downs			149,000,000
Cost Synergies | Cost of products sold
Restructuring Cost and Reserve [Line Items]
Charges			12,000,000
Cost Synergies | Selling, general, and administrative expense
Restructuring Cost and Reserve [Line Items]
Charges			4,000,000
Impairment of property, plant, and equipment | Cost Synergies
Restructuring Cost and Reserve [Line Items]
Restructuring reserve, payments and write-downs		$ 1,000,000		8,000,000
Inventory write-offs | Cost Synergies | Cost of products sold
Restructuring Cost and Reserve [Line Items]
Restructuring reserve, payments and write-downs				$ 10,000,000
Minimum | Pre tax exit and disposal costs and other | Enterprise Excellence
Restructuring Cost and Reserve [Line Items]
Expected cost	1,600,000,000		1,600,000,000
Maximum | Pre tax exit and disposal costs and other | Enterprise Excellence
Restructuring Cost and Reserve [Line Items]
Expected cost	$ 1,800,000,000		$ 1,800,000,000

Financial Instruments - Investm

Financial Instruments - Investments by Category and Related Balance Sheet Classification (Details) - USD ($) $ in Millions	Jan. 26, 2018	Apr. 28, 2017
Total available-for sale securities and investments measured at net asset value:
Cost	$ 8,366	$ 9,008
Unrealized Gains	179	127
Unrealized Losses	(229)	(246)
Fair Value	8,316	8,889
Cost method, equity method, and other investments:
Cost	407	589
Total investments [Abstract]
Cost	8,773	9,597
Unrealized Gains	179	127
Unrealized Losses	(229)	(246)
Fair Value	8,316	8,889
Investments
Total available-for sale securities and investments measured at net asset value:
Fair Value	8,078	8,741
Cost method, equity method, and other investments:
Cost	0	0
Total investments [Abstract]
Fair Value	8,078	8,741
Other Assets
Total available-for sale securities and investments measured at net asset value:
Fair Value	238	148
Cost method, equity method, and other investments:
Cost	407	589
Total investments [Abstract]
Fair Value	645	737
Level 1
Available-for-sale securities:
Cost	687	671
Unrealized Gains	126	51
Unrealized Losses	(18)	(9)
Fair Value	795	713
Level 1 | Investments
Available-for-sale securities:
Fair Value	602	610
Level 1 | Other Assets
Available-for-sale securities:
Fair Value	193	103
Level 2
Available-for-sale securities:
Cost	7,231	7,792
Unrealized Gains	53	76
Unrealized Losses	(203)	(228)
Fair Value	7,081	7,640
Level 2 | Investments
Available-for-sale securities:
Fair Value	7,081	7,640
Level 2 | Other Assets
Available-for-sale securities:
Fair Value	0	0
Level 3
Available-for-sale securities:
Cost	48	48
Unrealized Gains	0	0
Unrealized Losses	(3)	(3)
Fair Value	45	45
Cost method, equity method, and other investments:
Cost	407	589
Level 3 | Investments
Available-for-sale securities:
Fair Value	0	0
Cost method, equity method, and other investments:
Cost	0	0
Level 3 | Other Assets
Available-for-sale securities:
Fair Value	45	45
Cost method, equity method, and other investments:
Cost	407	589
U.S. government and agency securities | Level 1
Available-for-sale securities:
Cost	618	613
Unrealized Gains	0	2
Unrealized Losses	(16)	(5)
Fair Value	602	610
U.S. government and agency securities | Level 1 | Investments
Available-for-sale securities:
Fair Value	602	610
U.S. government and agency securities | Level 1 | Other Assets
Available-for-sale securities:
Fair Value	0	0
U.S. government and agency securities | Level 2
Available-for-sale securities:
Cost	882	860
Unrealized Gains	0	0
Unrealized Losses	(18)	(10)
Fair Value	864	850
U.S. government and agency securities | Level 2 | Investments
Available-for-sale securities:
Fair Value	864	850
U.S. government and agency securities | Level 2 | Other Assets
Available-for-sale securities:
Fair Value	0	0
Marketable equity securities | Other Assets
Available-for-sale securities:
Fair Value	193	103
Marketable equity securities | Level 1
Available-for-sale securities:
Cost	69	58
Unrealized Gains	126	49
Unrealized Losses	(2)	(4)
Fair Value	193	103
Marketable equity securities | Level 1 | Investments
Available-for-sale securities:
Fair Value	0	0
Marketable equity securities | Level 1 | Other Assets
Available-for-sale securities:
Fair Value	193	103
Corporate debt securities | Level 2
Available-for-sale securities:
Cost	4,254	4,643
Unrealized Gains	42	62
Unrealized Losses	(30)	(23)
Fair Value	4,266	4,682
Corporate debt securities | Level 2 | Investments
Available-for-sale securities:
Fair Value	4,266	4,682
Corporate debt securities | Level 2 | Other Assets
Available-for-sale securities:
Fair Value	0	0
Corporate debt securities | Level 3
Available-for-sale securities:
Cost	1	1
Unrealized Gains	0	0
Unrealized Losses	0	0
Fair Value	1	1
Corporate debt securities | Level 3 | Investments
Available-for-sale securities:
Fair Value	0	0
Corporate debt securities | Level 3 | Other Assets
Available-for-sale securities:
Fair Value	1	1
Mortgage-backed securities | Level 2
Available-for-sale securities:
Cost	753	766
Unrealized Gains	3	9
Unrealized Losses	(26)	(16)
Fair Value	730	759
Mortgage-backed securities | Level 2 | Investments
Available-for-sale securities:
Fair Value	730	759
Mortgage-backed securities | Level 2 | Other Assets
Available-for-sale securities:
Fair Value	0	0
Foreign government and agency securities | Level 2
Available-for-sale securities:
Cost	66	49
Unrealized Gains	0	0
Unrealized Losses	(1)	0
Fair Value	65	49
Foreign government and agency securities | Level 2 | Investments
Available-for-sale securities:
Fair Value	65	49
Foreign government and agency securities | Level 2 | Other Assets
Available-for-sale securities:
Fair Value	0	0
Other asset-backed securities | Level 2
Available-for-sale securities:
Cost	337	228
Unrealized Gains	1	1
Unrealized Losses	(2)	(1)
Fair Value	336	228
Other asset-backed securities | Level 2 | Investments
Available-for-sale securities:
Fair Value	336	228
Other asset-backed securities | Level 2 | Other Assets
Available-for-sale securities:
Fair Value	0	0
Debt funds
Investments measured at net asset value:
Cost	400	497
Unrealized Gains	0	0
Unrealized Losses	(5)	(6)
Fair Value	395	491
Debt funds | Investments
Investments measured at net asset value:
Fair Value	395	491
Debt funds | Other Assets
Investments measured at net asset value:
Fair Value	0	0
Debt funds | Level 2
Available-for-sale securities:
Cost	939	1,246
Unrealized Gains	7	4
Unrealized Losses	(126)	(178)
Fair Value	820	1,072
Debt funds | Level 2 | Investments
Available-for-sale securities:
Fair Value	820	1,072
Debt funds | Level 2 | Other Assets
Available-for-sale securities:
Fair Value	0	0
Auction rate securities | Level 3
Available-for-sale securities:
Cost	47	47
Unrealized Gains	0	0
Unrealized Losses	(3)	(3)
Fair Value	44	44
Auction rate securities | Level 3 | Investments
Available-for-sale securities:
Fair Value	0	0
Auction rate securities | Level 3 | Other Assets
Available-for-sale securities:
Fair Value	$ 44	$ 44

Financial Instruments - Availab

Financial Instruments - Available-For-Sale Securities in Continuous Unrealized Loss Position (Details) - USD ($) $ in Millions	Jan. 26, 2018	Apr. 28, 2017
AFS Continuous Unrealized Loss Position
Less than 12 months, Fair Value	$ 2,952	$ 2,749
Less than 12 months, Unrealized Losses	(49)	(43)
More than 12 months, Fair Value	1,999	1,312
More than 12 months, Unrealized Losses	(180)	(203)
Corporate debt securities
AFS Continuous Unrealized Loss Position
Less than 12 months, Fair Value	1,675	1,263
Less than 12 months, Unrealized Losses	(19)	(19)
More than 12 months, Fair Value	295	46
More than 12 months, Unrealized Losses	(11)	(4)
Auction rate securities
AFS Continuous Unrealized Loss Position
Less than 12 months, Fair Value	0	0
Less than 12 months, Unrealized Losses	0	0
More than 12 months, Fair Value	44	44
More than 12 months, Unrealized Losses	(3)	(3)
Mortgage-backed securities
AFS Continuous Unrealized Loss Position
Less than 12 months, Fair Value	435	276
Less than 12 months, Unrealized Losses	(9)	(4)
More than 12 months, Fair Value	107	95
More than 12 months, Unrealized Losses	(17)	(12)
U.S. government and agency securities
AFS Continuous Unrealized Loss Position
Less than 12 months, Fair Value	658	896
Less than 12 months, Unrealized Losses	(20)	(15)
More than 12 months, Fair Value	454	0
More than 12 months, Unrealized Losses	(14)	0
Foreign government and agency securities
AFS Continuous Unrealized Loss Position
Less than 12 months, Fair Value	0
Less than 12 months, Unrealized Losses	0
More than 12 months, Fair Value	36
More than 12 months, Unrealized Losses	(1)
Debt funds
AFS Continuous Unrealized Loss Position
Less than 12 months, Fair Value	0	173
Less than 12 months, Unrealized Losses	0	(1)
More than 12 months, Fair Value	1,001	1,125
More than 12 months, Unrealized Losses	(131)	(183)
Other asset-backed securities
AFS Continuous Unrealized Loss Position
Less than 12 months, Fair Value	184	127
Less than 12 months, Unrealized Losses	(1)	(1)
More than 12 months, Fair Value	61	0
More than 12 months, Unrealized Losses	(1)	0
Marketable equity securities
AFS Continuous Unrealized Loss Position
Less than 12 months, Fair Value	0	14
Less than 12 months, Unrealized Losses	0	(3)
More than 12 months, Fair Value	1	2
More than 12 months, Unrealized Losses	$ (2)	$ (1)

Financial Instruments - Unobser

Financial Instruments - Unobservable Inputs, and Items Measured at Fair Value on a Recurring Basis that Used Significant Unobservable Inputs (Level 3) (Details) - Recurring - Level 3 - Discounted cash flow - Auction rate securities	9 Months Ended
	Jan. 26, 2018
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Years to principal recovery	3 years
Illiquidity premium	6.00%
Minimum
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Years to principal recovery	2 years
Maximum
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Years to principal recovery	12 years

Financial Instruments - Activit

Financial Instruments - Activity Related to the Company's Investment Portfolio and Available-for-sale Debt Securities Contractual Maturities (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jan. 26, 2018	Jan. 27, 2017	Jan. 26, 2018	Jan. 27, 2017
AFS Debt Maturities
Due in one year or less	$ 885		$ 885
Due after one year through five years	2,748		2,748
Due after five years through ten years	3,161		3,161
Due after ten years	114		114
Total	6,908		6,908
Debt
AFS Gross Realized Gain (Loss)
Proceeds from sales	667	$ 661	3,021	$ 4,203
Gross realized gains	3	10	22	74
Gross realized losses	(2)	(7)	(17)	(56)
Impairment losses recognized	0	0	0	0
Equity
AFS Gross Realized Gain (Loss)
Proceeds from sales	39	1	39	83
Gross realized gains	8	0	15	29
Gross realized losses	0	0	0	0
Impairment losses recognized	$ (227)	$ (10)	$ (228)	$ (20)

Financial Instruments - Narrati

Financial Instruments - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended
	Jan. 26, 2018	Jan. 27, 2017	Jan. 26, 2018	Jan. 27, 2017	Oct. 27, 2017	Apr. 28, 2017
Schedule of Investments [Line Items]
Carrying amount of cost and equity method investments	$ 407,000,000		$ 407,000,000			$ 589,000,000
Investment loss	227,000,000	$ 0	227,000,000	$ 0
Cost and equity method investments, carrying value before realized loss					$ 317,000,000
Impairment, cost method investments		10,000,000		20,000,000
Other assets
Schedule of Investments [Line Items]
Carrying amount of cost and equity method investments	407,000,000		407,000,000			589,000,000
Debt securities
Schedule of Investments [Line Items]
Credit loss portion of other-than-temporary impairments	0		0			0
Reductions for available-for-sale securities sold	0	0	0	0
Marketable equity securities | Other expense, net
Schedule of Investments [Line Items]
Impairment charges, marketable securities	0	$ 0	0	$ 0
Marketable equity securities | Other assets
Schedule of Investments [Line Items]
Marketable securities	$ 193,000,000		$ 193,000,000			$ 103,000,000

Financing Arrangements - Long-T

Financing Arrangements - Long-Term Debt (Details) - USD ($) $ in Millions	9 Months Ended
	Jan. 26, 2018	Apr. 28, 2017
Debt Instrument [Line Items]
Current debt obligations	$ 2,902	$ 7,520
Long-term debt
Debt premium, net	123	135
Deferred financing costs	(114)	(128)
Long-term debt	$ 25,918	25,921
Senior notes | 5.600 percent ten-year 2009 senior notes
Long-term debt
Stated interest rate	5.60%
Term of debt instrument	10 years
Long-term debt, gross	$ 400	400
Senior notes | 1.700 percent two-year 2017 senior notes
Long-term debt
Stated interest rate	1.70%
Term of debt instrument	2 years
Long-term debt, gross	$ 1,000	1,000
Senior notes | 4.450 percent ten-year 2010 senior notes
Long-term debt
Stated interest rate	4.45%
Term of debt instrument	10 years
Long-term debt, gross	$ 766	766
Senior notes | 2.500 percent five-year 2015 senior notes
Long-term debt
Stated interest rate	2.50%
Term of debt instrument	5 years
Long-term debt, gross	$ 2,500	2,500
Senior notes | Floating rate five-year 2015 senior notes
Long-term debt
Term of debt instrument	5 years
Long-term debt, gross	$ 500	500
Senior notes | 4.200 percent ten-year 2010 CIFSA senior notes
Long-term debt
Stated interest rate	4.20%
Term of debt instrument	10 years
Long-term debt, gross	$ 600	600
Senior notes | 4.125 percent ten-year 2011 senior notes
Long-term debt
Stated interest rate	4.125%
Term of debt instrument	10 years
Long-term debt, gross	$ 500	500
Senior notes | 3.125 percent ten-year 2012 senior notes
Long-term debt
Stated interest rate	3.125%
Term of debt instrument	10 years
Long-term debt, gross	$ 675	675
Senior notes | 3.150 percent seven-year 2015 senior notes
Long-term debt
Stated interest rate	3.15%
Term of debt instrument	7 years
Long-term debt, gross	$ 2,500	2,500
Senior notes | 3.200 percent ten-year 2012 CIFSA senior notes
Long-term debt
Stated interest rate	3.20%
Term of debt instrument	10 years
Long-term debt, gross	$ 650	650
Senior notes | 2.750 percent ten-year 2013 senior notes
Long-term debt
Stated interest rate	2.75%
Term of debt instrument	10 years
Long-term debt, gross	$ 530	530
Senior notes | 2.950 percent ten-year 2013 CIFSA senior notes
Long-term debt
Stated interest rate	2.95%
Term of debt instrument	10 years
Long-term debt, gross	$ 310	310
Senior notes | 3.625 percent ten-year 2014 senior notes
Long-term debt
Stated interest rate	3.625%
Term of debt instrument	10 years
Long-term debt, gross	$ 850	850
Senior notes | 3.500 percent ten-year 2015 senior notes
Long-term debt
Stated interest rate	3.50%
Term of debt instrument	10 years
Long-term debt, gross	$ 4,000	4,000
Senior notes | 3.350 percent ten-year 2017 senior notes
Long-term debt
Stated interest rate	3.35%
Term of debt instrument	10 years
Long-term debt, gross	$ 850	850
Senior notes | 4.375 percent twenty-year 2015 senior notes
Long-term debt
Stated interest rate	4.375%
Term of debt instrument	20 years
Long-term debt, gross	$ 2,382	2,382
Senior notes | 6.550 percent thirty-year 2008 CIFSA senior notes
Long-term debt
Stated interest rate	6.55%
Term of debt instrument	30 years
Long-term debt, gross	$ 374	374
Senior notes | 6.500 percent thirty-year 2009 senior notes
Long-term debt
Stated interest rate	6.50%
Term of debt instrument	30 years
Long-term debt, gross	$ 300	300
Senior notes | 5.550 percent thirty-year 2010 senior notes
Long-term debt
Stated interest rate	5.55%
Term of debt instrument	30 years
Long-term debt, gross	$ 500	500
Senior notes | 4.500 percent thirty-year 2012 senior notes
Long-term debt
Stated interest rate	4.50%
Term of debt instrument	30 years
Long-term debt, gross	$ 400	400
Senior notes | 4.000 percent thirty-year 2013 senior notes
Long-term debt
Stated interest rate	4.00%
Term of debt instrument	30 years
Long-term debt, gross	$ 325	325
Senior notes | 4.625 percent thirty-year 2014 senior notes
Long-term debt
Stated interest rate	4.625%
Term of debt instrument	30 years
Long-term debt, gross	$ 650	650
Senior notes | 4.625 percent thirty-year 2015 senior notes
Long-term debt
Stated interest rate	4.625%
Term of debt instrument	30 years
Long-term debt, gross	$ 4,150	4,150
Interest rate swaps
Long-term debt
Long-term debt, gross	10	40
Capital lease obligations
Long-term debt
Capital lease obligations	22	23
Bank borrowings
Long-term debt
Long-term debt, gross	$ 165	$ 139

Financing Arrangements - Narrat

Financing Arrangements - Narrative (Details) - USD ($)	3 Months Ended	9 Months Ended
	Jan. 26, 2018	Jan. 26, 2018	Apr. 28, 2017
Debt Instrument, Fair Value Disclosure [Abstract]
Long-term debt, including the current portion, fair value	$ 29,300,000,000	$ 29,300,000,000	$ 30,400,000,000
Long-term debt, including the current portion, principal value	27,700,000,000	27,700,000,000	28,900,000,000
2015 Commercial Paper Program | Commercial Paper
Commercial Paper [Abstract]
Commercial paper, maximum borrowing amount	3,500,000,000	3,500,000,000
Commercial paper, amount outstanding	$ 504,000,000	$ 504,000,000	901,000,000
Weighted average original maturity	24 days	29 days
Weighted average interest rate	1.44%	1.33%
Amended and Restated Revolving Credit Agreement | Line of Credit
Line of Credit Facility
Line of credit, maximum capacity	$ 3,500,000,000	$ 3,500,000,000
Term of debt instrument		5 years
Line of credit, amount outstanding	$ 0	$ 0	$ 0

Derivatives and Currency Exch57

Derivatives and Currency Exchange Risk Management - Gains (Losses) on Derivatives and Amounts Reclassified into Income (Details) - Currency exchange rate contracts - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jan. 26, 2018	Jan. 27, 2017	Jan. 26, 2018	Jan. 27, 2017
Cash flow hedging
Derivative Instruments, Gain (Loss) [Line Items]
Recognized in AOCI	$ (287)	$ 190	$ (507)	$ 378
Other expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Currency exchange rate contract (losses) gains	(181)	67	(318)	27
Other expense, net | Cash flow hedging
Derivative Instruments, Gain (Loss) [Line Items]
Recognized in Income	$ (11)	$ 68	$ 1	$ 89

Derivatives and Currency Exch58

Derivatives and Currency Exchange Risk Management - Classification and Fair Value Amounts of Derivative Instruments in Balance Sheets (Details) - USD ($) $ in Millions	Jan. 26, 2018	Apr. 28, 2017
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	$ 155	$ 262
Liability Derivatives, Fair Value	448	104
Currency exchange rate contracts
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	83	216
Liability Derivatives, Fair Value	435	93
Interest rate contracts
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	15	41
Liability Derivatives, Fair Value	5
Total return swap
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	22
Stock warrants
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	29
Cross currency interest rate contracts
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	6	5
Liability Derivatives, Fair Value	8	11
Derivatives designated as hedging instruments
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	46	241
Liability Derivatives, Fair Value	367	57
Derivatives designated as hedging instruments | Currency exchange rate contracts | Other current assets
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	23	152
Derivatives designated as hedging instruments | Currency exchange rate contracts | Other assets
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	8	48
Derivatives designated as hedging instruments | Currency exchange rate contracts | Other accrued expenses
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	249	43
Derivatives designated as hedging instruments | Currency exchange rate contracts | Other liabilities
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	113	14
Derivatives designated as hedging instruments | Interest rate contracts | Other assets
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	15	41
Derivatives designated as hedging instruments | Interest rate contracts | Other liabilities
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	5	0
Derivatives not designated as hedging instruments
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	109	21
Liability Derivatives, Fair Value	81	47
Derivatives not designated as hedging instruments | Currency exchange rate contracts | Other current assets
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	52	16
Derivatives not designated as hedging instruments | Currency exchange rate contracts | Other accrued expenses
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	73	36
Derivatives not designated as hedging instruments | Total return swap | Other current assets
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	22
Derivatives not designated as hedging instruments | Total return swap | Other accrued expenses
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	0
Derivatives not designated as hedging instruments | Stock warrants | Other assets
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	29
Derivatives not designated as hedging instruments | Stock warrants | Other liabilities
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	0
Derivatives not designated as hedging instruments | Cross currency interest rate contracts | Other assets
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	6	5
Derivatives not designated as hedging instruments | Cross currency interest rate contracts | Other liabilities
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	$ 8	$ 11

Derivatives and Currency Exch59

Derivatives and Currency Exchange Risk Management - Derivative Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Recurring - USD ($) $ in Millions	Jan. 26, 2018	Apr. 28, 2017
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets	$ 83	$ 216
Derivative liabilities	435	93
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets	72	46
Derivative liabilities	$ 13	$ 11

Derivatives and Currency Exch60

Derivatives and Currency Exchange Risk Management - Offsetting Assets and Liabilities (Details) - USD ($) $ in Millions	Jan. 26, 2018	Apr. 28, 2017
Offsetting Assets and Liabilities [Line Items]
Derivative Assets, Gross Amount of Recorded Assets (Liabilities)	$ 155	$ 262
Derivative Assets, Gross Amount Not Offset on the Balance Sheet, Financial Instruments	(70)	(75)
Derivative Assets, Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	0	(60)
Derivative Assets, Net Amount	85	127
Derivative Liabilities, Gross Amount of Recorded Assets (Liabilities)	(448)	(104)
Derivative Liabilities, Gross Amount Not Offset on the Balance Sheet, Financial Instruments	70	75
Derivative Liabilities, Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	99	0
Derivative Liabilities, Net Amount	(279)	(29)
Gross Amount of Recorded Assets (Liabilities)	(293)	158
Gross Amount Not Offset on the Balance Sheet, Financial Instruments	0	0
Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	99	(60)
Net Amount	(194)	98
Currency exchange rate contracts
Offsetting Assets and Liabilities [Line Items]
Derivative Assets, Gross Amount of Recorded Assets (Liabilities)	83	216
Derivative Assets, Gross Amount Not Offset on the Balance Sheet, Financial Instruments	(56)	(58)
Derivative Assets, Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	0	(55)
Derivative Assets, Net Amount	27	103
Derivative Liabilities, Gross Amount of Recorded Assets (Liabilities)	(435)	(93)
Derivative Liabilities, Gross Amount Not Offset on the Balance Sheet, Financial Instruments	66	73
Derivative Liabilities, Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	98	0
Derivative Liabilities, Net Amount	(271)	(20)
Interest rate contracts
Offsetting Assets and Liabilities [Line Items]
Derivative Assets, Gross Amount of Recorded Assets (Liabilities)	15	41
Derivative Assets, Gross Amount Not Offset on the Balance Sheet, Financial Instruments	(12)	(15)
Derivative Assets, Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	0	(5)
Derivative Assets, Net Amount	3	21
Derivative Liabilities, Gross Amount of Recorded Assets (Liabilities)	(5)
Derivative Liabilities, Gross Amount Not Offset on the Balance Sheet, Financial Instruments	2
Derivative Liabilities, Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	1
Derivative Liabilities, Net Amount	(2)
Cross currency interest rate contracts
Offsetting Assets and Liabilities [Line Items]
Derivative Assets, Gross Amount of Recorded Assets (Liabilities)	6	5
Derivative Assets, Gross Amount Not Offset on the Balance Sheet, Financial Instruments	(2)	(2)
Derivative Assets, Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	0	0
Derivative Assets, Net Amount	4	3
Derivative Liabilities, Gross Amount of Recorded Assets (Liabilities)	(8)	(11)
Derivative Liabilities, Gross Amount Not Offset on the Balance Sheet, Financial Instruments	2	2
Derivative Liabilities, Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	0	0
Derivative Liabilities, Net Amount	(6)	$ (9)
Stock warrants
Offsetting Assets and Liabilities [Line Items]
Derivative Assets, Gross Amount of Recorded Assets (Liabilities)	29
Derivative Assets, Gross Amount Not Offset on the Balance Sheet, Financial Instruments	0
Derivative Assets, Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	0
Derivative Assets, Net Amount	29
Total return swap
Offsetting Assets and Liabilities [Line Items]
Derivative Assets, Gross Amount of Recorded Assets (Liabilities)	22
Derivative Assets, Gross Amount Not Offset on the Balance Sheet, Financial Instruments	0
Derivative Assets, Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	0
Derivative Assets, Net Amount	$ 22

Derivatives and Currency Exch61

Derivatives and Currency Exchange Risk Management - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended
	Jan. 26, 2018	Jan. 27, 2017	Jan. 26, 2018	Jan. 27, 2017	Apr. 28, 2017
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gains (losses) relating to ineffectiveness of cash flow hedges	$ 0	$ 0	$ 0	$ 0
Gains (losses) relating to ineffectiveness of forward starting interest rate derivatives		0		0
After-tax net unrealized gains (losses) associated with cash flow hedging instruments recorded in AOCI	(309,000,000)		(309,000,000)		$ 37,000,000
Cash flow hedge unrealized losses to be reclassified over the next 12 months			169,000,000
Debt, face amount	27,700,000,000		27,700,000,000		28,900,000,000
Gains (losses) relating to ineffectiveness of interest rate fair value hedges	0	0	0	0
Gains (losses) on firm commitments that no longer qualify as fair value hedges	0	0	0	0
Currency exchange rate contracts
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, notional amount	12,600,000,000		12,600,000,000		10,800,000,000
Currency exchange rate contracts | Cash flow hedging
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gains (losses) recognized in AOCI	(287,000,000)	190,000,000	(507,000,000)	378,000,000
Currency exchange rate contracts | Derivatives not designated as hedging instruments
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, notional amount	5,500,000,000		5,500,000,000		4,900,000,000
Currency exchange rate contracts | Derivatives designated as hedging instruments | Cash flow hedging
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, notional amount	7,000,000,000		$ 7,000,000,000		5,800,000,000
Maximum remaining maturity of foreign currency derivatives			3 years
Interest rate swaps
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gains (losses) recognized in AOCI		28,000,000		22,000,000
Interest rate swaps | Cash flow hedging | Interest expense, net
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Effective portion of net gains (losses) on derivative instruments reclassified from accumulated other comprehensive loss	0	0	$ 0	0
Interest rate swaps | Derivatives designated as hedging instruments | Cash flow hedging
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, notional amount		$ 300,000,000		$ 300,000,000
Average interest rate		3.10%		3.10%
Interest rate swaps | Derivatives designated as hedging instruments | Fair value hedging
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, notional amount	1,200,000,000		1,200,000,000		1,200,000,000
Market value of outstanding interest rate swap agreements - net unrealized gain	(10,000,000)		(10,000,000)		(41,000,000)
Market value of hedged item - net unrealized loss	$ 10,000,000		$ 10,000,000		41,000,000
4.125 percent ten-year 2011 senior notes | Senior notes
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Stated interest rate	4.125%		4.125%
4.125 percent ten-year 2011 senior notes | Senior notes | Interest rate swaps | Derivatives designated as hedging instruments | Fair value hedging
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Debt, face amount	$ 500,000,000		$ 500,000,000		$ 500,000,000
Stated interest rate	4.125%		4.125%		4.125%
3.125 percent ten-year 2012 senior notes | Senior notes
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Stated interest rate	3.125%		3.125%
3.125 percent ten-year 2012 senior notes | Senior notes | Interest rate swaps | Derivatives designated as hedging instruments | Fair value hedging
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Debt, face amount	$ 675,000,000		$ 675,000,000		$ 675,000,000
Stated interest rate	3.125%		3.125%		3.125%

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Jan. 26, 2018	Apr. 28, 2017
Inventory Disclosure [Abstract]
Finished goods	$ 2,472	$ 2,211
Work in-process	523	458
Raw materials	756	669
Total	$ 3,751	$ 3,338

Goodwill and Other Intangible63

Goodwill and Other Intangible Assets - Changes in the Carrying Amount of Goodwill (Details) $ in Millions	9 Months Ended
	Jan. 26, 2018USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 38,515
Goodwill as a result of acquisitions	27
Purchase accounting adjustments	54
Currency translation	1,199
Ending balance	39,795
Cardiac and Vascular Group
Goodwill [Roll Forward]
Beginning balance	6,651
Goodwill as a result of acquisitions	0
Purchase accounting adjustments	54
Currency translation	110
Ending balance	6,815
Minimally Invasive Therapies Group
Goodwill [Roll Forward]
Beginning balance	20,411
Goodwill as a result of acquisitions	11
Purchase accounting adjustments	0
Currency translation	959
Ending balance	21,381
Restorative Therapies Group
Goodwill [Roll Forward]
Beginning balance	9,600
Goodwill as a result of acquisitions	9
Purchase accounting adjustments	0
Currency translation	130
Ending balance	9,739
Diabetes Group
Goodwill [Roll Forward]
Beginning balance	1,853
Goodwill as a result of acquisitions	7
Purchase accounting adjustments	0
Currency translation	0
Ending balance	$ 1,860

Goodwill and Other Intangible64

Goodwill and Other Intangible Assets - Carrying Amount and Accumulated Amortization of Intangible Assets (Details) - USD ($) $ in Millions	Jan. 26, 2018	Apr. 28, 2017
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount, Amortizable	$ 29,443	$ 29,172
Accumulated Amortization	(7,759)	(6,359)
IPR&D
Indefinite-lived Intangible Assets [Line Items]
Gross Carrying Amount, Non-Amortizable	494	594
Customer-related
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount, Amortizable	16,989	16,862
Accumulated Amortization	(2,901)	(2,166)
Purchased technology and patents
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount, Amortizable	11,548	11,461
Accumulated Amortization	(4,248)	(3,690)
Trademarks and tradenames
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount, Amortizable	822	772
Accumulated Amortization	(562)	(461)
Other
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount, Amortizable	84	77
Accumulated Amortization	$ (48)	$ (42)

Goodwill and Other Intangible65

Goodwill and Other Intangible Assets - Estimated Future Aggregate Amortization Expense of Amortizable Intangible Assets (Details) $ in Millions	Jan. 26, 2018USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Remaining 2,018	$ 433
2,019	1,684
2,020	1,631
2,021	1,611
2,022	1,572
2,023	$ 1,494

Goodwill and Other Intangible66

Goodwill and Other Intangible Assets - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended
	Jan. 26, 2018	Jan. 27, 2017	Jan. 26, 2018	Jan. 27, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill impairment	$ 0	$ 0	$ 0	$ 0
Impairment of definite-lived intangible assets	0	0	0	0
Impairment of indefinite-lived intangible assets	63,000,000	0	68,000,000	0
Amortization expense	$ 461,000,000	$ 497,000,000	$ 1,375,000,000	$ 1,484,000,000

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Jan. 26, 2018	Jan. 27, 2017	Jan. 26, 2018	Jan. 27, 2017	Apr. 27, 2018	Apr. 28, 2017
Income Tax Contingency [Line Items]
Effective tax rate	235.50%	15.20%	58.70%	9.70%
Tax Cuts and Jobs Act of 2017, provisional income tax expense	$ 2,200		$ 2,200
Tax Cuts and Jobs Act of 2017, provisional transition tax for accumulated foreign earnings	2,400		2,400
Tax Cuts and Jobs Act of 2017, remeasure of deferred tax assets and liabilities, provisional tax benefit	155		155
Certain tax adjustments, settlements and other				$ 1,900
Tax benefit from sales of intellectual property			(398)
Tax expense from sale of business			37
Income tax charge due to the disallowance of net operating losses		$ 86
Tax adjustment related to redemption of intercompany minority interest				29
Gross unrecognized tax benefits	1,800		1,800			$ 1,900
Accrued gross interest and penalties	420		420
Unrecognized tax benefits that would impact effective tax rate	1,700		1,700
Accrued income taxes
Income Tax Contingency [Line Items]
Gross unrecognized tax benefits	$ 15		$ 15
Ardian, CoreValve and Ablation
Income Tax Contingency [Line Items]
Charge (benefit), settlements				371
Subsidiaries
Income Tax Contingency [Line Items]
Charge (benefit), settlements				$ 431
Scenario, Forecast
Income Tax Contingency [Line Items]
Blended statutory tax rate					30.50%

Earnings Per Share - Schedule o

Earnings Per Share - Schedule of Basic and Diluted Earnings (Loss) Per Share(Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Jan. 26, 2018	Jan. 27, 2017	Jan. 26, 2018	Jan. 27, 2017
Numerator:
Net (loss) income attributable to ordinary shareholders	$ (1,389)	$ 821	$ 1,644	$ 2,865
Denominator:
Basic weighted average shares outstanding (shares)	1,354	1,372.2	1,357.2	1,381.9
Effect of dilutive securities:
Employee stock options (shares)	0	7.9	8.1	9.2
Employee restricted stock units (shares)	0	3	3.4	3.4
Other (shares)	0	0	0.2	0.2
Diluted weighted average shares outstanding (shares)	1,354	1,383.1	1,368.9	1,394.7
Basic (loss) earnings per share (usd per share)	$ (1.03)	$ 0.60	$ 1.21	$ 2.07
Diluted (loss) earnings per share (usd per share)	$ (1.03)	$ 0.59	$ 1.20	$ 2.05

Earnings Per Share - Narrative

Earnings Per Share - Narrative (Details) - shares shares in Millions	3 Months Ended		9 Months Ended
	Jan. 26, 2018	Jan. 27, 2017	Jan. 26, 2018	Jan. 27, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (shares)	10.5
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (shares)	10	10	9	6

Stock-Based Compensation (Detai

Stock-Based Compensation (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jan. 26, 2018	Jan. 27, 2017	Jan. 26, 2018	Jan. 27, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 72	$ 82	$ 270	$ 272
Income tax benefits	(12)	(23)	(69)	(77)
Total stock-based compensation expense, net of tax	60	59	201	195
Cost of products sold
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	10	12	34	38
Research and development expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	8	10	29	32
Selling, general, and administrative expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	53	55	187	179
Restructuring charges, net
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	0	0	0	2
Acquisition-related items
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	1	5	4	21
Divestiture-related items
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	0	0	16	0
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	28	37	105	128
Restricted stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	38	40	145	128
Employee stock purchase plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 6	$ 5	$ 20	$ 16

Retirement Benefit Plans (Detai

Retirement Benefit Plans (Details) - Pension plans - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jan. 26, 2018	Jan. 27, 2017	Jan. 26, 2018	Jan. 27, 2017
U.S.
Net Periodic Benefit Cost
Service cost	$ 29	$ 29	$ 87	$ 87
Interest cost	29	27	89	81
Expected return on plan assets	(51)	(47)	(155)	(141)
Amortization of net actuarial loss	20	23	60	69
Plan settlement	15	0	15	0
Net periodic benefit cost	42	32	96	96
Non-U.S.
Net Periodic Benefit Cost
Service cost	17	19	51	57
Interest cost	7	6	21	18
Expected return on plan assets	(13)	(12)	(39)	(36)
Amortization of net actuarial loss	4	4	12	12
Plan settlement	0	0	0	0
Net periodic benefit cost	$ 15	$ 17	$ 45	$ 51

Accumulated Other Comprehensi72

Accumulated Other Comprehensive Income and Supplemental Equity Disclosure - Changes in AOCI (Details) - USD ($)	3 Months Ended		9 Months Ended
	Jan. 26, 2018	Jan. 27, 2017	Jan. 26, 2018	Jan. 27, 2017
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance			$ 50,416,000,000	$ 52,063,000,000
Other comprehensive income (loss)	$ 678,000,000	$ (551,000,000)	1,231,000,000	(1,011,000,000)
Balance	50,340,000,000	49,493,000,000	50,340,000,000	49,493,000,000
Unrealized (Loss) Gain on Available-for-Sale Securities
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance			(69,000,000)	(107,000,000)
Other comprehensive income (loss) before reclassifications			50,000,000	(25,000,000)
Reclassifications			(9,000,000)	(15,000,000)
Other comprehensive income (loss)			41,000,000	(40,000,000)
Balance	(28,000,000)	(147,000,000)	(28,000,000)	(147,000,000)
Other Comprehensive Income (Loss), Tax [Abstract]
Other comprehensive income (loss) before reclassifications, tax expense (benefit)			33,000,000	5,000,000
Reclassifications, tax expense (benefit)			4,000,000	8,000,000
Cumulative Translation Adjustment
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance			(1,452,000,000)	(474,000,000)
Other comprehensive income (loss) before reclassifications			1,559,000,000	(1,239,000,000)
Reclassifications			(34,000,000)	0
Other comprehensive income (loss)			1,525,000,000	(1,239,000,000)
Balance	73,000,000	(1,713,000,000)	73,000,000	(1,713,000,000)
Net Change in Retirement Obligations
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance			(1,129,000,000)	(1,197,000,000)
Other comprehensive income (loss) before reclassifications			(38,000,000)	0
Reclassifications			49,000,000	66,000,000
Other comprehensive income (loss)			11,000,000	66,000,000
Balance	(1,118,000,000)	(1,131,000,000)	(1,118,000,000)	(1,131,000,000)
Other Comprehensive Income (Loss), Tax [Abstract]
Other comprehensive income (loss) before reclassifications, tax expense (benefit)			(6,000,000)	0
Reclassifications, tax expense (benefit)			21,000,000	15,000,000
Unrealized (Loss) Gain on Derivative Financial Instruments
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance			37,000,000	(90,000,000)
Other comprehensive income (loss) before reclassifications			(351,000,000)	255,000,000
Reclassifications			5,000,000	(53,000,000)
Other comprehensive income (loss)			(346,000,000)	202,000,000
Balance	(309,000,000)	112,000,000	(309,000,000)	112,000,000
Other Comprehensive Income (Loss), Tax [Abstract]
Other comprehensive income (loss) before reclassifications, tax expense (benefit)			(156,000,000)	145,000,000
Reclassifications, tax expense (benefit)				32,000,000
Total Accumulated Other Comprehensive (Loss) Income
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance			(2,613,000,000)	(1,868,000,000)
Other comprehensive income (loss) before reclassifications			1,220,000,000	(1,009,000,000)
Reclassifications			11,000,000	(2,000,000)
Other comprehensive income (loss)			1,231,000,000	(1,011,000,000)
Balance	$ (1,382,000,000)	$ (2,879,000,000)	$ (1,382,000,000)	$ (2,879,000,000)

Accumulated Other Comprehensi73

Accumulated Other Comprehensive Income and Supplemental Equity Disclosure - Supplemental Equity Schedule (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jan. 26, 2018	Jan. 27, 2017	Jan. 26, 2018	Jan. 27, 2017	Apr. 28, 2017
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance			$ 50,416	$ 52,063
Net (loss) income	$ (1,392)	$ 820	1,630	2,860
Other comprehensive income (loss)	678	(551)	1,231	(1,011)
Dividends to shareholders			(1,870)	(1,782)
Issuance of shares under stock purchase and award plans			266	309
Repurchase of ordinary shares			(1,897)	(3,409)
Tax benefit from exercise of stock-based awards				80
Stock-based compensation			270	272
Cumulative effect of change in accounting principle					$ 296
Reductions of noncontrolling ownership interests			(2)
Additions of noncontrolling ownership interests				111
Balance	50,340	49,493	50,340	49,493
Total Shareholders' Equity
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance			50,294	52,063
Net (loss) income			1,644	2,865
Other comprehensive income (loss)			1,231	(1,011)
Dividends to shareholders			(1,870)	(1,782)
Issuance of shares under stock purchase and award plans			266	309
Repurchase of ordinary shares			(1,897)	(3,409)
Tax benefit from exercise of stock-based awards				80
Stock-based compensation			270	272
Cumulative effect of change in accounting principle					$ 296
Balance	50,234	49,387	50,234	49,387
Noncontrolling Interests
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance			122	0
Net (loss) income			(14)	(5)
Other comprehensive income (loss)			0	0
Reductions of noncontrolling ownership interests			(2)
Additions of noncontrolling ownership interests				111
Balance	$ 106	$ 106	$ 106	$ 106

Commitments and Contingencies (

Commitments and Contingencies (Details) $ in Millions	Mar. 01, 2018claim	Dec. 14, 2011patent	Jun. 29, 2007	May 31, 2017claim	Jan. 26, 2018USD ($)claimlandfill	Apr. 29, 2016USD ($)claim	Apr. 28, 2017USD ($)	Apr. 26, 2013USD ($)
Loss Contingencies [Line Items]
Accrued certain litigation charges					$ 1,000		$ 1,100
Patents not infringed upon | patent		6
Covidien plc
Loss Contingencies [Line Items]
Tax sharing percentage, parent			42.00%
Tax sharing percentage, former parent			27.00%
Tax sharing percentage, former affiliate			31.00%
Orrington, Maine chemical manufacturing facility
Loss Contingencies [Line Items]
Number of landfills requiring removal | landfill					2
Number of landfills requiring capping | landfill					3
Indemnification agreement | Covidien plc | Tax Years Prior To 2013
Loss Contingencies [Line Items]
Maximum potential loss for tax indemnification								$ 200
INFUSE | Product liability litigation
Loss Contingencies [Line Items]
Number of pending claims | claim					6,000
Pelvic mesh | Product liability litigation
Loss Contingencies [Line Items]
Number of pending claims | claim					15,800
Settlement receivable						$ 121
Number of claims settled | claim				5,000		11,000
Pelvic mesh | Product liability litigation | Subsequent Event
Loss Contingencies [Line Items]
Number of claims settled | claim	13,400
Ethicon
Loss Contingencies [Line Items]
Patents infringed | patent		1
Minimum | Penobscot River and Bay remediation
Loss Contingencies [Line Items]
Cost estimate for potential remediation					$ 25
Maximum | Penobscot River and Bay remediation
Loss Contingencies [Line Items]
Cost estimate for potential remediation					$ 235

Segment and Geographic Inform75

Segment and Geographic Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Jan. 26, 2018	Jan. 27, 2017	Jan. 26, 2018	Jan. 27, 2017
Segment Reporting Information [Line Items]
Net sales	$ 7,369,000,000	$ 7,283,000,000	$ 21,809,000,000	$ 21,794,000,000
Income before Income Taxes by Reportable Segment
Income from operations before income taxes	1,027,000,000	967,000,000	3,950,000,000	3,167,000,000
Amortization of intangible assets	(461,000,000)	(497,000,000)	(1,375,000,000)	(1,484,000,000)
Restructuring and associated costs	(7,000,000)	(21,000,000)	(23,000,000)	(162,000,000)
Acquisition-related items	(26,000,000)	(68,000,000)	(77,000,000)	(148,000,000)
Certain litigation charges	(61,000,000)	(218,000,000)	(61,000,000)	(300,000,000)
Divestiture-related items	0	0	(114,000,000)	0
Gain on sale of businesses	0	0	697,000,000	0
Special charge	0	(100,000,000)	(80,000,000)	(100,000,000)
Interest expense, net	(172,000,000)	(180,000,000)	(539,000,000)	(532,000,000)
Americas
Segment Reporting Information [Line Items]
Net sales	4,202,000,000	4,417,000,000	12,659,000,000	13,185,000,000
U.S.
Segment Reporting Information [Line Items]
Net sales	3,900,000,000	4,100,000,000	11,700,000,000	12,300,000,000
EMEA
Segment Reporting Information [Line Items]
Net sales	1,895,000,000	1,652,000,000	5,319,000,000	4,895,000,000
Asia-Pacific
Segment Reporting Information [Line Items]
Net sales	815,000,000	818,000,000	2,506,000,000	2,530,000,000
Greater China
Segment Reporting Information [Line Items]
Net sales	457,000,000	396,000,000	1,325,000,000	1,184,000,000
Operating Segments
Income before Income Taxes by Reportable Segment
Income from operations before income taxes	2,822,000,000	2,687,000,000	8,205,000,000	8,055,000,000
Segment Reconciling Items
Income before Income Taxes by Reportable Segment
Amortization of intangible assets	(461,000,000)	(497,000,000)	(1,375,000,000)	(1,484,000,000)
Restructuring and associated costs	(30,000,000)	(21,000,000)	(62,000,000)	(172,000,000)
Acquisition-related items	(30,000,000)	(68,000,000)	(101,000,000)	(148,000,000)
Certain litigation charges	(61,000,000)	(218,000,000)	(61,000,000)	(300,000,000)
IPR&D impairment	(46,000,000)	0	(46,000,000)	0
Divestiture-related items	0	0	(115,000,000)	0
Gain on sale of businesses	0	0	697,000,000	0
Special charge	0	(100,000,000)	(80,000,000)	(100,000,000)
Hurricane Maria	0	0	(34,000,000)	0
Impact of inventory step-up	0	0	0	(38,000,000)
Centralized distribution costs	(471,000,000)	(364,000,000)	(1,399,000,000)	(1,211,000,000)
Interest expense, net	(172,000,000)	(180,000,000)	(539,000,000)	(532,000,000)
Corporate, Non-Segment
Income before Income Taxes by Reportable Segment
Corporate	(524,000,000)	(272,000,000)	(1,140,000,000)	(903,000,000)
Cardiac and Vascular Group
Segment Reporting Information [Line Items]
Net sales	2,800,000,000	2,548,000,000	8,219,000,000	7,650,000,000
Cardiac and Vascular Group | Operating Segments
Income before Income Taxes by Reportable Segment
Income from operations before income taxes	1,082,000,000	965,000,000	3,197,000,000	2,936,000,000
Minimally Invasive Therapies Group
Segment Reporting Information [Line Items]
Net sales	2,041,000,000	2,417,000,000	6,479,000,000	7,314,000,000
Minimally Invasive Therapies Group | Operating Segments
Income before Income Taxes by Reportable Segment
Income from operations before income taxes	797,000,000	820,000,000	2,433,000,000	2,530,000,000
Restorative Therapies Group
Segment Reporting Information [Line Items]
Net sales	1,944,000,000	1,817,000,000	5,616,000,000	5,415,000,000
Restorative Therapies Group | Operating Segments
Income before Income Taxes by Reportable Segment
Income from operations before income taxes	756,000,000	717,000,000	2,186,000,000	2,087,000,000
Diabetes Group
Segment Reporting Information [Line Items]
Net sales	584,000,000	501,000,000	1,495,000,000	1,415,000,000
Diabetes Group | Operating Segments
Income before Income Taxes by Reportable Segment
Income from operations before income taxes	$ 187,000,000	$ 185,000,000	$ 389,000,000	$ 502,000,000

Guarantor Financial Informati76

Guarantor Financial Information - Additional Information (Details) - USD ($) $ in Millions	Jan. 26, 2018	Apr. 28, 2017	Jan. 27, 2017	Apr. 29, 2016
Condensed Financial Statements, Captions [Line Items]
Increase (decrease) in investment in subsidiaries	$ 0	$ 0
Increase (decrease) in shareholders' equity balances	50,340	50,416	$ 49,493	$ 52,063
Medtronic Senior Notes | Medtronic, Inc. | Reportable Legal Entities
Condensed Financial Statements, Captions [Line Items]
Increase (decrease) in investment in subsidiaries	58,914	55,811
Increase (decrease) in shareholders' equity balances	14,611	13,969
Medtronic Senior Notes | Revision | Medtronic, Inc. | Reportable Legal Entities
Condensed Financial Statements, Captions [Line Items]
Increase (decrease) in investment in subsidiaries		(16,000)
Increase (decrease) in shareholders' equity balances		(16,000)
CIFSA Senior Notes | Medtronic, Inc. | Reportable Legal Entities
Condensed Financial Statements, Captions [Line Items]
Increase (decrease) in investment in subsidiaries	53,153	47,248
Increase (decrease) in shareholders' equity balances	$ 51,962	45,558
CIFSA Senior Notes | Revision | Medtronic, Inc. | Reportable Legal Entities
Condensed Financial Statements, Captions [Line Items]
Increase (decrease) in investment in subsidiaries		16,000
Increase (decrease) in shareholders' equity balances		$ 16,000

Guarantor Financial Informati77

Guarantor Financial Information - Consolidating Statement of Comprehensive Income (Details) - USD ($)	3 Months Ended		9 Months Ended
	Jan. 26, 2018	Jan. 27, 2017	Jan. 26, 2018	Jan. 27, 2017
Condensed Statement of Income Captions [Line Items]
Net sales	$ 7,369,000,000	$ 7,283,000,000	$ 21,809,000,000	$ 21,794,000,000
Costs and expenses:
Cost of products sold	2,191,000,000	2,268,000,000	6,660,000,000	6,855,000,000
Research and development expense	558,000,000	530,000,000	1,661,000,000	1,640,000,000
Selling, general, and administrative expense	2,499,000,000	2,388,000,000	7,422,000,000	7,232,000,000
Amortization of intangible assets	461,000,000	497,000,000	1,375,000,000	1,484,000,000
Restructuring charges, net	7,000,000	21,000,000	23,000,000	162,000,000
Acquisition-related items	26,000,000	68,000,000	77,000,000	148,000,000
Certain litigation charges	61,000,000	218,000,000	61,000,000	300,000,000
Divestiture-related items	0	0	114,000,000	0
Gain on sale of businesses	0	0	(697,000,000)	0
Special charge	0	100,000,000	80,000,000	100,000,000
Other (income) expense, net	140,000,000	46,000,000	317,000,000	174,000,000
Operating profit (loss)	1,426,000,000	1,147,000,000	4,716,000,000	3,699,000,000
Investment loss	227,000,000		227,000,000
Interest income	(98,000,000)	(88,000,000)	(290,000,000)	(272,000,000)
Interest expense	270,000,000	268,000,000	829,000,000	804,000,000
Interest expense, net	172,000,000	180,000,000	539,000,000	532,000,000
Equity in net (income) loss of subsidiaries	0	0	0	0
Income before income taxes	1,027,000,000	967,000,000	3,950,000,000	3,167,000,000
Income tax (benefit) provision	2,419,000,000	147,000,000	2,320,000,000	307,000,000
Net (loss) income	(1,392,000,000)	820,000,000	1,630,000,000	2,860,000,000
Net loss attributable to noncontrolling interests	3,000,000	1,000,000	14,000,000	5,000,000
Net (loss) income attributable to Medtronic	(1,389,000,000)	821,000,000	1,644,000,000	2,865,000,000
Other comprehensive income (loss), net of tax	678,000,000	(551,000,000)	1,231,000,000	(1,011,000,000)
Other comprehensive loss attributable to noncontrolling interests	3,000,000	1,000,000	14,000,000	5,000,000
Comprehensive (loss) income attributable to Medtronic	(711,000,000)	270,000,000	2,875,000,000	1,854,000,000
Consolidating Adjustments | Medtronic Senior Notes
Condensed Statement of Income Captions [Line Items]
Net sales	(275,000,000)	(237,000,000)	(877,000,000)	(918,000,000)
Costs and expenses:
Cost of products sold	(178,000,000)	(153,000,000)	(581,000,000)	(626,000,000)
Research and development expense	0	0	0	0
Selling, general, and administrative expense	0	0	0	0
Amortization of intangible assets	0	0	0	0
Restructuring charges, net	0	0	0	0
Acquisition-related items	0	0	0	0
Certain litigation charges	0	0	0	0
Divestiture-related items			0
Gain on sale of businesses			0
Special charge		0	0	0
Other (income) expense, net	(108,000,000)	(98,000,000)	(322,000,000)	(306,000,000)
Operating profit (loss)	11,000,000	14,000,000	26,000,000	14,000,000
Investment loss	0		0
Interest income	535,000,000	425,000,000	1,370,000,000	1,107,000,000
Interest expense	(535,000,000)	(425,000,000)	(1,370,000,000)	(1,107,000,000)
Interest expense, net	0	0	0	0
Equity in net (income) loss of subsidiaries	(3,849,000,000)	2,329,000,000	5,120,000,000	8,237,000,000
Income before income taxes	3,860,000,000	(2,315,000,000)	(5,094,000,000)	(8,223,000,000)
Income tax (benefit) provision	0	0	0	0
Net (loss) income	3,860,000,000	(2,315,000,000)	(5,094,000,000)	(8,223,000,000)
Net loss attributable to noncontrolling interests	0	0	0	0
Net (loss) income attributable to Medtronic	3,860,000,000	(2,315,000,000)	(5,094,000,000)	(8,223,000,000)
Other comprehensive income (loss), net of tax	(1,770,000,000)	1,318,000,000	(3,373,000,000)	2,568,000,000
Other comprehensive loss attributable to noncontrolling interests	0	0	0	0
Comprehensive (loss) income attributable to Medtronic	2,090,000,000	(997,000,000)	(8,467,000,000)	(5,655,000,000)
Consolidating Adjustments | CIFSA Senior Notes
Condensed Statement of Income Captions [Line Items]
Net sales	0	0	0	0
Costs and expenses:
Cost of products sold	0	0	0	0
Research and development expense	0	0	0	0
Selling, general, and administrative expense	0	0	0	0
Amortization of intangible assets	0	0	0	0
Restructuring charges, net	0	0	0	0
Acquisition-related items	0	0	0	0
Certain litigation charges	0	0	0	0
Divestiture-related items			0
Gain on sale of businesses			0
Special charge		0	0	0
Other (income) expense, net	0	0	0	0
Operating profit (loss)	0	0	0	0
Investment loss	0		0
Interest income	206,000,000	201,000,000	502,000,000	596,000,000
Interest expense	(206,000,000)	(201,000,000)	(502,000,000)	(596,000,000)
Interest expense, net	0	0	0	0
Equity in net (income) loss of subsidiaries	(1,927,000,000)	2,168,000,000	5,450,000,000	6,910,000,000
Income before income taxes	1,927,000,000	(2,168,000,000)	(5,450,000,000)	(6,910,000,000)
Income tax (benefit) provision	0	0	0	0
Net (loss) income	1,927,000,000	(2,168,000,000)	(5,450,000,000)	(6,910,000,000)
Net loss attributable to noncontrolling interests	0	0	0	0
Net (loss) income attributable to Medtronic	1,927,000,000	(2,168,000,000)	(5,450,000,000)	(6,910,000,000)
Other comprehensive income (loss), net of tax	(1,601,000,000)	1,460,000,000	(2,776,000,000)	2,407,000,000
Other comprehensive loss attributable to noncontrolling interests	0	0	0	0
Comprehensive (loss) income attributable to Medtronic	326,000,000	(708,000,000)	(8,226,000,000)	(4,503,000,000)
Medtronic plc | Medtronic Senior Notes
Costs and expenses:
Special charge		0		0
Medtronic plc | CIFSA Senior Notes
Costs and expenses:
Certain litigation charges			0
Medtronic plc | Reportable Legal Entities | Medtronic Senior Notes
Condensed Statement of Income Captions [Line Items]
Net sales	0	0	0	0
Costs and expenses:
Cost of products sold	0	0	0	0
Research and development expense	0	0	0	0
Selling, general, and administrative expense	4,000,000	4,000,000	9,000,000	9,000,000
Amortization of intangible assets	0	0	0	0
Restructuring charges, net	0	0	0	0
Acquisition-related items	0	0	0	0
Certain litigation charges	0	0	0	0
Divestiture-related items			0
Gain on sale of businesses			0
Special charge			0
Other (income) expense, net	10,000,000	80,000,000	35,000,000	5,000,000
Operating profit (loss)	(14,000,000)	(84,000,000)	(44,000,000)	(14,000,000)
Investment loss	0		0
Interest income	0	0	0	0
Interest expense	63,000,000	32,000,000	172,000,000	74,000,000
Interest expense, net	63,000,000	32,000,000	172,000,000	74,000,000
Equity in net (income) loss of subsidiaries	1,314,000,000	(937,000,000)	(1,855,000,000)	(2,949,000,000)
Income before income taxes	(1,391,000,000)	821,000,000	1,639,000,000	2,861,000,000
Income tax (benefit) provision	(2,000,000)	0	(5,000,000)	(4,000,000)
Net (loss) income	(1,389,000,000)	821,000,000	1,644,000,000	2,865,000,000
Net loss attributable to noncontrolling interests	0	0	0	0
Net (loss) income attributable to Medtronic	(1,389,000,000)	821,000,000	1,644,000,000	2,865,000,000
Other comprehensive income (loss), net of tax	678,000,000	(551,000,000)	1,231,000,000	(1,011,000,000)
Other comprehensive loss attributable to noncontrolling interests	0	0	0	0
Comprehensive (loss) income attributable to Medtronic	(711,000,000)	270,000,000	2,875,000,000	1,854,000,000
Medtronic plc | Reportable Legal Entities | CIFSA Senior Notes
Condensed Statement of Income Captions [Line Items]
Net sales	0	0	0	0
Costs and expenses:
Cost of products sold	0	0	0	0
Research and development expense	0	0	0	0
Selling, general, and administrative expense	4,000,000	4,000,000	9,000,000	9,000,000
Amortization of intangible assets	0	0	0	0
Restructuring charges, net	0	0	0	0
Acquisition-related items	0	0	0	0
Certain litigation charges	0	0		0
Divestiture-related items			0
Gain on sale of businesses			0
Special charge		0	0	0
Other (income) expense, net	10,000,000	80,000,000	35,000,000	5,000,000
Operating profit (loss)	(14,000,000)	(84,000,000)	(44,000,000)	(14,000,000)
Investment loss	0		0
Interest income	0	0	0	0
Interest expense	63,000,000	32,000,000	172,000,000	74,000,000
Interest expense, net	63,000,000	32,000,000	172,000,000	74,000,000
Equity in net (income) loss of subsidiaries	1,314,000,000	(937,000,000)	(1,855,000,000)	(2,949,000,000)
Income before income taxes	(1,391,000,000)	821,000,000	1,639,000,000	2,861,000,000
Income tax (benefit) provision	(2,000,000)	0	(5,000,000)	(4,000,000)
Net (loss) income	(1,389,000,000)	821,000,000	1,644,000,000	2,865,000,000
Net loss attributable to noncontrolling interests	0	0	0	0
Net (loss) income attributable to Medtronic	(1,389,000,000)	821,000,000	1,644,000,000	2,865,000,000
Other comprehensive income (loss), net of tax	678,000,000	(551,000,000)	1,231,000,000	(1,011,000,000)
Other comprehensive loss attributable to noncontrolling interests	0	0	0	0
Comprehensive (loss) income attributable to Medtronic	(711,000,000)	270,000,000	2,875,000,000	1,854,000,000
Subsidiary issuer | Medtronic Senior Notes
Costs and expenses:
Special charge		100,000,000		100,000,000
Subsidiary issuer | CIFSA Senior Notes
Costs and expenses:
Certain litigation charges			0
Subsidiary issuer | Reportable Legal Entities | Medtronic Senior Notes
Condensed Statement of Income Captions [Line Items]
Net sales	275,000,000	237,000,000	879,000,000	919,000,000
Costs and expenses:
Cost of products sold	243,000,000	214,000,000	693,000,000	706,000,000
Research and development expense	165,000,000	147,000,000	492,000,000	469,000,000
Selling, general, and administrative expense	346,000,000	264,000,000	1,020,000,000	828,000,000
Amortization of intangible assets	2,000,000	3,000,000	6,000,000	9,000,000
Restructuring charges, net	0	22,000,000	2,000,000	40,000,000
Acquisition-related items	27,000,000	36,000,000	45,000,000	96,000,000
Certain litigation charges	24,000,000	0	24,000,000	0
Divestiture-related items			15,000,000
Gain on sale of businesses			0
Special charge			80,000,000
Other (income) expense, net	(768,000,000)	(462,000,000)	(1,397,000,000)	(1,431,000,000)
Operating profit (loss)	236,000,000	(87,000,000)	(101,000,000)	102,000,000
Investment loss	172,000,000		172,000,000
Interest income	(90,000,000)	(62,000,000)	(225,000,000)	(183,000,000)
Interest expense	464,000,000	397,000,000	1,330,000,000	1,203,000,000
Interest expense, net	374,000,000	335,000,000	1,105,000,000	1,020,000,000
Equity in net (income) loss of subsidiaries	1,161,000,000	(594,000,000)	(1,599,000,000)	(2,785,000,000)
Income before income taxes	(1,471,000,000)	172,000,000	221,000,000	1,867,000,000
Income tax (benefit) provision	316,000,000	(105,000,000)	3,000,000	(179,000,000)
Net (loss) income	(1,787,000,000)	277,000,000	218,000,000	2,046,000,000
Net loss attributable to noncontrolling interests	0	0	0	0
Net (loss) income attributable to Medtronic	(1,787,000,000)	277,000,000	218,000,000	2,046,000,000
Other comprehensive income (loss), net of tax	428,000,000	(183,000,000)	948,000,000	(472,000,000)
Other comprehensive loss attributable to noncontrolling interests	0	0	0	0
Comprehensive (loss) income attributable to Medtronic	(1,359,000,000)	94,000,000	1,166,000,000	1,574,000,000
Subsidiary issuer | Reportable Legal Entities | CIFSA Senior Notes
Condensed Statement of Income Captions [Line Items]
Net sales	0	0	0	0
Costs and expenses:
Cost of products sold	0	0	0	0
Research and development expense	0	0	0	0
Selling, general, and administrative expense	0	0	0	1,000,000
Amortization of intangible assets	0	0	0	0
Restructuring charges, net	0	0	0	0
Acquisition-related items	0	0	0	0
Certain litigation charges	0	0		0
Divestiture-related items			0
Gain on sale of businesses			0
Special charge		0	0	0
Other (income) expense, net	0	0	1,000,000	1,000,000
Operating profit (loss)	0	0	(1,000,000)	(2,000,000)
Investment loss	0		0
Interest income	(13,000,000)	(23,000,000)	(45,000,000)	(71,000,000)
Interest expense	19,000,000	26,000,000	63,000,000	81,000,000
Interest expense, net	6,000,000	3,000,000	18,000,000	10,000,000
Equity in net (income) loss of subsidiaries	(765,000,000)	(434,000,000)	(1,938,000,000)	(1,462,000,000)
Income before income taxes	759,000,000	431,000,000	1,919,000,000	1,450,000,000
Income tax (benefit) provision	0	0	0	0
Net (loss) income	759,000,000	431,000,000	1,919,000,000	1,450,000,000
Net loss attributable to noncontrolling interests	0	0	0	0
Net (loss) income attributable to Medtronic	759,000,000	431,000,000	1,919,000,000	1,450,000,000
Other comprehensive income (loss), net of tax	245,000,000	(358,000,000)	314,000,000	(385,000,000)
Other comprehensive loss attributable to noncontrolling interests	0	0	0	0
Comprehensive (loss) income attributable to Medtronic	1,004,000,000	73,000,000	2,233,000,000	1,065,000,000
Medtronic Luxco | Medtronic Senior Notes
Costs and expenses:
Special charge		0		0
Medtronic Luxco | CIFSA Senior Notes
Costs and expenses:
Certain litigation charges			0
Medtronic Luxco | Reportable Legal Entities | Medtronic Senior Notes
Condensed Statement of Income Captions [Line Items]
Net sales	0	0	0	0
Costs and expenses:
Cost of products sold	0	0	0	0
Research and development expense	0	0	0	0
Selling, general, and administrative expense	0	0	0	0
Amortization of intangible assets	0	0	0	0
Restructuring charges, net	0	0	0	0
Acquisition-related items	0	0	0	0
Certain litigation charges	0	0	0	0
Divestiture-related items			0
Gain on sale of businesses			0
Special charge			0
Other (income) expense, net	0	0	0	0
Operating profit (loss)	0	0	0	0
Investment loss	0		0
Interest income	(133,000,000)	(157,000,000)	(344,000,000)	(477,000,000)
Interest expense	73,000,000	18,000,000	155,000,000	31,000,000
Interest expense, net	(60,000,000)	(139,000,000)	(189,000,000)	(446,000,000)
Equity in net (income) loss of subsidiaries	1,374,000,000	(798,000,000)	(1,666,000,000)	(2,503,000,000)
Income before income taxes	(1,314,000,000)	937,000,000	1,855,000,000	2,949,000,000
Income tax (benefit) provision	0	0	0	0
Net (loss) income	(1,314,000,000)	937,000,000	1,855,000,000	2,949,000,000
Net loss attributable to noncontrolling interests	0	0	0	0
Net (loss) income attributable to Medtronic	(1,314,000,000)	937,000,000	1,855,000,000	2,949,000,000
Other comprehensive income (loss), net of tax	678,000,000	(551,000,000)	1,231,000,000	(1,011,000,000)
Other comprehensive loss attributable to noncontrolling interests	0	0	0	0
Comprehensive (loss) income attributable to Medtronic	(636,000,000)	386,000,000	3,086,000,000	1,938,000,000
Medtronic Luxco | Reportable Legal Entities | CIFSA Senior Notes
Condensed Statement of Income Captions [Line Items]
Net sales	0	0	0	0
Costs and expenses:
Cost of products sold	0	0	0	0
Research and development expense	0	0	0	0
Selling, general, and administrative expense	0	0	1,000,000	2,000,000
Amortization of intangible assets	0	0	0	0
Restructuring charges, net	0	0	0	0
Acquisition-related items	0	0	0	0
Certain litigation charges	0	0		0
Divestiture-related items			0
Gain on sale of businesses			0
Special charge		0	0	0
Other (income) expense, net	0	0	0	0
Operating profit (loss)	0	0	(1,000,000)	(2,000,000)
Investment loss	0		0
Interest income	(137,000,000)	(158,000,000)	(355,000,000)	(482,000,000)
Interest expense	73,000,000	18,000,000	156,000,000	30,000,000
Interest expense, net	(64,000,000)	(140,000,000)	(199,000,000)	(452,000,000)
Equity in net (income) loss of subsidiaries	1,378,000,000	(797,000,000)	(1,657,000,000)	(2,499,000,000)
Income before income taxes	(1,314,000,000)	937,000,000	1,855,000,000	2,949,000,000
Income tax (benefit) provision	0	0	0	0
Net (loss) income	(1,314,000,000)	937,000,000	1,855,000,000	2,949,000,000
Net loss attributable to noncontrolling interests	0	0	0	0
Net (loss) income attributable to Medtronic	(1,314,000,000)	937,000,000	1,855,000,000	2,949,000,000
Other comprehensive income (loss), net of tax	678,000,000	(551,000,000)	1,231,000,000	(1,011,000,000)
Other comprehensive loss attributable to noncontrolling interests	0	0	0	0
Comprehensive (loss) income attributable to Medtronic	(636,000,000)	386,000,000	3,086,000,000	1,938,000,000
Subsidiary Non-guarantors | Medtronic Senior Notes
Costs and expenses:
Special charge		0		0
Subsidiary Non-guarantors | CIFSA Senior Notes
Costs and expenses:
Certain litigation charges			61,000,000
Subsidiary Non-guarantors | Reportable Legal Entities | Medtronic Senior Notes
Condensed Statement of Income Captions [Line Items]
Net sales	7,369,000,000	7,283,000,000	21,807,000,000	21,793,000,000
Costs and expenses:
Cost of products sold	2,126,000,000	2,207,000,000	6,548,000,000	6,775,000,000
Research and development expense	393,000,000	383,000,000	1,169,000,000	1,171,000,000
Selling, general, and administrative expense	2,149,000,000	2,120,000,000	6,393,000,000	6,395,000,000
Amortization of intangible assets	459,000,000	494,000,000	1,369,000,000	1,475,000,000
Restructuring charges, net	7,000,000	(1,000,000)	21,000,000	122,000,000
Acquisition-related items	(1,000,000)	32,000,000	32,000,000	52,000,000
Certain litigation charges	37,000,000	218,000,000	37,000,000	300,000,000
Divestiture-related items			99,000,000
Gain on sale of businesses			(697,000,000)
Special charge			0
Other (income) expense, net	1,006,000,000	526,000,000	2,001,000,000	1,906,000,000
Operating profit (loss)	1,193,000,000	1,304,000,000	4,835,000,000	3,597,000,000
Investment loss	55,000,000		55,000,000
Interest income	(410,000,000)	(294,000,000)	(1,091,000,000)	(719,000,000)
Interest expense	205,000,000	246,000,000	542,000,000	603,000,000
Interest expense, net	(205,000,000)	(48,000,000)	(549,000,000)	(116,000,000)
Equity in net (income) loss of subsidiaries	0	0	0	0
Income before income taxes	1,343,000,000	1,352,000,000	5,329,000,000	3,713,000,000
Income tax (benefit) provision	2,105,000,000	252,000,000	2,322,000,000	490,000,000
Net (loss) income	(762,000,000)	1,100,000,000	3,007,000,000	3,223,000,000
Net loss attributable to noncontrolling interests	3,000,000	1,000,000	14,000,000	5,000,000
Net (loss) income attributable to Medtronic	(759,000,000)	1,101,000,000	3,021,000,000	3,228,000,000
Other comprehensive income (loss), net of tax	664,000,000	(584,000,000)	1,194,000,000	(1,085,000,000)
Other comprehensive loss attributable to noncontrolling interests	3,000,000	1,000,000	14,000,000	5,000,000
Comprehensive (loss) income attributable to Medtronic	(95,000,000)	517,000,000	4,215,000,000	2,143,000,000
Subsidiary Non-guarantors | Reportable Legal Entities | CIFSA Senior Notes
Condensed Statement of Income Captions [Line Items]
Net sales	7,369,000,000	7,283,000,000	21,809,000,000	21,794,000,000
Costs and expenses:
Cost of products sold	2,191,000,000	2,268,000,000	6,660,000,000	6,855,000,000
Research and development expense	558,000,000	530,000,000	1,661,000,000	1,640,000,000
Selling, general, and administrative expense	2,495,000,000	2,384,000,000	7,412,000,000	7,220,000,000
Amortization of intangible assets	461,000,000	497,000,000	1,375,000,000	1,484,000,000
Restructuring charges, net	7,000,000	21,000,000	23,000,000	162,000,000
Acquisition-related items	26,000,000	68,000,000	77,000,000	148,000,000
Certain litigation charges	61,000,000	218,000,000		300,000,000
Divestiture-related items			114,000,000
Gain on sale of businesses			(697,000,000)
Special charge		100,000,000	80,000,000	100,000,000
Other (income) expense, net	130,000,000	(34,000,000)	281,000,000	168,000,000
Operating profit (loss)	1,440,000,000	1,231,000,000	4,762,000,000	3,717,000,000
Investment loss	227,000,000		227,000,000
Interest income	(154,000,000)	(108,000,000)	(392,000,000)	(315,000,000)
Interest expense	321,000,000	393,000,000	940,000,000	1,215,000,000
Interest expense, net	167,000,000	285,000,000	548,000,000	900,000,000
Equity in net (income) loss of subsidiaries	0	0	0	0
Income before income taxes	1,046,000,000	946,000,000	3,987,000,000	2,817,000,000
Income tax (benefit) provision	2,421,000,000	147,000,000	2,325,000,000	311,000,000
Net (loss) income	(1,375,000,000)	799,000,000	1,662,000,000	2,506,000,000
Net loss attributable to noncontrolling interests	3,000,000	1,000,000	14,000,000	5,000,000
Net (loss) income attributable to Medtronic	(1,372,000,000)	800,000,000	1,676,000,000	2,511,000,000
Other comprehensive income (loss), net of tax	678,000,000	(551,000,000)	1,231,000,000	(1,011,000,000)
Other comprehensive loss attributable to noncontrolling interests	3,000,000	1,000,000	14,000,000	5,000,000
Comprehensive (loss) income attributable to Medtronic	$ (694,000,000)	$ 249,000,000	$ 2,907,000,000	$ 1,500,000,000

Guarantor Financial Informati78

Guarantor Financial Information - Condensed Consolidating Balance Sheet (Details) - USD ($) $ in Millions	Jan. 26, 2018	Apr. 28, 2017	Jan. 27, 2017	Apr. 29, 2016
Current assets:
Cash and cash equivalents	$ 6,358	$ 4,967	$ 2,768	$ 2,876
Investments	8,078	8,741
Accounts receivable, net	5,775	5,591
Inventories, net	3,751	3,338
Intercompany receivable	0	0
Other current assets	2,645	1,865
Current assets held for sale	0	371
Total current assets	26,607	24,873
Property, plant, and equipment, net	4,517	4,361
Goodwill	39,795	38,515
Other intangible assets, net	22,178	23,407
Tax assets	1,537	1,509
Investment in subsidiaries	0	0
Intercompany loans receivable	0	0
Other assets	1,166	1,232
Noncurrent assets held for sale	0	5,919
Total assets	95,800	99,816
Current liabilities:
Current debt obligations	2,902	7,520
Accounts payable	1,809	1,731
Intercompany payable	0	0
Accrued compensation	1,645	1,860
Accrued income taxes	925	633
Other accrued expenses	3,652	2,442
Current liabilities held for sale	0	34
Total current liabilities	10,933	14,220
Long-term debt	25,918	25,921
Accrued compensation and retirement benefits	1,524	1,641
Accrued income taxes	4,758	2,405
Intercompany loans payable	0	0
Deferred tax liabilities	1,363	2,978
Other liabilities	964	1,515
Noncurrent liabilities held for sale	0	720
Total liabilities	45,460	49,400
Shareholders’ equity	50,234	50,294
Noncontrolling interests	106	122
Total equity	50,340	50,416	49,493	52,063
Total liabilities and equity	95,800	99,816
Consolidating Adjustments | Medtronic Senior Notes
Current assets:
Cash and cash equivalents	0	0	0	0
Investments	0	0
Accounts receivable, net	0	0
Inventories, net	(154)	(178)
Intercompany receivable	(47,916)	(46,827)
Other current assets	0	0
Current assets held for sale		0
Total current assets	(48,070)	(47,005)
Property, plant, and equipment, net	0	0
Goodwill	0	0
Other intangible assets, net	0	0
Tax assets	0	0
Investment in subsidiaries	(177,967)	(164,262)
Intercompany loans receivable	(60,387)	(51,265)
Other assets	0	0
Noncurrent assets held for sale		0
Total assets	(286,424)	(262,532)
Current liabilities:
Current debt obligations	0	0
Accounts payable	0	0
Intercompany payable	(47,916)	(46,827)
Accrued compensation	0	0
Accrued income taxes	0	0
Other accrued expenses	0	0
Current liabilities held for sale		0
Total current liabilities	(47,916)	(46,827)
Long-term debt	0	0
Accrued compensation and retirement benefits	0	0
Accrued income taxes	0	0
Intercompany loans payable	(60,387)	(51,265)
Deferred tax liabilities	0	0
Other liabilities	0	0
Noncurrent liabilities held for sale		0
Total liabilities	(108,303)	(98,092)
Shareholders’ equity	(178,121)	(164,440)
Noncontrolling interests	0	0
Total equity	(178,121)	(164,440)
Total liabilities and equity	(286,424)	(262,532)
Consolidating Adjustments | CIFSA Senior Notes
Current assets:
Cash and cash equivalents	0	0	0	0
Investments	0	0
Accounts receivable, net	0	0
Inventories, net	0	0
Intercompany receivable	(9,233)	(8,491)
Other current assets	0	0
Current assets held for sale		0
Total current assets	(9,233)	(8,491)
Property, plant, and equipment, net	0	0
Goodwill	0	0
Other intangible assets, net	0	0
Tax assets	0	0
Investment in subsidiaries	(170,873)	(154,375)
Intercompany loans receivable	(39,796)	(32,241)
Other assets	0	0
Noncurrent assets held for sale		0
Total assets	(219,902)	(195,107)
Current liabilities:
Current debt obligations	0	0
Accounts payable	0	0
Intercompany payable	(9,233)	(8,491)
Accrued compensation	0	0
Accrued income taxes	0	0
Other accrued expenses	0	0
Current liabilities held for sale		0
Total current liabilities	(9,233)	(8,491)
Long-term debt	0	0
Accrued compensation and retirement benefits	0	0
Accrued income taxes	0	0
Intercompany loans payable	(39,796)	(32,241)
Deferred tax liabilities	0	0
Other liabilities	0	0
Noncurrent liabilities held for sale		0
Total liabilities	(49,029)	(40,732)
Shareholders’ equity	(170,873)	(154,375)
Noncontrolling interests	0	0
Total equity	(170,873)	(154,375)
Total liabilities and equity	(219,902)	(195,107)
Medtronic plc | CIFSA Senior Notes
Current assets:
Cash and cash equivalents			0	0
Medtronic plc | Reportable Legal Entities | Medtronic Senior Notes
Current assets:
Cash and cash equivalents	0	0	0	0
Investments	0	0
Accounts receivable, net	0	0
Inventories, net	0	0
Intercompany receivable	40	51
Other current assets	5	10
Current assets held for sale		0
Total current assets	45	61
Property, plant, and equipment, net	0	0
Goodwill	0	0
Other intangible assets, net	0	0
Tax assets	0	0
Investment in subsidiaries	59,130	55,833
Intercompany loans receivable	3,000	3,000
Other assets	0	0
Noncurrent assets held for sale		0
Total assets	62,175	58,894
Current liabilities:
Current debt obligations	0	0
Accounts payable	0	0
Intercompany payable	0	0
Accrued compensation	18	9
Accrued income taxes	14	13
Other accrued expenses	2	0
Current liabilities held for sale		0
Total current liabilities	34	22
Long-term debt	0	0
Accrued compensation and retirement benefits	0	0
Accrued income taxes	10	10
Intercompany loans payable	11,897	8,568
Deferred tax liabilities	0	0
Other liabilities	0	0
Noncurrent liabilities held for sale		0
Total liabilities	11,941	8,600
Shareholders’ equity	50,234	50,294
Noncontrolling interests	0	0
Total equity	50,234	50,294
Total liabilities and equity	62,175	58,894
Medtronic plc | Reportable Legal Entities | CIFSA Senior Notes
Current assets:
Cash and cash equivalents	0	0
Investments	0	0
Accounts receivable, net	0	0
Inventories, net	0	0
Intercompany receivable	40	51
Other current assets	5	10
Current assets held for sale		0
Total current assets	45	61
Property, plant, and equipment, net	0	0
Goodwill	0	0
Other intangible assets, net	0	0
Tax assets	0	0
Investment in subsidiaries	59,130	55,833
Intercompany loans receivable	3,000	3,000
Other assets	0	0
Noncurrent assets held for sale		0
Total assets	62,175	58,894
Current liabilities:
Current debt obligations	0	0
Accounts payable	0	0
Intercompany payable	0	0
Accrued compensation	18	9
Accrued income taxes	14	13
Other accrued expenses	2	0
Current liabilities held for sale		0
Total current liabilities	34	22
Long-term debt	0	0
Accrued compensation and retirement benefits	0	0
Accrued income taxes	10	10
Intercompany loans payable	11,897	8,568
Deferred tax liabilities	0	0
Other liabilities	0	0
Noncurrent liabilities held for sale		0
Total liabilities	11,941	8,600
Shareholders’ equity	50,234	50,294
Noncontrolling interests	0	0
Total equity	50,234	50,294
Total liabilities and equity	62,175	58,894
Subsidiary issuer | CIFSA Senior Notes
Current assets:
Cash and cash equivalents			81	208
Subsidiary issuer | Reportable Legal Entities | Medtronic Senior Notes
Current assets:
Cash and cash equivalents	38	45	40	55
Investments	0	0
Accounts receivable, net	0	0
Inventories, net	166	155
Intercompany receivable	14,773	16,301
Other current assets	313	227
Current assets held for sale		0
Total current assets	15,290	16,728
Property, plant, and equipment, net	1,378	1,311
Goodwill	0	0
Other intangible assets, net	13	20
Tax assets	564	727
Investment in subsidiaries	58,914	55,811
Intercompany loans receivable	6,520	6,530
Other assets	267	434
Noncurrent assets held for sale		0
Total assets	82,946	81,561
Current liabilities:
Current debt obligations	2,000	5,000
Accounts payable	368	304
Intercompany payable	25,285	23,380
Accrued compensation	624	734
Accrued income taxes	0	0
Other accrued expenses	640	352
Current liabilities held for sale		0
Total current liabilities	28,917	29,770
Long-term debt	21,771	21,782
Accrued compensation and retirement benefits	988	1,120
Accrued income taxes	1,710	1,658
Intercompany loans payable	14,885	13,109
Deferred tax liabilities	0	0
Other liabilities	64	153
Noncurrent liabilities held for sale		0
Total liabilities	68,335	67,592
Shareholders’ equity	14,611	13,969
Noncontrolling interests	0	0
Total equity	14,611	13,969
Total liabilities and equity	82,946	81,561
Subsidiary issuer | Reportable Legal Entities | CIFSA Senior Notes
Current assets:
Cash and cash equivalents	0	33
Investments	0	0
Accounts receivable, net	0	0
Inventories, net	0	0
Intercompany receivable	0	0
Other current assets	0	0
Current assets held for sale		0
Total current assets	0	33
Property, plant, and equipment, net	0	0
Goodwill	0	0
Other intangible assets, net	0	0
Tax assets	0	0
Investment in subsidiaries	53,153	47,248
Intercompany loans receivable	2,316	2,978
Other assets	0	0
Noncurrent assets held for sale		0
Total assets	55,469	50,259
Current liabilities:
Current debt obligations	0	1,176
Accounts payable	0	0
Intercompany payable	1,278	1,269
Accrued compensation	0	0
Accrued income taxes	0	0
Other accrued expenses	12	23
Current liabilities held for sale		0
Total current liabilities	1,290	2,468
Long-term debt	2,117	2,133
Accrued compensation and retirement benefits	0	0
Accrued income taxes	0	0
Intercompany loans payable	100	100
Deferred tax liabilities	0	0
Other liabilities	0	0
Noncurrent liabilities held for sale		0
Total liabilities	3,507	4,701
Shareholders’ equity	51,962	45,558
Noncontrolling interests	0	0
Total equity	51,962	45,558
Total liabilities and equity	55,469	50,259
Medtronic Luxco | CIFSA Senior Notes
Current assets:
Cash and cash equivalents			0	0
Medtronic Luxco | Reportable Legal Entities | Medtronic Senior Notes
Current assets:
Cash and cash equivalents	61	5	0	0
Investments	0	0
Accounts receivable, net	0	0
Inventories, net	0	0
Intercompany receivable	0	0
Other current assets	0	0
Current assets held for sale		0
Total current assets	61	5
Property, plant, and equipment, net	0	0
Goodwill	0	0
Other intangible assets, net	0	0
Tax assets	0	0
Investment in subsidiaries	59,923	52,618
Intercompany loans receivable	18,357	16,114
Other assets	0	0
Noncurrent assets held for sale		0
Total assets	78,341	68,737
Current liabilities:
Current debt obligations	504	901
Accounts payable	0	0
Intercompany payable	7,833	7,111
Accrued compensation	0	0
Accrued income taxes	0	0
Other accrued expenses	15	4
Current liabilities held for sale		0
Total current liabilities	8,352	8,016
Long-term debt	1,843	1,842
Accrued compensation and retirement benefits	0	0
Accrued income taxes	0	0
Intercompany loans payable	16,023	10,049
Deferred tax liabilities	0	0
Other liabilities	0	0
Noncurrent liabilities held for sale		0
Total liabilities	26,218	19,907
Shareholders’ equity	52,123	48,830
Noncontrolling interests	0	0
Total equity	52,123	48,830
Total liabilities and equity	78,341	68,737
Medtronic Luxco | Reportable Legal Entities | CIFSA Senior Notes
Current assets:
Cash and cash equivalents	61	5
Investments	0	0
Accounts receivable, net	0	0
Inventories, net	0	0
Intercompany receivable	1,338	1,329
Other current assets	0	0
Current assets held for sale		0
Total current assets	1,399	1,334
Property, plant, and equipment, net	0	0
Goodwill	0	0
Other intangible assets, net	0	0
Tax assets	0	0
Investment in subsidiaries	58,590	51,294
Intercompany loans receivable	18,357	16,114
Other assets	0	0
Noncurrent assets held for sale		0
Total assets	78,346	68,742
Current liabilities:
Current debt obligations	504	901
Accounts payable	0	0
Intercompany payable	7,833	7,111
Accrued compensation	0	0
Accrued income taxes	0	0
Other accrued expenses	19	8
Current liabilities held for sale		0
Total current liabilities	8,356	8,020
Long-term debt	1,843	1,842
Accrued compensation and retirement benefits	0	0
Accrued income taxes	0	0
Intercompany loans payable	16,023	10,050
Deferred tax liabilities	0	0
Other liabilities	1	0
Noncurrent liabilities held for sale		0
Total liabilities	26,223	19,912
Shareholders’ equity	52,123	48,830
Noncontrolling interests	0	0
Total equity	52,123	48,830
Total liabilities and equity	78,346	68,742
Subsidiary Non-guarantors | CIFSA Senior Notes
Current assets:
Cash and cash equivalents			2,687	2,668
Subsidiary Non-guarantors | Reportable Legal Entities | Medtronic Senior Notes
Current assets:
Cash and cash equivalents	6,259	4,917	$ 2,728	$ 2,821
Investments	8,078	8,741
Accounts receivable, net	5,775	5,591
Inventories, net	3,739	3,361
Intercompany receivable	33,103	30,475
Other current assets	2,327	1,628
Current assets held for sale		371
Total current assets	59,281	55,084
Property, plant, and equipment, net	3,139	3,050
Goodwill	39,795	38,515
Other intangible assets, net	22,165	23,387
Tax assets	973	782
Investment in subsidiaries	0	0
Intercompany loans receivable	32,510	25,621
Other assets	899	798
Noncurrent assets held for sale		5,919
Total assets	158,762	153,156
Current liabilities:
Current debt obligations	398	1,619
Accounts payable	1,441	1,427
Intercompany payable	14,798	16,336
Accrued compensation	1,003	1,117
Accrued income taxes	911	620
Other accrued expenses	2,995	2,086
Current liabilities held for sale		34
Total current liabilities	21,546	23,239
Long-term debt	2,304	2,297
Accrued compensation and retirement benefits	536	521
Accrued income taxes	3,038	737
Intercompany loans payable	17,582	19,539
Deferred tax liabilities	1,363	2,978
Other liabilities	900	1,362
Noncurrent liabilities held for sale		720
Total liabilities	47,269	51,393
Shareholders’ equity	111,387	101,641
Noncontrolling interests	106	122
Total equity	111,493	101,763
Total liabilities and equity	158,762	153,156
Subsidiary Non-guarantors | Reportable Legal Entities | CIFSA Senior Notes
Current assets:
Cash and cash equivalents	6,297	4,929
Investments	8,078	8,741
Accounts receivable, net	5,775	5,591
Inventories, net	3,751	3,338
Intercompany receivable	7,855	7,111
Other current assets	2,640	1,855
Current assets held for sale		371
Total current assets	34,396	31,936
Property, plant, and equipment, net	4,517	4,361
Goodwill	39,795	38,515
Other intangible assets, net	22,178	23,407
Tax assets	1,537	1,509
Investment in subsidiaries	0	0
Intercompany loans receivable	16,123	10,149
Other assets	1,166	1,232
Noncurrent assets held for sale		5,919
Total assets	119,712	117,028
Current liabilities:
Current debt obligations	2,398	5,443
Accounts payable	1,809	1,731
Intercompany payable	122	111
Accrued compensation	1,627	1,851
Accrued income taxes	911	620
Other accrued expenses	3,619	2,411
Current liabilities held for sale		34
Total current liabilities	10,486	12,201
Long-term debt	21,958	21,946
Accrued compensation and retirement benefits	1,524	1,641
Accrued income taxes	4,748	2,395
Intercompany loans payable	11,776	13,523
Deferred tax liabilities	1,363	2,978
Other liabilities	963	1,515
Noncurrent liabilities held for sale		720
Total liabilities	52,818	56,919
Shareholders’ equity	66,788	59,987
Noncontrolling interests	106	122
Total equity	66,894	60,109
Total liabilities and equity	$ 119,712	$ 117,028

Guarantor Financial Informati79

Guarantor Financial Information - Condensed Consolidating Statement of Cash Flows (Details) - USD ($) $ in Millions	9 Months Ended
	Jan. 26, 2018	Jan. 27, 2017
Operating Activities:
Net cash provided by (used in) operating activities	$ 3,646	$ 5,107
Investing Activities:
Acquisitions, net of cash acquired	(111)	(1,328)
Proceeds from sale of businesses	6,058	0
Additions to property, plant, and equipment	(776)	(924)
Purchases of investments	(2,479)	(3,354)
Sales and maturities of investments	3,060	4,286
Capital contribution paid	0	0
Other investing activities, net	(5)	21
Net cash provided by (used in) investing activities	5,747	(1,299)
Financing Activities:
Acquisition-related contingent consideration	(43)	(58)
Change in current debt obligations, net	(391)	1,118
Repayment of short-term borrowings (maturities greater than 90 days)	(44)	(2)
Proceeds from short-term borrowings (maturities greater than 90 days)	1	4
Issuance of long-term debt	21	131
Payments on long-term debt	(4,167)	(361)
Dividends to shareholders	(1,870)	(1,782)
Issuance of ordinary shares	333	309
Repurchase of ordinary shares	(1,964)	(3,409)
Net intercompany loan borrowings (repayments)	0	0
Intercompany dividend paid	0	0
Capital contribution received	0	0
Other financing activities	(2)	80
Net cash provided by (used in) financing activities	(8,126)	(3,970)
Effect of exchange rate changes on cash and cash equivalents	124	54
Net change in cash and cash equivalents	1,391	(108)
Cash and cash equivalents at beginning of period	4,967	2,876
Cash and cash equivalents at end of period	6,358	2,768
Consolidating Adjustments | Medtronic Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities	0	0
Investing Activities:
Acquisitions, net of cash acquired	0	0
Proceeds from sale of businesses	0
Additions to property, plant, and equipment	0	0
Purchases of investments	0	162
Sales and maturities of investments	0	(162)
Capital contribution paid	4,259	241
Other investing activities, net	0	0
Net cash provided by (used in) investing activities	4,259	241
Financing Activities:
Acquisition-related contingent consideration	0	0
Change in current debt obligations, net	0	0
Repayment of short-term borrowings (maturities greater than 90 days)	0	0
Proceeds from short-term borrowings (maturities greater than 90 days)	0	0
Issuance of long-term debt	0	0
Payments on long-term debt	0	0
Dividends to shareholders	0	0
Issuance of ordinary shares	0	0
Repurchase of ordinary shares	0	0
Net intercompany loan borrowings (repayments)	0	0
Capital contribution received	(4,259)	(241)
Other financing activities	0	0
Net cash provided by (used in) financing activities	(4,259)	(241)
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	0	0
Cash and cash equivalents at beginning of period	0	0
Cash and cash equivalents at end of period	0	0
Consolidating Adjustments | CIFSA Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities	(1,048)	(920)
Investing Activities:
Acquisitions, net of cash acquired	0	0
Proceeds from sale of businesses	0
Additions to property, plant, and equipment	0	0
Purchases of investments	0	0
Sales and maturities of investments	0	0
Capital contribution paid	4,731	537
Other investing activities, net	0	0
Net cash provided by (used in) investing activities	4,731	537
Financing Activities:
Acquisition-related contingent consideration	0	0
Change in current debt obligations, net	0	0
Repayment of short-term borrowings (maturities greater than 90 days)	0	0
Proceeds from short-term borrowings (maturities greater than 90 days)	0	0
Issuance of long-term debt	0	0
Payments on long-term debt	0	0
Dividends to shareholders	0	0
Issuance of ordinary shares	0	0
Repurchase of ordinary shares	0	0
Net intercompany loan borrowings (repayments)	0	0
Intercompany dividend paid	1,048	920
Capital contribution received	(4,731)	(537)
Other financing activities	0	0
Net cash provided by (used in) financing activities	(3,683)	383
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	0	0
Cash and cash equivalents at beginning of period	0	0
Cash and cash equivalents at end of period	0	0
Medtronic plc | Medtronic Senior Notes
Financing Activities:
Repayment of short-term borrowings (maturities greater than 90 days)		0
Medtronic plc | CIFSA Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities		834
Investing Activities:
Acquisitions, net of cash acquired		0
Additions to property, plant, and equipment		0
Purchases of investments		0
Sales and maturities of investments		0
Capital contribution paid		0
Other investing activities, net		0
Net cash provided by (used in) investing activities		0
Financing Activities:
Acquisition-related contingent consideration		0
Change in current debt obligations, net		0
Repayment of short-term borrowings (maturities greater than 90 days)		0
Proceeds from short-term borrowings (maturities greater than 90 days)		0
Issuance of long-term debt		0
Payments on long-term debt		0
Dividends to shareholders		(1,782)
Issuance of ordinary shares		309
Repurchase of ordinary shares		(3,409)
Net intercompany loan borrowings (repayments)		4,048
Intercompany dividend paid		0
Capital contribution received		0
Other financing activities		0
Net cash provided by (used in) financing activities		(834)
Effect of exchange rate changes on cash and cash equivalents		0
Net change in cash and cash equivalents		0
Cash and cash equivalents at beginning of period		0
Cash and cash equivalents at end of period		0
Medtronic plc | Reportable Legal Entities | Medtronic Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities	172	834
Investing Activities:
Acquisitions, net of cash acquired	0	0
Proceeds from sale of businesses	0
Additions to property, plant, and equipment	0	0
Purchases of investments	0	0
Sales and maturities of investments	0	0
Capital contribution paid	0	0
Other investing activities, net	0	0
Net cash provided by (used in) investing activities	0	0
Financing Activities:
Acquisition-related contingent consideration	0	0
Change in current debt obligations, net	0	0
Repayment of short-term borrowings (maturities greater than 90 days)	0
Proceeds from short-term borrowings (maturities greater than 90 days)	0	0
Issuance of long-term debt	0	0
Payments on long-term debt	0	0
Dividends to shareholders	(1,870)	(1,782)
Issuance of ordinary shares	333	309
Repurchase of ordinary shares	(1,964)	(3,409)
Net intercompany loan borrowings (repayments)	3,329	4,048
Capital contribution received	0	0
Other financing activities	0	0
Net cash provided by (used in) financing activities	(172)	(834)
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	0	0
Cash and cash equivalents at beginning of period	0	0
Cash and cash equivalents at end of period	0	0
Medtronic plc | Reportable Legal Entities | CIFSA Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities	172
Investing Activities:
Acquisitions, net of cash acquired	0
Proceeds from sale of businesses	0
Additions to property, plant, and equipment	0
Purchases of investments	0
Sales and maturities of investments	0
Capital contribution paid	0
Other investing activities, net	0
Net cash provided by (used in) investing activities	0
Financing Activities:
Acquisition-related contingent consideration	0
Change in current debt obligations, net	0
Repayment of short-term borrowings (maturities greater than 90 days)	0
Proceeds from short-term borrowings (maturities greater than 90 days)	0
Issuance of long-term debt	0
Payments on long-term debt	0
Dividends to shareholders	(1,870)
Issuance of ordinary shares	333
Repurchase of ordinary shares	(1,964)
Net intercompany loan borrowings (repayments)	3,329
Intercompany dividend paid	0
Capital contribution received	0
Other financing activities	0
Net cash provided by (used in) financing activities	(172)
Effect of exchange rate changes on cash and cash equivalents	0
Net change in cash and cash equivalents	0
Cash and cash equivalents at beginning of period	0
Cash and cash equivalents at end of period	0
Subsidiary issuer | Medtronic Senior Notes
Financing Activities:
Repayment of short-term borrowings (maturities greater than 90 days)		0
Subsidiary issuer | CIFSA Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities		867
Investing Activities:
Acquisitions, net of cash acquired		0
Additions to property, plant, and equipment		0
Purchases of investments		0
Sales and maturities of investments		0
Capital contribution paid		(537)
Other investing activities, net		0
Net cash provided by (used in) investing activities		(537)
Financing Activities:
Acquisition-related contingent consideration		0
Change in current debt obligations, net		0
Repayment of short-term borrowings (maturities greater than 90 days)		0
Proceeds from short-term borrowings (maturities greater than 90 days)		0
Issuance of long-term debt		0
Payments on long-term debt		0
Dividends to shareholders		0
Issuance of ordinary shares		0
Repurchase of ordinary shares		0
Net intercompany loan borrowings (repayments)		(457)
Intercompany dividend paid		0
Capital contribution received		0
Other financing activities		0
Net cash provided by (used in) financing activities		(457)
Effect of exchange rate changes on cash and cash equivalents		0
Net change in cash and cash equivalents		(127)
Cash and cash equivalents at beginning of period		208
Cash and cash equivalents at end of period		81
Subsidiary issuer | Reportable Legal Entities | Medtronic Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities	(958)	933
Investing Activities:
Acquisitions, net of cash acquired	0	(940)
Proceeds from sale of businesses	0
Additions to property, plant, and equipment	(234)	(257)
Purchases of investments	0	0
Sales and maturities of investments	0	210
Capital contribution paid	(59)	(241)
Other investing activities, net	0	0
Net cash provided by (used in) investing activities	(293)	(1,228)
Financing Activities:
Acquisition-related contingent consideration	0	0
Change in current debt obligations, net	0	0
Repayment of short-term borrowings (maturities greater than 90 days)	0
Proceeds from short-term borrowings (maturities greater than 90 days)	0	0
Issuance of long-term debt	0	0
Payments on long-term debt	(3,000)	(29)
Dividends to shareholders	0	0
Issuance of ordinary shares	0	0
Repurchase of ordinary shares	0	0
Net intercompany loan borrowings (repayments)	4,244	275
Capital contribution received	0	0
Other financing activities	0	34
Net cash provided by (used in) financing activities	1,244	280
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	(7)	(15)
Cash and cash equivalents at beginning of period	45	55
Cash and cash equivalents at end of period	38	40
Subsidiary issuer | Reportable Legal Entities | CIFSA Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities	978
Investing Activities:
Acquisitions, net of cash acquired	0
Proceeds from sale of businesses	0
Additions to property, plant, and equipment	0
Purchases of investments	0
Sales and maturities of investments	0
Capital contribution paid	(531)
Other investing activities, net	0
Net cash provided by (used in) investing activities	(531)
Financing Activities:
Acquisition-related contingent consideration	0
Change in current debt obligations, net	0
Repayment of short-term borrowings (maturities greater than 90 days)	0
Proceeds from short-term borrowings (maturities greater than 90 days)	0
Issuance of long-term debt	0
Payments on long-term debt	(1,150)
Dividends to shareholders	0
Issuance of ordinary shares	0
Repurchase of ordinary shares	0
Net intercompany loan borrowings (repayments)	670
Intercompany dividend paid	0
Capital contribution received	0
Other financing activities	0
Net cash provided by (used in) financing activities	(480)
Effect of exchange rate changes on cash and cash equivalents	0
Net change in cash and cash equivalents	(33)
Cash and cash equivalents at beginning of period	33
Cash and cash equivalents at end of period	0
Medtronic Luxco | Medtronic Senior Notes
Financing Activities:
Repayment of short-term borrowings (maturities greater than 90 days)		0
Medtronic Luxco | CIFSA Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities		15
Investing Activities:
Acquisitions, net of cash acquired		0
Additions to property, plant, and equipment		0
Purchases of investments		0
Sales and maturities of investments		0
Capital contribution paid		0
Other investing activities, net		0
Net cash provided by (used in) investing activities		0
Financing Activities:
Acquisition-related contingent consideration		0
Change in current debt obligations, net		1,099
Repayment of short-term borrowings (maturities greater than 90 days)		0
Proceeds from short-term borrowings (maturities greater than 90 days)		0
Issuance of long-term debt		0
Payments on long-term debt		0
Dividends to shareholders		0
Issuance of ordinary shares		0
Repurchase of ordinary shares		0
Net intercompany loan borrowings (repayments)		(1,114)
Intercompany dividend paid		0
Capital contribution received		0
Other financing activities		0
Net cash provided by (used in) financing activities		(15)
Effect of exchange rate changes on cash and cash equivalents		0
Net change in cash and cash equivalents		0
Cash and cash equivalents at beginning of period		0
Cash and cash equivalents at end of period		0
Medtronic Luxco | Reportable Legal Entities | Medtronic Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities	200	161
Investing Activities:
Acquisitions, net of cash acquired	0	0
Proceeds from sale of businesses	0
Additions to property, plant, and equipment	0	0
Purchases of investments	0	0
Sales and maturities of investments	0	0
Capital contribution paid	(4,200)	0
Other investing activities, net	0	0
Net cash provided by (used in) investing activities	(4,200)	0
Financing Activities:
Acquisition-related contingent consideration	0	0
Change in current debt obligations, net	(397)	1,099
Repayment of short-term borrowings (maturities greater than 90 days)	0
Proceeds from short-term borrowings (maturities greater than 90 days)	0	0
Issuance of long-term debt	0	0
Payments on long-term debt	0	0
Dividends to shareholders	0	0
Issuance of ordinary shares	0	0
Repurchase of ordinary shares	0	0
Net intercompany loan borrowings (repayments)	4,453	(1,260)
Capital contribution received	0	0
Other financing activities	0	0
Net cash provided by (used in) financing activities	4,056	(161)
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	56	0
Cash and cash equivalents at beginning of period	5	0
Cash and cash equivalents at end of period	61	0
Medtronic Luxco | Reportable Legal Entities | CIFSA Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities	210
Investing Activities:
Acquisitions, net of cash acquired	0
Proceeds from sale of businesses	0
Additions to property, plant, and equipment	0
Purchases of investments	0
Sales and maturities of investments	0
Capital contribution paid	(4,200)
Other investing activities, net	0
Net cash provided by (used in) investing activities	(4,200)
Financing Activities:
Acquisition-related contingent consideration	0
Change in current debt obligations, net	(397)
Repayment of short-term borrowings (maturities greater than 90 days)	0
Proceeds from short-term borrowings (maturities greater than 90 days)	0
Issuance of long-term debt	0
Payments on long-term debt	0
Dividends to shareholders	0
Issuance of ordinary shares	0
Repurchase of ordinary shares	0
Net intercompany loan borrowings (repayments)	4,443
Intercompany dividend paid	0
Capital contribution received	0
Other financing activities	0
Net cash provided by (used in) financing activities	4,046
Effect of exchange rate changes on cash and cash equivalents	0
Net change in cash and cash equivalents	56
Cash and cash equivalents at beginning of period	5
Cash and cash equivalents at end of period	61
Subsidiary Non-guarantors | CIFSA Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities		4,311
Investing Activities:
Acquisitions, net of cash acquired		(1,328)
Additions to property, plant, and equipment		(924)
Purchases of investments		(3,354)
Sales and maturities of investments		4,286
Capital contribution paid		0
Other investing activities, net		21
Net cash provided by (used in) investing activities		(1,299)
Financing Activities:
Acquisition-related contingent consideration		(58)
Change in current debt obligations, net		19
Repayment of short-term borrowings (maturities greater than 90 days)		(2)
Proceeds from short-term borrowings (maturities greater than 90 days)		4
Issuance of long-term debt		131
Payments on long-term debt		(361)
Dividends to shareholders		0
Issuance of ordinary shares		0
Repurchase of ordinary shares		0
Net intercompany loan borrowings (repayments)		(2,477)
Intercompany dividend paid		(920)
Capital contribution received		537
Other financing activities		80
Net cash provided by (used in) financing activities		(3,047)
Effect of exchange rate changes on cash and cash equivalents		54
Net change in cash and cash equivalents		19
Cash and cash equivalents at beginning of period		2,668
Cash and cash equivalents at end of period		2,687
Subsidiary Non-guarantors | Reportable Legal Entities | Medtronic Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities	4,232	3,179
Investing Activities:
Acquisitions, net of cash acquired	(111)	(388)
Proceeds from sale of businesses	6,058
Additions to property, plant, and equipment	(542)	(667)
Purchases of investments	(2,479)	(3,516)
Sales and maturities of investments	3,060	4,238
Capital contribution paid	0	0
Other investing activities, net	(5)	21
Net cash provided by (used in) investing activities	5,981	(312)
Financing Activities:
Acquisition-related contingent consideration	(43)	(58)
Change in current debt obligations, net	6	19
Repayment of short-term borrowings (maturities greater than 90 days)	(44)	(2)
Proceeds from short-term borrowings (maturities greater than 90 days)	1	4
Issuance of long-term debt	21	131
Payments on long-term debt	(1,167)	(332)
Dividends to shareholders	0	0
Issuance of ordinary shares	0	0
Repurchase of ordinary shares	0	0
Net intercompany loan borrowings (repayments)	(12,026)	(3,063)
Capital contribution received	4,259	241
Other financing activities	(2)	46
Net cash provided by (used in) financing activities	(8,995)	(3,014)
Effect of exchange rate changes on cash and cash equivalents	124	54
Net change in cash and cash equivalents	1,342	(93)
Cash and cash equivalents at beginning of period	4,917	2,821
Cash and cash equivalents at end of period	6,259	$ 2,728
Subsidiary Non-guarantors | Reportable Legal Entities | CIFSA Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities	3,334
Investing Activities:
Acquisitions, net of cash acquired	(111)
Proceeds from sale of businesses	6,058
Additions to property, plant, and equipment	(776)
Purchases of investments	(2,479)
Sales and maturities of investments	3,060
Capital contribution paid	0
Other investing activities, net	(5)
Net cash provided by (used in) investing activities	5,747
Financing Activities:
Acquisition-related contingent consideration	(43)
Change in current debt obligations, net	6
Repayment of short-term borrowings (maturities greater than 90 days)	(44)
Proceeds from short-term borrowings (maturities greater than 90 days)	1
Issuance of long-term debt	21
Payments on long-term debt	(3,017)
Dividends to shareholders	0
Issuance of ordinary shares	0
Repurchase of ordinary shares	0
Net intercompany loan borrowings (repayments)	(8,442)
Intercompany dividend paid	(1,048)
Capital contribution received	4,731
Other financing activities	(2)
Net cash provided by (used in) financing activities	(7,837)
Effect of exchange rate changes on cash and cash equivalents	124
Net change in cash and cash equivalents	1,368
Cash and cash equivalents at beginning of period	4,929
Cash and cash equivalents at end of period	$ 6,297